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Abstract 
An absence of dystrophin in muscle has a massive impact throughout muscle 
development, and Duchene Muscular Dystrophy (DMD) is one of the consequences. 
The disruption of the dystrophin-glycoprotein complex (DGC) is caused by a mutation 
in the DMD gene, which affects muscle integrity, resulting in progressive muscle 
degeneration and weakness. In this study, dfd13 (dystrophin-deficient) and C2C12 
(non-dystrophic) myoblasts were cultured in low mitogen conditions for 10 days to 
induce differentiation; however, dfd13 myoblasts did not achieve terminal 
differentiation. It has been suggested that Pax7 may play a major role during 
myogenesis, therefore its expression pattern and transport protein were examined for 
any impairments. It was established that Pax7 localises in the cytoplasm of dystrophin-
deficient myoblasts and high expression is retained during differentiation. Co-
localisation analysis of Pax7 with subcellular markers indicated that Pax7 is synthesised 
during the proliferative state. Pax7 was shown to possess a nuclear location signal and 
KPNA2 was suggested as escort protein for Pax7 translocation into the nucleus. The 
PTEN-PI3K/Akt signalling pathway was investigated and protein synthesis regulation 
and FoxO3 were found to be impaired. Autophagy related genes were found to be highly 
expressed; however, LC3 lipidation and autophagy flux showed a reduction upon 
differentiation, indicating defective autophagy. The contribution of PTEN 
overexpression was assessed in relation to endoplasmic reticulum (ER) stress and 
activation of the unfolding protein response (UPR). It was established that a reduction 
in ER stress and changes to UPR activation lead to apoptosis. Finally, minidystrophin-
transfection of both types of myoblasts was utilised to examine the effect, especially in 
dystrophin-deficient myoblasts. Minidystrophin improved protein synthesis activation 
and increased autophagy (increased LC3 lipidation), suggesting that minidystrophin 
ameliorates dystrophic events (at the level of autophagosome formation. To conclude, 
destabilisation of the plasma membrane owing to a dystrophin mutation causes cell 
signalling alterations which minidystrophin restoration can partly improve.  
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Chapter 1 - Introduction 
Muscular dystrophy (MD) has been observed to begin early in the embryonic stage. It 
has been shown that the attrition of Pax7-positive cells and a substantial reduction in 
Pax7 expression occurred at the E15.5 and E17.5 stages in mdx embryos, the mouse 
model of Duchenne Muscular Dystrophy (DMD) (Merrick et al. 2009). Pax7-positive 
cell fragments also have been found in dystrophic muscle, suggesting that cells were 
undergoing apoptosis. These findings suggest that Pax7 play as a major role during 
myogenesis in the embryonic stage. At the postnatal stage, myoblasts have been 
reported to undergo extensive cell proliferation (hyper-proliferation) and increased 
apoptosis in mdx mice (Merrick et al. 2009) and in DMD patients (Sandri et al. 1998). 
Pax7 also has been reported play a role in satellite cells during the postnatal stage 
(Oustanina, Hause, and Braun 2004) but is indispensable during the adult stage 
(Sambasivan et al. 2011). 
In this study, dfd13 myoblasts have been used as the main subject by comparing 
it with the established C2C12 myoblast cell line. The dfd13 myoblast is derived from a 
5-week-old mdx mouse, which is has dystrophin-deficient myoblasts (Smith and 
Schofield 1994; Smith and Schofield 1997). In the mdx mouse the period of myopathy 
has been reported to begin after the three weeks of proliferative post-natal growth ends 
(Duddy et al. 2015). Therefore, dfd13 myoblasts were isolated from a 5-week-old mdx 
mouse and expanded via the micro-explant culture technique (Merrick et al. 2009). In 
addition, progressive muscle degeneration has been reported to begin at this stage. 
Therefore, the aim of the project was to investigate/characterise these dystrophin-
deficient myoblasts in terms of Pax7 expression patterns and levels of the associated 
2 
proteins. Intrinsic protein signalling, i.e. the PI3K/Akt pathway that leads to autophagy 
modulation, as well as phospholipase C (PLC) and endoplasmic reticulum (ER) stress 
during differentiation is also investigated. Finally, minidystrophin restoration is carried 
out in order to determine whether it could improve the impairment in dystrophin-
deficient myoblasts. 
1.1 Muscular Dystrophy 
1.1.1 Types of Muscular Dystrophy  
It has been reported that more than 70,000 people in the UK are affected by MD, and 
approximately 1 in 5,000 boys are born with Duchenne muscular dystrophy (DMD) 
(Muscular Dystrophy Campaign website). DMD is inherited muscle diseases caused by 
deletion, duplication or a point mutation of the DMD gene (dystrophin) which is located 
on the human X chromosome (Hoffman, Brown, and Kunkel 1987). These diseases are 
characterised by progressive skeletal muscle weakness, defects in muscle proteins, and 
the death of muscle tissue (Meryon 1852). A person suffering from the disease will 
gradually lose the ability to perform daily routine activities, starting as early as after 
birth to 2 years old, and by around the ages of ten years old they will need a wheelchair 
for movement, with  death occurring in their early 30s, mostly due to cardiomyopathy 
together with respiratory failure (Walton and Nattrass 1954; Eagle et al. 2002; 
Passamano et al. 2012). The life expectancy for each individual who has MD depends 
on the degree of weakened muscles in the heart.  
Types of MD are classified according to the age onset, muscles affected, as well 
as rate of progression. According to the National Institute of Child Health and Human 
Development (NICHD), there are more than 30 forms of MD which have been classified 
into nine primary types (Table 1.1), and  Figure 1.1 illustrates the classification of MD 
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according to the muscles affected. However, there remains no treatment to cure MD, 
either drugs based or reverse genetic mutations. Currently, drug therapy, i.e. 
corticosteroids, is used to slow muscle degeneration, while physical therapy, speech 
therapy and orthopaedic appliances are used to support MD patients in their daily lives 
(Angelini and Peterle 2012). 
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Table 1.1: Primary types of muscular dystrophy 
Source: University of Rochester Medical Center website 
https://www.urmc.rochester.edu/encyclopedia/content.aspx?ContentTypeID=85&ContentID=
P00792  
Type Age at onset 
Symptoms, rate of progression, and life 
expectancy 
Becker 
Adolescence to 
early adulthood 
Symptoms are almost identical to Duchenne, 
but less severe; progresses more slowly than 
Duchenne; survival into middle age. 
Congenital Birth 
Symptoms include general muscle weakness 
and possible joint deformities; disease 
progresses slowly; shortened life span. 
Duchenne 2 to 6 years 
Symptoms include general muscle weakness 
and wasting; affects pelvis, upper arms, and 
upper legs; eventually involves all voluntary 
muscles; survival beyond 20s is rare. 
Distal 40 to 60 years 
Symptoms include weakness and wasting of 
muscles of the hands, forearms, and lower legs; 
progression is slow; rarely leads to total 
incapacity. 
Emery-Dreifuss 
Childhood to 
early teens 
Symptoms include weakness and wasting of 
shoulder, upper arm, and shin muscles; joint 
deformities are common; progression is slow; 
sudden death may occur from cardiac problems. 
Facioscapulohumeral 
Childhood to 
early adults 
Symptoms include facial muscle weakness and 
weakness with some wasting of shoulders and 
upper arms; progression is slow with periods of 
rapid deterioration; life span may be many 
decades after onset. 
Limb-Girdle 
Late childhood 
to middle age 
Symptoms include weakness and wasting, 
affecting shoulder girdle and pelvic girdle first; 
progression is slow; death is usually due to 
cardiopulmonary complications. 
Myotonic 20 to 40 years 
Symptoms include weakness of all muscle 
groups accompanied by delayed relaxation of 
muscles after contraction; affects face, feet, 
hands, and neck first; progression is slow, 
sometimes spanning 50 to 60 years. 
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Figure 1.1: Different types of muscular dystrophy with defects in different muscles 
Image from http://patient.info/health/muscular-dystrophies-an-overview   
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1.1.2 Duchene Muscular Dystrophy 
DMD is the most well-known and the severest form of MD, and is caused by a mutation 
in the DMD gene which encodes the protein dystrophin (Hoffman, Brown, and Kunkel 
1987; Nowak and Davies 2004). DMD can be diagnosed using several tests, including 
that for creatine phosphokinase (CK), which can be detected through high levels in the 
blood as it leaks out from damaged muscle. A DNA test also can be performed to 
examine whether the specific mutation present is a deletion, duplication or point 
mutation of the dmd gene (Muscular Dystrophy Association website). As DMD is an 
inherited disease, it is essential that family members who are potential carriers can 
access genetic counselling.  
Dystrophin plays an important role in providing stability to the cell membrane, 
and connects the extracellular matrix and cytoskeleton components via the sarcolemma 
membrane (D. J. Blake et al. 2002). Dystrophin is associated with other protein partners, 
such as β-dystroglycan and sarcoglycan, which together form the dystrophin-associated 
glycoprotein complex (DGC) which is embedded in the sarcolemma membrane. 
Sarcospan, dystrobrevin and syntrophins are located in the cytoplasm, while α-
dystroglycan as well as laminin 2 are present in an extracellular matrix (Figure 1.2A) 
(Ervasti and Campbell 1991; D. J. Blake et al. 2002). Based on its complex and 
important connections, the absence of dystrophin causes membrane instability (Figure 
1.2B). The characterisation of this impairment is much worse in humans compared to 
the animal model, the mdx mouse; however, its reproducibility and applicability 
provides vital evidence and is the best available model for pre-clinical scientific 
research. Other models have also been developed for the mutations present in  other 
types of MD (Figure 1.3). These animal models aid in the understanding of the 
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molecular basis of MD and are expected to enable the development of effective 
treatments. 
 
 
 
 
 
 
 
 
 
Figure 1.2: Absence of dystrophin causes membrane instability in the sarcolemma 
membrane 
Schematic of the normal structure of the dystrophin-associated glycoprotein complex (DGC) 
and absence of dystrophin showing membrane instability within the sarcolemma membrane.  
(Modified from (Fiorillo et al. 2015)) 
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Figure 1.3: Animal models of the mutations in different types of muscular dystrophy 
Two animals model for Duchenne/Becker MD have been developed; Golden Retriever MD 
(GRMD) and mouse models (including mdx, mdx/utrn, utrn-/-, mdx2-5cv). Swiss Jim Lambert 
(SJL) mice is a model for Lim-Girdle muscular dystrophy-2B (LGMD2B), while sarcoglycan-
gamma/alpha/beta/delta (Sgd-g/a/b/d) are mouse models for LGMD2B/2C/2D/2E/2F, 
respectively. dy mice are a model for congenital muscular dystrophy (CMD),  α7 and α5 mice 
are a  model for congenital myopathy, and Adbn mice are a model for dystrobrevin deficiency. 
(modified from (Allamand and Campbell 2000; McGreevy et al. 2015)).  
 
 
C. elegans 
Sapje Zebrafish 
Drosophila 
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1.2 Myogenesis 
Myogenesis is the process of muscle tissue development throughout life, and 
predominantly occurs during embryonic stages with muscle regeneration taking place 
during adult stages. There are three different types of myoblasts, embryonic myoblasts, 
foetal myoblasts and satellite cells, which are involved in myogenesis and the transitions 
between these myoblasts are thought to overlap (Messina and Cossu 2009). Myogenesis 
is thought to have two myogenic waves with a distinct muscle fibre morphology being 
formed during the gestational period. There are four key factors which play an important 
role in differentiating progenitor myoblasts into the myofibres Myf5, MyoD, myogenin, 
and Mrf4. 
1.2.1 Embryonic Myogenesis 
In chick embryos the somite develops from the ventral region of the mesoderm, where 
it generally gives rise to major axial structures, i.e. cartilage cells (vertebrae and ribs), 
all skeletal muscles (including limbs) and also the dermis. The dermomyotome is 
formed from cells located in the dorsal and lateral regions of the somite, and consists of 
the myotome and dermatome which give rise to all trunk muscle cells and dermis, 
respectively. The dermomyotome also gives rise to muscle cells that migrate into the 
limb bud (Figure 1.4) (Wolpert et al. 2002). Initially, delamination of the cells from the 
edges of the dermomyotome causes the formation of the epithelial dermomyotome and 
skeletal muscle of the myotome. At this stage, Pax3 is highly expressed in migrating 
hypaxial cells and dermomyotome cells where is mediates the transcription of c-Met. 
The survival and proliferation of myoblasts is regulated by c-Met prior to migration and 
during secondary myogenesis (Wolpert et al. 2002). 
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Figure 1.4: Fate map of the somite within the chick embryo 
The sclerotome (forms cartilage) and dermomyotome arise from the somite. The myotome, part 
of the dermomyotome, gives rise to muscle cells. During day four embryogenesis, cells from 
the medial region of the somite will form the axial and back muscles, whereas cells from the 
lateral region migrate to give rise to abdominal and limb muscles.  
(Modified from Wolpert et al., 2002). 
During embryogenesis, skeletal muscles are derived from the paraxial mesoderm of the 
somite. Early myogenesis, also known as primary myogenesis, begins at E8.5 to E10.5 
and is composed of myocytes. The fusion of myocytes to form multinucleate muscle 
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fibre cells between E10.5 and E12.0 establishes the basic muscle pattern. At this stage, 
the key factors for muscle differentiation, i.e. MyoD and myogenin, begin to be 
expressed, together with myosin heavy chain (MyHC). Pax7 expression commences 
during E11.5, and it begins to take over the role of Pax3, which is down-regulated after 
E13.5+ (Figure 1.5). 
1.2.2 Foetal Myogenesis 
The second wave of myogenesis, also known as foetal myogenesis, begins at E13.5. At 
this stage, the bulk of the newly formed muscle has a longer and thinner shape formed 
around the primary fibres (Cossu et al. 1996). These fibres are the result of the fusion 
of foetal myoblasts with each other or fusion with primary fibres. At the end of this 
stage, E17.5, a basal lamina is formed with satellite cells residing between the fibres 
and sarcolemmal membrane. These satellite cells have been morphologically identified 
as mononucleated cells which are responsible for postnatal growth and muscle 
regeneration in adults (Messina and Cossu 2009). 
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Figure 1.5: Timeline of the initiation of genes involved in the regulation of myogenesis 
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1.2.3 Adult Myogenesis and Muscle Regeneration 
The third wave of myogenesis occurs at the postnatal stage, immediately after birth until 
the third or fourth week. At this stage, satellite cells, play an important role in 
maintaining muscle, for instance, during muscle injuries. A previous study showed that 
Pax7 and Pax3 are  indispensable in adults (Sambasivan et al. 2011). Satellite cells will 
remain in a quiescent state until the signal for muscle generation is received and the 
satellite cell is activated ready to commit to differentiation. Once the signal is received, 
satellite cells undergone a series of activation steps involving specific protein 
expression, subsequently achieving terminal differentiation (Figure 1.6). 
1.2.4 Satellite Cells 
Satellite cells also known as skeletal muscle stem cells are localised between the 
sarcolemma and basement membrane of myofibres (Hawke and Garry 2001). ISatellit 
cells have the ability to differentiate into myotube to provide additional muscle fibres 
(Siegel, Kuhlmann, and Cornelison 2011) and to self-renew to maintain the stem cells 
pool (Zammit et al. 2004). The satellite cells are the main source of new myonuclei for 
growing myofibers which is a cellular unit of adult skeletal muscle. Previous study has 
proved that Satellite cells can repair damaged muscle tissue in acute injury (Lepper, 
Partridge, and Fan 2011). The performance of this stem cell pool within each myofiber 
is a critical factor for maintaining myofiber integrity throughout life. Myofibres are 
sustained by hundreds of post mitotic myonuclei and are efficiently repaired and 
regenerated in damaged tissues (Zammit and Beauchamp 2001). Satellite cells have 
been reported to express the paired box transcription factor family member Pax7. This 
factor plays a critical role in the specification of satellite cells in skeletal muscle (Kuang 
et al. 2006). The inactivation of Pax7 results in severe depletion of these muscle stem 
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cells, thus trigger the development of muscle cells process (Lepper, Partridge, and Fan 
2011). 2011). 
1.3 Paired-type Homeobox Transcription Factors 
1.3.1 Pax protein 
Pax proteins are the key factors in the development of tissues and organs during 
embryogenesis. These proteins are characterised by the presence of a paired domain 
(PD), which specifically binds to DNA sequences where it acts as a transcription 
repressor or activator, and is generally located in the N-terminal part. Pax genes may 
also have an octapeptide (OP) motif and a homeobox DNA-binding domain 
(homeodomain; HD). Pax genes can be categorised into four subfamilies according to 
their structural characteristics Table 1.2). Within these subfamilies there is some overlap 
in expression during the development of tissues or organs in determining the choice of 
cell fate (Buckingham and Relaix 2007).  
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Figure 1.6: Sequence of myogenic regulatory expression within satellite cells 
Quiescent and activated satellite cells express Pax3 and Pax7, which then start to differentiate 
into myocytes initiated by Myf5. Myogenic differentiation factors, i.e. MyoD, myogenin and 
Mrf4, are then expressed during the differentiation process. 
  
Self-renewal 
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Table 1.2: Pax genes and the four subfamilies 
Pax genes are classified into four subfamilies based on their structural characteristics. 
(Buckingham and Relaix 2007). 
Pax 
gene 
Structural 
Characteristics 
Expression in developing 
tissues/organs 
Examples of human 
diseases associated with 
pax mutations 
Pax3 
 
 
Pax7 
 
 
Central nervous system, 
craniofacial tissue, trunk 
neural crest, somites/skeletal 
muscle 
Central nervous system, 
craniofacial tissue, 
somites/skeletal muscle 
Waardenburg syndrome, 
rhabdomyosarcoma,  
 
Melanoma, neuroblastoma, 
rhabdomyosarcoma, 
Pax4 
 
Pax6 
 Pancreas, gut 
 
Central nervous system, 
pancreas, gut, nose, eye 
Diabetes 
 
Aniridia, cataracts, G1 
tumors 
Pax2 
 
 
Pax8 
 
Pax5 
 
 
 
Central nervous system, 
kidney, ears 
 
Central nervous system, 
kidney, thyroid 
 
Central nervous system, B-
lymphocytes 
Kidney disease, e.g., 
Colomba syndrome, renal 
carcinomas 
Congenital hypothyroidism, 
thyroid follicular 
carcinomas 
 
Lymphomas 
Pax1 
 
 
Pax9 
 
 
Skeleton, thymus, 
oarathyroid 
 
Skeleton, Thymus, 
craniofacial tissue, teeth 
Vertebral malformations, 
e.g., Klippell-Feil syndrome 
 
Oligodentia 
Key: red box – Paired Domain, Blue box -  Octapeptide and yellow box – Homeodomain1/2/3. 
1.3.2 Pax3 and Pax7 
Pax3 and Pax7 have been widely studied due to their role in myogenesis and as a marker 
of the origin of myogenic progenitor cells during the embryonic and foetal stages 
(Relaix et al. 2006; Lagha et al. 2008). During muscle development and muscle 
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regeneration in the postnatal and adult stages, respectively, Pax3 and Pax7 are known 
to be essential for satellite cells to play their important role (Buckingham and Relaix 
2007; Relaix et al. 2006), while in embryos, these proteins play a role as a regulator of 
the myogenic programme. Both Pax3 and Pax7 have been shown to coordinate MyoD 
expression in adult skeletal muscle during chronic skeletal muscle overload, suggesting 
that both are involved in muscle development and regeneration (Hyatt et al. 2008).  
Pax3 is initially expressed in all cells that form somites, specifically the 
dermomyotome, from as early as day 3 of embryogenesis in mouse and chick. It is 
modulated by a member of the TGF beta superfamily, BMP-4, and Wnt family proteins, 
to become muscle precursors (Wolpert et al. 2002). A Pax3-deficient embryo cannot 
survive due to multiple defects in the neural tube, myogenesis and morphogenesis. The 
hypaxial muscle development by Myf5 is Pax3 dependent, but the regulation of the 
entry of cells into the myogenic programme is Pax3 independent (Bajard et al. 2006). 
In the embryo, Pax3 is known to be expressed in both quiescent and activated cells of 
adult mice at different frequencies in different muscles; it is abundantly present in the 
diaphragm (Relaix et al. 2006). A study by Zhou et al. (2008) showed that a pax3 
heterozygous mutation causes a semi-dominant phenotype, which means that different 
levels/dosages of Pax3 expression are required in each different muscle in the mouse 
and human (Zhou et al. 2008). 
Pax7 is expressed specifically during the development of the nervous and 
muscular system. A study by Merrick et al. (2009) showed that Pax7 can be detected as 
early as E11.5 in wild-type embryos and its level increases throughout the gestational 
period (Merrick et al. 2009). It plays a role in the regulation of muscle precursor cell 
proliferation by recruiting the histone-3-lysine-4 methyltransferase (H3K4 HMT) 
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complex via Pax3/7BP and the Wdr5 adaptor. This complex then target genes, i.e. 
Cdc20 and Id3, which are involved in cell-division cycle activation and the transcription 
inhibition process, respectively (Diao et al. 2012). The down-regulation of pax7 protein 
levels in an embryo correlates with an increased level of apoptosis in myoblasts isolated 
from mdx and cav3-/- mice (Merrick et al. 2009). 
The diversion function of Pax3 and Pax7 was shown by Relaix et al. (2004), 
when Pax3 was replaced by Pax7 in gene targeting, and the migration of muscle 
progenitor cells (pax3+ cells) showed a negative substitution indicating that pax7 is 
unable to replace pax3 function in the embryo (Relaix et al. 2004). Constitutive 
expression of both pax genes in both satellite cells and C2C12 cells showed an increased 
proliferation rate but a decrease in size (Collins et al. 2009). In the absence of Pax3 and 
Pax7 skeletal muscle differentiation still can occur, as Myf5 can activate myogenin 
directly (Relaix et al. 2006). Pax3 has previously been found to be sufficient for the 
establishment of muscle development in a pax7-/- mice as pax3+ cells were found in the 
interstitial space of adult skeletal muscle at pax7+ cells population location, that is 
essential for growth and regeneration (Kuang et al. 2006). 
Further observations have shown the attrition of a Pax7-positive cell population 
in mdx and cav3-/- embryos until late in gestation. Pax7-positive cells fragments were 
found in dystrophic muscle (E15.5: cav3-/- and mdx; E17.5: mdx)  and was much more 
severe in mdx/cav3+/-, suggesting that these cells may undergo apoptosis (Merrick et al. 
2009). From the results, the severity of the double mutant showed that dystrophin and 
cav-3 play an important role for the survival of Pax7-positive cells during myogenesis. 
However, in vitro analysis of apoptosis in dystrophin-deficient myoblasts is lacking, 
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which would demonstrate the frequency of apoptosis, as well as the significance of the 
event.  
Further study on caveolins showed that the over-expression of caveolin-3 (Cav-
3) caused the up- and down-regulation of Pax7 protein levels in dystrophin-deficient 
myoblasts and WT myoblasts, respectively, whilst the over-expression of caveolin-1 
(Cav-1) resulted in the down-regulation of Pax7 protein level in both cell lines. 
Furthermore, a knockdown of cav-3 leads to the up-regulation of Pax7 protein levels in 
both dystrophin-deficient myoblasts and WT myoblasts, whilst a knockdown of cav-1 
resulted in the up-regulation of Pax7 only in dystrophin-deficient myoblasts. Therefore, 
it has been suggested that Pax7 regulation is affected by the ratio of Cav-1/Cav-3 in 
myoblasts and that the homeostasis of Pax7/Cav-1/Cav-3 has been disturbed in 
dystrophin-deficient myoblasts. It has also been suggested that reduced protein levels 
of Pax7 in mdx mice may be attributable to the up-regulation of IGF-2 protein levels 
mediated through Cav-1 and Cav-3, as IGF-2 is associated with Pax7 and was found to 
be expressed at high levels at E17.5 in mdx embryos (Hung-chih 2013).  
1.3.3 Post-Translational Modification of Pax7 
Generally, translated proteins change their confirmational structure in order to carry out 
specific functions within a cell. One such modification within a cell is phosphorylation, 
which can either activate or deactivate an enzyme via the action of kinases at specific 
phosphorylation sites. Amino acids where phosphorylation can occur are serine (S), 
threonine (T), tyrosine (Y), histidine (H) and aspartate (D), with serine being the most 
common site followed by threonine. The structural characteristics of Pax7 are illustrated 
in Figure 1.7. 
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Pax3 has been demonstrated to be phosphorylated at ser205 in the region of 
surrounding the octapeptide domain in proliferating mouse primary myoblasts by casein 
kinase two alpha 1 (CK2A1) (Miller, Dietz, and Hollenbach 2008). Further study has 
also shown that GSK3β phosphorylates Pax3 at ser201 and -209, and that all three sites 
demonstrate a changing pattern in early myogenic differentiation. However, the 
phosphorylation pattern is different for Pax3-FOXO1 in the alveolar 
rhabdomyosarcoma (ARMS) cell line, suggesting that an alteration in phosphorylation 
sites may contribute to protein fusion (Dietz et al. 2011). To date, there have been no 
studies on Pax7 phosphorylation sites or on the Pax7-FOXO1 fusion protein. 
Transcriptional misregulation in cancer of both Pax3 and Pax7 has been reported 
in alveolar rhabdomyosarcoma (ARMS). This is a soft tissue malignancy which mostly 
occurs in children aged 1 to 5 years old but less commonly in teens. This sarcoma 
possesses a fusion protein consisting of Pax3 or Pax7 with FOXO1, result in the 
formation of cytoplasmic pax-FOXO1 (fusion protein), a transcriptional activator which 
alters transcriptional activity in the nucleus. Chromosomal aberrations occur involving 
the translocations t(2;13) (q35;q14) and t(1;13) (p36;q14), which have been identified 
in about 75-80% of ARMS cells (Bridge et al. 2010). 
Recently, it has been reported that Pax7 is regulated/modified by SUMOylation. 
Pax7 interacts with the SUMO conjugating enzyme known as UBC9, which 
SUMOylates Pax7 at lysine85 (K85) within the DNA binding domain (Luan et al. 
2013). SUMOylated-Pax7 is essential during neural crest development, C2C12 
myogenic differentiation, and transcriptional transactivation. In adult satellite cells, the 
arginine methyltransferase Carm1, specifically methylates an arginine present in the N-
terminus of Pax7, and thus is recruited to the WDR5-ASH2L-MLL2 complex for up-
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regulating Pax7 target genes (Kawabe et al. 2012). Pax3/7 have also been shown to 
interact with other proteins involved in chromatin binding, including HIRA, DAXX and 
PAX3/7BP (Figure 1.8) (Buckingham and Relaix 2015). This binding is important for 
the up-regulation of Pax7 target genes, such as Id3 and Cdc20. Id3 is a helix-loop-helix 
(HLH) protein that can also bind with other HLH proteins as a heterodimer. The lack of 
a basic DNA-binding domain inhibits other HLH proteins from binding to DNA, thus 
acting as a transcription inhibitor. Binding of Pax7 to the Id3 promoter is also thought 
to up-regulate and increase its expression during differentiation. Cdc20 is a regulatory 
protein that interacts with other proteins during cell division and is highly expressed in 
proliferating cells. It is responsible for mediating the association of the anaphase protein 
complex with the mitotic spindle checkpoint protein, MAD1L1 (Kim et al. 2011). 
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Figure 1.7: Structural characteristics of Pax7 
Pax-7 contains a transactivation domain and a DNA-binding domain (also known as a paired 
domain (PD)). The DNA-binding domain consists of PAI and RED subdomains, which are 
composed of a three helix-turn-helix motif. There is also an additional DNA-binding 
homeodomain and octapeptide region.  
(modified from (J. A. Blake and Ziman 2014) 
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Figure 1.8: Pax3/7 interactions with other proteins 
Pax3/7 interacts with proteins that are involved in chromatin binding and regulate the activation 
of specific genes. It also interacts with B-catenin, TAZ, GLI, RB and Calmyrin, where it is 
involved in Wnt, Hippo, Hedghog signalling, cell cycle regulation and Ca2+ signalling, 
respectively. 
(reviewed in Buckingham and Relaix, 2015)  
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1.4 Nuclear-Cytoplasmic Machinery 
Different from prokaryotic cells, the nucleus and cytoplasm are separated by a double 
lipid bilayer nuclear envelope (NE) in eukaryotic cells. The nuclear pore complex 
(NPC), in the NE, tightly mediates the bidirectional traffic of molecules, including 
proteins, nucleic acids and small molecules, via aqueous channel either passively or 
actively (Kau, Way, and Silver 2004; Wente and Rout 2010). The nuclear-cytoplasmic 
machinery involves the NPC, cellular apoptosis susceptibility (CAS), RanGTP, 
karyopherins (also known as importins/exportins) as well as the specific proteins/RNA 
complex to be transported. Alterations to any of these factors can cause the failure of 
protein regulation within a cell, thus affecting the whole process, i.e. up-regulation or 
down-regulation of genes. For instance, in carcinoma cells the overexpression of CAS 
(a nuclear export receptor) causes a disruption to the nuclear import of p53 by 
karyopherin-α, resulting in the cytoplasmic mislocalisation of p53 (Schlamp et al. 
1997). CAS overexpression leads to constitutive binding of karyopherin-α and RanGTP, 
thus depleting karyopherin-α stores for nuclear import (Kau, Way, and Silver 2004).  
1.4.1 Nuclear-Cytoplasmic Transport Mechanism for Pax Proteins 
The regulation of translated proteins in the cytoplasm is control by various signalling 
mechanisms, either for secretion or to remain within a cell. For those proteins that play 
a role as an activator, adaptor or gene regulator, specific transcription factors are need 
to already be present in the nucleus for the up-regulation, as well as down-regulation of 
genes, thus they need to be transported into the nucleus. As most of these proteins are 
larger than 40 kDa, protein adaptors (β-karyopherins) are needed to shuttle them 
through the nuclear membrane. 
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Transport receptors, also known as β-karyopherins (importins/exportins), only 
recognise proteins containing a nuclear localisation signal (NLS). This is a sequence 
highly enriched with the basic amino acids lysine (K), arginine (R) and histidine (H). It 
has been reported that phosphorylation of the NLS enhances the binding affinity of 
importin-α to become part of a complex (Nardozzi, Lott, and Cingolani 2010), which 
then binds to importin-β and is translocated into the nucleus via the NPC as the 
karyopherin-β has a binding affinity for nucleoporins within the NPC. This 
translocation process is also regulated by the gradient of RanGTP, which is 
asymmetrically distributed and predominantly found in the nucleus. Dissociation of the 
NLS-protein complex by RanGTP occurs within the nucleus, where the concentration 
of RanGTP is controlled by RanGEF which converts RanGDP to RanGTP. Importin-β 
is carried out of the nucleus by RanGTP, while importin-α needs a protein receptor 
(CAS) to form a complex with in order for RanGTP to be recycled back into the 
cytoplasm. This nuclear-cytoplasmic transport mechanism is summarised in Figure 1.9 
(Kau, Way, and Silver 2004). 
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Figure 1.9: Nuclear-cytoplasmic transport of proteins 
Karyopherin-α recognises proteins with a nuclear location sequence (NLS) and forms a complex 
with karyopherin-β before being translocated into the nucleus, where the complex is dissociated 
by RanGTP. Both karyopherin-β and karyopherin-α are recycled back to the cytoplasm with the 
aid of RanGTP and CAS, respectively.  
(Kau, Way, and Silver 2004) 
  
 27 
1.5 The PI3K/Akt Signalling Network in Skeletal Muscles 
1.5.1 Regulation of PI3K/Akt in Skeletal Muscle 
Skeletal muscle growth is regulated by a highly conserved signalling pathway known 
as insulin-like growth factor-1 (Igf-1) (Schiaffino and Mammucari 2011; Yu et al. 
2015). Activation via the specific growth factor Igf-1 is through binding to the Igf-1 
receptor (IGF-1R), a transmembrane protein that resides within the cell plasma 
membrane and the membrane of subcellular compartments. It has been classified as a 
class II receptor tyrosine kinase (RTK). Binding of Igf-1 to IGF-1R leads to the 
activation of protein tyrosine kinase and a series of phosphorylation events. 
Phosphorylated tyrosine kinase also triggers neighbouring kinases, subsequently 
generating docking sites for the insulin receptor substrate (IRS), which is also 
phosphorylated by IGF-1R. Phosphorylated IRS then activates phosphatidylinositol-
4,5-biphosphate 3-kinase, also known phosphatidylinositide-3-kinase (PI3K), which is  
responsible for phosphoinositide-3,4,5-triphosphate (PIP3) production through 
phosphorylation of the membrane lipid, phosphoinositide-4,5-biphosphate (PIP2). PIP3 
acts as a docking site for phosphoinositide dependent kinase-1 (PDK1) and protein 
kinase B (Akt). Meanwhile, PDK1 is also responsible for Akt phosphorylation at 
Thr308, which is also phosphorylated at Ser473 by mTORC2 (Sarbassov et al. 2005). 
Activated Akt regulates various cell signalling activities, including proliferation, 
differentiation, protein synthesis, protein degradation and apoptosis (Figure 1.10) 
(Schiaffino and Mammucari 2011).  
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Figure 1.10: The insulin-like growth factor 1 (Igf-1) signalling pathway 
The binding of Igf-1 protein to its receptor activates two distinct pathways: 1) PI3K/Akt and 2) 
Ras/Raf/MEK. The PI3K/Akt pathway results in various cell signalling activities, such as 
protein synthesis and growth, glucose metabolism, cell cycle, cell proliferation, apoptosis and 
cell survival. Meanwhile, Ras/Raf/MEK activates cell proliferation signalling. 
(Modified from Jin-Jung and Suh, 2015) 
1.5.2 Akt 
Protein kinase B (PKB), also known as Akt, is a serine/threonine-specific protein kinase 
that widely regulates various cell signalling activities. It has three distinct isoforms, 
Akt1, Akt2 and Akt3, with each isoform playing a distinct role in cell regulation. Akt 
has three major domains, a regulatory domain (hydrophobic region), a catalytic kinase 
domain, and a pleckstrin homology domain (Du and Tsichlis 2005). Nascent Akt is 
phosphorylated by mTORC2 at Thr450 within the C-terminal region and this is 
important for the stability of AGC kinases (Liao and Hung 2010). Phosphorylated Akt 
is localised to the cytoplasmic compartment in its inactive form until another two 
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phosphorylation events take place; phosphorylation at Ser473 by mTORC2 and at 
Thr308 by PDK1. Both phosphorylations have been reported to be important for the full 
activation of Akt (Sarbassov et al. 2005) however, it remains debatable whether both 
phosphorylations are necessary in skeletal muscle development. 
1.5.3 Mammalian Target of Rapamycin (mTOR) Complexes 
mTOR is a protein that functions within multiprotein complexes. It was named after the 
anti-fungal rapamycin, which specifically targets mTOR and causes association 
disruption within mTOR complexes. mTOR is an important regulator of skeletal 
myogenesis and regulates various signalling mechanisms, particularly those involved 
in myoblast fusion and myotube formation (Shu and Houghton 2009). mTOR exists in 
two complexes, mTORC1 and mTORC2, and details for each complex are illustrated 
in Figure 1.11 (Tchevkina and Komelkov 2012). 
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mTORC1 mTORC2 
mTOR 
Catalytic subunit of the complex 
mLST8 
mTORC1: essential for nutrient- and rapamycin-sensitive interaction between Raptor 
and mTOR 
mTORC2: importance for the Rictor-mTOR interaction 
Deptor 
DEP-domain containing mTOR-interacting protein 
Raptor 
Regulatory-associated protein of mTOR 
Rictor 
Rapamycin-insensitive companion of 
mTOR 
PRAS40 
Proline-rich Akt substrate 40 kDa 
Protor-1 
Protein observed with rictor-1 
 
 
 
 
 
mSIN1 
mammalian stress-activated protein 
kinase interacting protein  
Figure 1.11: The mTORC complexes 
mTOR exists in two complexes which contain three similar components, i.e. mTOR, mLST8 
and Deptor (yellow). In addition, mTORC1 contains Raptor and PRAS40, while mTORC2 
contains Rictor, Protor-1 and mSIN1. 
1.5.4 PTEN (Phosphatase & Tensin Homologue Protein) 
The phosphatase Tensin homologue deletion on chromosome 10, PTEN, is also known 
to be a tumour suppressor. PTEN is mainly found in the cytosol and nucleus (Bononi 
and Pinton 2015) and contains three domains,  a phosphatase domain located at the N-
terminal region, a C2 domain and a PDZ domain located at the C-terminal region. The 
phosphatase domain contains a motif for PIP2 binding, while the C2 domain is essential 
for membrane targeting. The C-terminal region contains multiple phosphorylation sites 
that regulate its stability, activity and recruitment to the membrane. PTEN acts as a 
negative regulator for PIP3 by hydrolysing phosphates in position 3′ to form PIP2 (Ono 
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et al. 2001). In its unphosphorylated form, PTEN assumes an open conformation which 
can activate its phosphatase domain for phosphate hydrolysation. Phosphorylation of 
PTEN at Ser380 assumes a closed conformation and represents the inactive form. 
1.5.5 PI3K/Akt Regulation in Muscular Dystrophy 
Many studies have been carried out concerning PI3K/Akt impairment in the mdx mouse 
as well as in DMD in humans. Activation of Akt has been found to be higher in the mdx 
mouse compared to non-dystrophic mouse (Dogra et al. 2006; Clara De Palma et al. 
2014) and also in DMD patients (Peter and Crosbie 2006). As Akt plays a major role in 
cell signalling, its impairment leads to  various defects in downstream protein 
signalling, including cell proliferation, differentiation, apoptosis, autophagy and protein 
synthesis perturbation.  
Akt has also been reported to be highly activated and associated with α-integrin 
in the mdx/utr-/- mouse model (Boppart, Burkin, and Kaufman 2011). Boppart et al. 
(2011) demonstrated that α-integrin transgenic mdx/utr-/- mice (α7βX2-mdx/utr-/-) 
showed increased phosphorylation of Akt at Ser473, indicating that α-integrin 
expression is connected to Akt. The mdx/utr-/- mouse lacks both dystrophin and 
utrophin, and develops a severe pathology that closely resembles that seen in DMD 
(Boppart, Burkin, and Kaufman 2011).   
Similarly, PTEN has been reported to contribute to the MD phenotype. A study 
by Feron et al. (2009) on the Golden Retriever muscular dystrophy (GRMD) dog 
demonstrated that PTEN was present at high levels, which led to a reduction of Akt1, 
glycogen synthase kinase-3β (GSK3β) and p70S6K, in addition, ERK1/2 displayed 
decreased phosphorylation levels in GRMD dog muscle. The GRMD dog is 
characterised by rapidly progressive clinical dysfunction, severe muscle weakness, and 
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displays a disease progression that is more similar to human DMD compared to the mdx 
mouse (Feron et al. 2009).  
1.6 Autophagy in Skeletal Muscle   
1.6.1 Mechanisms of Autophagosome Formation 
Autophagy is the process of engulfment of cargo into the double lipid formation known 
as a autophagosome, which eventually fuses with a lysosome and is degraded (Glick, 
Barth, and Macleod 2010). Autophagic activity is rapidly increased in cells under stress 
conditions and nutrient deprivation in order to maintain cell homeostasis (Grumati and 
Bonaldo 2012).  
Several autophagy related genes are known to be involved in the formation of 
autophagosomes. FoxO3 has been shown to induce multiple autophagy genes, including 
LC3B transcription within skeletal muscle (Mammucari et al. 2007). The light chain 3B 
(LC3B) isoform of LC3 plays a critical role in this event and undergoes post-
translational modification. Next, LC3B-I is converted to lipidated-LC3B-II by the 
conjugation of membrane lipid phosphatidylethanoleamine (PE) involving the E1-like 
enzyme ubiquitin Atg7 (Autophagy related 7) and the E2-like enzyme Atg10. LC3B-II 
then binds to the isolation membrane and mediates membrane elongation until its edges 
fuse to create an autophagosome. The isolation membrane appears when a cell is placed 
under starvation conditions. Atg7 also conjugates Atg5 to Atg12 to become the Atg5-
Atg12 complex, which then binds to the isolation membrane together with Atg16. This 
complex binding is necessary for autophagosome formation (Banduseela et al. 2013). 
A schematic of autophagosome formation is illustrated in Figure 1.12. 
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1.6.2 FoxO3 
Forkhead Box O3 (FoxO3) is a transcription factor/activator and belongs to the O 
subclasses forkhead family (Webb and Brunet 2014). Its fork head DNA-binding 
domain recognises and binds to DNA sequences to promote gene activation. It has been 
reported that FoxO3 up-regulates autophagy related genes (Mammucari et al. 2007).  
FoxO3 is responsible for regulating two major pathways of muscle protein degradation: 
1) the proteasomal-lysosomal, and 2) autophagic-lysosomal pathways (Schiaffino and 
Mammucari 2011). 
1.6.3 LC3B 
LC3B is a subunit of microtubule-associated proteins 1A/1B light chain 3B 
(MAP1LC3B). LC3B belongs to the LC3 family, which consists of three members, 
LC3A, LC3B and LC3C. LC3B is a structural protein found in the autophagosome 
membrane. Initially, LC3 is cleaved by Atg4 to produce active LC3B-I, which  in turn 
is activated by Atg7 and becomes membrane-bound during autophagosome formation 
(Ichimura et al. 2000; Banduseela et al. 2013).   
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Figure 1.12: Schematic of autophagosome formation 
After being translated, LC3B is cleaved by Atg4 to form LC3-I, which is conjugated to PE by 
Atg7 to become lipidated-LC3-II. LC3-II binds to the isolated membrane and subsequently 
forms an autophagosome 
(Modified from Banduseela et al., 2013) 
1.6.4 Autophagy in Models of Muscular Dystrophy 
Generally, defective autophagy exhibits a dual response; at high levels it causes muscle 
atrophy, whilst at low levels it contributes to muscle degeneration. High levels of 
autophagy result in excessive protein degradation due to high levels of autophagy gene 
activation (Grumati and Bonaldo 2012). In this state activation of Akt inhibits the 
activation of autophagy related genes indirectly via mTOR and/or directly 
phosphorylates the FoxO3a transcription factor (Tchevkina and Komelkov 2012). This 
event leads to reduced muscle mass and muscle wasting. In contrast, low level 
autophagy is defined as low autophagy activity which causes an accumulation of 
dysfunction and unused organelles, i.e. mitochondria, as well as unfolded protein within 
skeletal muscle. This condition leads to an altered muscle structure with prominent 
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myonuclei centralisation and fusion abnormalities, which eventually weakens the 
muscle leading to the dystrophic phenotype (Masiero et al. 2009).  Therefore, 
maintaining autophagy at the appropriate level is crucial within skeletal muscle. 
Autophagy is defective in mdx mice (Neel, Lin, and Pessin 2013) and DMD 
humans (C De Palma et al. 2012). Restoration of beclin1 levels in Col6a1-/- animals and 
long-term exposure to a low-protein diet (Grumati et al. 2010; Clara De Palma et al. 
2014) can reactivate autophagy and partly ameliorate the dystrophic 
features/phenotype. Col6a1-/- animals display an impairment of basal autophagy, which 
determines the persistence of dysfunctional organelles in muscle fibres leading to 
muscle degeneration (Grumati et al. 2010). Treatment with a long-term low-protein diet 
can reactivate autophagy by normalised Akt activation, thus increasing LC3B 
conversion and up-regulating autophagy related genes (Langenbach and Rando 2002; 
C De Palma et al. 2012). 
1.7 Endoplasmic Reticulum Stress in Skeletal Muscles 
1.7.1 Activation and Regulation of Endoplasmic Reticulum Stress 
ER stress occurs when ER homeostasis is disturbed, i.e. there is an imbalance in calcium 
levels, as well as impaired protein modification in the ER lumen. As a result, the 
unfolded protein response (UPR) is triggered to alleviate the situation (Rayavarapu, 
Coley, and Nagaraju 2012; Vandewynckel et al. 2013). UPR activation involves the 
activation of three distinct ER membrane associated protein receptors: 1) PKR-like 
eukaryotic initiation factor 2α kinase (PERK); (2) inositol requiring enzyme-1 (IRE1); 
and (3) activating transcription-6 (ATF6) (Figure 1.13) (Pluquet, Pourtier, and Abbadie 
2015).  
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ER stress causes the dissociation of the Ca2+ chaperon protein, BiP (binding 
immunoglobulin protein) from its conformational binding state on the receptors, thereby 
activating the receptors (Mekahli et al. 2011). Activated PERK phosphorylates 
eukaryotic initiation factor-2α (eIF2α) and blocks assembly of 80S ribosomes, thus 
protein synthesis is disturbed which causes cell cycle arrest. Phosphorylated-eIF2α, in 
some cases up-regulates activating transcription factor-4 (ATF4) expression to initiate 
CHOP regulation expression (Rao and Bredesen 2004). 
Dissociation of BiP from IRE1 is one aspect of UPR activation, and activated 
IRE1 acts as a ribonuclease (RNase), which splices the mRNA of X-box-binding 
protein-1 (XBP1). Consequently, the translational frame is shifted and spliced-XBP1 
encodes for ER chaperons and proteins implicated in ER-associated degradation 
(ERAD) (Rao and Bredesen 2004). Dissociation of BiP also causes the translocation of 
ATF6 to the Golgi, where it undergoes cleavage by serine protease site-1 (S1P) and 
metalloprotease site-2 protease (S2P) (Chen, Shen, and Prywes 2002; Nakanishi, Sudo, 
and Morishima 2005). This results in an active transcription factor being produced 
which is translocated to the nucleus and induces ER gene activation. 
1.7.2 CHOP 
CHOP, also known as growth arrest and DNA damage inducible protein 153 
(GADD153), is a member of the C/EBP (CCAAT-enhancer binding protein) group of 
proteins which consists of C/EBPα, C/EBPβ, C/EBPγ, C/EBPδ, and C/EBPε; CHOP is 
the newest member of this group identified by Ron and Habrer (1992). CHOP is able to 
dimerise with other C/EBP members and act as a dominant-negative inhibitor 
(McCullough et al. 2001). Once dimerised, it impairs the C/EBP binding site thus 
inhibiting C/EBP expression.  
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Figure 1.13: Schematic of the unfolded protein response activation 
The UPR is activated via three ER transmembrane proteins: 1) PKR-like eukaryotic initiation 
factor 2α kinase (PERK), (2) inositol requiring enzyme-1 (IRE1); and (3) activating 
transcription-6 (ATF6). The activated protein receptors subsequently activate ER chaperons to 
alleviate the ER stress condition. 
(Modified from (Pluquet, Pourtier, and Abbadie 2015)) 
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1.8 Hypothesis 
In this study, it is hypothesised that pax7 is misregulated and the restoration of 
minidystrophin to dystrophin-deficient myoblasts can repair/improve/mitigate the 
dynamics of the protein signalling pathway of PTEN-PI3K/Akt/mTOR, PLC and PKC, 
as well as alleviate ER stress. 
1.9 Aim and Objectives 
The goal of this project is to understand Pax7 expression patterns and the underlying 
protein signalling pathway in dystrophin-deficient myoblasts and to establish whether 
minidystrophin can fully or partly improve this condition. To achieve this goal, several 
objectives need to be completed and are listed below: 
1. Determine Pax7 expression patterns and its transport protein in dystrophin-
deficient myoblasts  
It has been reported that the Pax7 expression level is decreased in mdx embryos upon 
gestation (Merrick et al. 2009). However, no study has described the levels in vitro, 
specifically in dystrophin-deficient myoblasts. The first objective is to determine Pax7 
expression patterns sub-cellularly in dystrophin-deficient myoblasts. This was achieved 
via immunofluorescence labelling, as well as immunoblotting. In silico analysis, 
immunoprecipitation and co-immunoprecipitation technique s are used to examine 
candidates for Pax7 transport, generally known as karyopherins that are responsible for 
facilitating the transport of Pax7 within the nucleocytoplasmic machinery. 
 
2. Investigate the PTEN-PI3K/Akt/mTOR signalling pathway and autophagy 
modulation in dystrophin-deficient myoblasts during differentiation 
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PI3K/Akt/mTOR is a conserved pathway that is activated via the IGF-IR by Igf-1. It 
has previously been reported that Igf-1 is responsible for myoblast differentiation and 
that Igf2 triggers myoblast differentiation which controlled by mTOR at the 
transcriptional level (Erbay et al. 2003). The second objective is therefore to investigate 
PTEN-PI3K expression in the control of the Akt/mTOR signalling pathway and 
autophagy modulation in dystrophin-deficient myoblasts. This is achieved by using 
immunoblotting methods to determine protein expression levels and 
immunofluorescence for protein localisation. Flow cytometry is used for autophagy flux 
analysis.  
3. Investigate the relationship between PTEN elevation and ER stress events in 
dystrophin-deficient myoblasts during differentiation  
A previous study showed that ER stress occurs during myoblast differentiation and 
consequently the UPR is activated. During ER stress unfolded and misfolded proteins 
accumulate in the ER lumen. In the short term, the UPR inhibits protein synthesis but 
in the longer term it leads to adaptive changes, such as an increase in ER protein folding 
chaperones. If this is not sufficient to alleviate the stress, apoptosis will occur. Therefore 
the third objective is to investigate the effects of PTEN overexpression in differentiating 
dystrophin-deficient myoblasts on PLC and PKC regulation which subsequently affects 
ER stress and UPR activation. Immunoblotting is used to determine protein expression 
levels during differentiating stages. 
4. Examination of the effects of minidystrophin restoration in dystrophin-deficient 
myoblasts during differentiation 
The absence of dystrophin within a myoblast causes impairments in myoblast 
differentiation. As full-length dystrophin is very large, minidystrophin restoration will 
be used to test whether it can improve protein signalling and subsequently improve the 
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effectiveness of myoblast differentiation. Therefore, the fourth objective is to examine 
the effects of minidystrophin restoration within dystrophin-deficient myoblasts. 
PI3K/Akt/mTOR, as well as PLC, PKC and UPR activation, are examined via 
immunoblotting techniques.  
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Chapter 2 - Materials and Methods 
2.1 Tissue Culture Techniques 
Sterile techniques were applied throughout whilst handling all cell lines, culture media 
and cell culture reagents within the tissue culture room. This room was kept in a clean 
condition to avoid any contamination.  
2.1.1 Cell Lines 
The C2C12 myoblast cell line was used in this study, and was established from an adult 
mouse myoblast C2 cell line derived from the thigh muscle of a 2-month-old mice. The 
dfd13 cell line was derived from a 5 week-old mdx mouse (Smith and Schofield 1994; 
Smith and Schofield 1997). Mouse embryonic fibroblast (MEF) cells were a gift from 
Adil Rashid, University of Birmingham, and were used as a control for the 
phosphorylation of Akt at threonine-308. 
2.1.2 Thawing Cell Lines 
Before taking a vial containing cells out from the liquid nitrogen tank, the growth 
medium (GM) was pre-warmed in a water bath at 37°C, and approximately 5 mL of 
growth medium was added to a new falcon tube. The vial was taken out and quickly 
thawed in a 37°C water bath until three-quarters melted, before transferring the cells to 
the falcon tube and subjecting them to centrifugation for 3 minutes at 1200 rpm. The 
supernatant was discarded and the pelleted cells re-suspended in 5 mL growth medium 
before repeating the centrifugation step. The supernatant was again discarded and the 
cells re-suspended in 5 mL growth medium and transferred to a T25 flask with a filter 
cap before being incubated in a 37°C incubator supplied with 5% CO2 overnight. The 
cells were monitored and observed daily under a microscope and sub-cultured when 
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they reached 70% to 80% confluence, as greater than 80% confluency will cause cells 
to differentiate. 
2.1.3 Sub-culture of Cell Lines 
After 2 or 3 days of culture, or when ~70% to 80% confluence was reached, cells were 
sub-cultured into a new flask using the 1:10 ratio. The spent medium was removed and 
the cells rinsed twice with phosphate buffered saline (PBS). Approximately 1 mL of 
trypsin-EDTA was added and the cells were incubated in a 37°C incubator supplied 
with 5% CO2 for 3 minutes to allow the cells to detach. The flask was then knocked 
gently and observed under a microscope to check whether the cells had fully detached 
from the surface. Approximately 1 mL of growth medium was added to stop the trypsin-
EDTA reaction and the cells were then split using the 1:10 ratio into new flasks or 
frozen down for stocks. 
2.1.4 Freezing Down Cell Lines 
After trypsinisation the cells were collected by centrifugation at 1200 rpm for 3 minutes, 
and the supernatant discarded and the pelleted cells resuspend in 5 mL growth medium. 
The centrifugation step was then repeated, the supernatant replaced with freezing 
medium (growth medium + 10% DMSO), and the cells aliquoted into labelled vials. 
The vials were stored in a -80°C freezer overnight prior to transfer into a liquid nitrogen 
tank the following day. 
2.2 Determination of the Cell Number 
A haemocytometer was used to determine the number of cells. After trypsinisation, 
approximately 10 µL of the cell suspension was removed and pipetted slowly onto the 
haemocytometer with cover glass on it (Figure 2.1). Both counting chambers were filled 
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with cells and placed under an inverted microscope in order to visualise the cells within 
the large square (grids) of the haemocytometer (Figure 2.1). The cells were counted and 
the total cell number was calculated according to the formula: 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 2.1: Haemocytometer for counting the cell number 
Cells were pipetted between the slide and cover slip prior to counting the number of cells on 
the numbered grids. 
1 
4 3 
2 
×     104    ×   
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Average cell number counted 
4 squares 
= 
 44 
2.3 Production of Pax7-FLAG and Mini-Dystrophin∆H2-R19 Myoblasts 
2.3.1 Bacterial Culture for Plasmid Amplification 
Bacterial stocks containing recombinant plasmid and control plasmid (obtained from 
Dr. Chen Hung-Chih) were removed from a -80°C freezer and thawed on ice. 
Approximately 200 µL of bacterial stock was added to 250 mL of Luria-Bertani (LB) 
medium containing 100 µg/mL ampicillin (Sigma Aldrich, UK) and incubated with 
vigorous shaking at 37°C in incubator shaker (INNOVA™ 433, New Brunswick 
Scientific) for ~18 hours. The cultures were then transferred into universal tubes and 
subjected to centrifugation (Avanti™ 30 centrifuge, Beckman Coulter, UK) at 4°C for 
10 minutes before proceeding with the plasmid purification. 
2.3.2 Plasmid Purification using the PureYield™ Plasmid MaxiPrep 
System 
Recombinant plasmids were purified using the commercial kit PureYield™ Plasmid 
MaxiPrep System (Promega, UK), and the purification was performed according to the 
manufacturer’s protocol. The cultures were pelleted by centrifugation at 6000 rpm 
(Avanti 30 centrifuge, Beckman Coulter, UK) at 4°C for 10 minutes and cells lysed 
using the cell lysis solution before subjecting to centrifugation at 6000 rpm at 4°C for 
30 minutes. The pellets were discarded and the supernatant transferred to a new tube 
for the plasmid purification step. A special binding column attached to a vacuum 
manifold was used to obtain plasmid DNA. To the column bound-plasmid, endotoxin 
removal solution was added to eliminate endotoxin contamination before washing and 
eluting the plasmid DNA in nuclease-free water. The yield was determined via optical 
density (OD) readings. 
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2.3.3 Introduction of the Pax7-FLAG Plasmid into Myoblasts via the K2® 
Transfection System  
K2 transfection system is based on powerful cationic lipids. It is also containing 
multiplier which decreased cells’ ability to detect nucleic acids thus reduced defense 
modus activation (immune system activation). Approximately 9.0 x 105 myoblasts were 
added to a 6 well-plate and cultured until 90% to 100% confluence was reached. When 
the cell growth coverage area is at its strongest them this allows the uptake of plasmid 
DNA into the nucleus through the break up and rebuilding of the core membrane during 
cell division. Approximately 2.4 µg of plasmid DNA was introduced into both C2C12 
and dfd13 myoblasts. 
2.3.4 Introduction of the Minidystrophin-eGFP Plasmid into Myoblasts 
using Lipofectamine® LTX and PLUS™ Reagents  
Transfection of minidystrophin-eGFP myoblasts was undertaken by Dr. Chen Hung-
Chih during his doctoral research under the supervision of Dr. Janet Smith (Hung-chih 
2013). A schematic of minidystrophin-eGFP is illustrated in Figure 2.2. Selection of the 
transfectants was performed by myself. Approximately 3 x 105 myoblasts were plated 
in a 24-well plate and cultured until they reached 80-100% confluence. About 1.5 µg of 
plasmid DNA was diluted in 100 µL of SFM and 1.5 µL of PLUS™, and the mixture 
mixed and incubated at room temperature for 5 minutes. Lipofectamine® LTX was then 
added and incubated for 20 minutes at room temperature. Cells were washed with SFM 
during the DNA-liposome complex formation and after 20 minutes of incubation the 
DNA-liposome complex was dropped onto the cells and incubated for at least 16 hours 
at 37°C. The medium was replaced with fresh medium and cultured for 24 hours before 
selection.  
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2.3.5 Transfectant Selection and Verification 
All the cells were selected for stable plasmid expression  of minidystrophin-eGFP. The 
cells were selected by culture in growth medium containing 800 µg/mL of geniticin 
(G418; Invitrogen, UK). The medium was changed every two days until the colonies 
derived from the transfectants appeared and non-transfected cells died when treated 
with geniticin. Transfectants were picked and transferred to a 25cm flask in order to 
expand the culture. For further verification of the selected cells, immunoblots and 
immunofluorescence techniques were performed to confirm the effectiveness of the 
transfection. Details of the antibiotics for the selection of are listed in Table 2.1. 
 
Figure 2.2: Schematic of pCR3.1 EGFP-minidystrophin 
(From Chapdelaine et al., 2000) 
 
Table 2.1: Plasmids used in this study and selection markers 
Plasmids Antibiotic selection markers Gentamycin selection 
pBRIT-Pax7-FLAG 
Ampicillin 
- 
pBRIT His/FLAG - 
pCR3.1-minidystrophin-eGFP 
Kanamycin 
+ 
pCR3.1-eGFP + 
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2.4 Preparation of Cells for Immunofluorescence  
2.4.1 Preparation of Acid Etching Cover Slips  
Cover slips (9 mm2) were placed in a beaker without overlapping and concentrated nitric 
acid was carefully added onto the cover slips in a fume hood and left for 5 minutes. 
Used nitric acid was transferred into another beaker filled with water and poured down 
the sink with copious tap water. Acid-etched cover slips were washed under running tap 
water for at least 1 hour before soaking in methanol and transferring onto a tissue culture 
hood to allow complete evaporation overnight. Acid etched-cover slips were sterilised 
by baking.  
2.4.2 Cell Fixation  
Culture medium was removed and cells washed with PBS at room temperature for 5 
minutes on a shaker. Cells were fixed by adding 4% paraformaldehyde (PFA) to each 
well and the cells were incubated at room temperature for 10 minutes on a shaker. Each 
well was rinsed twice in PBS containing 30mM glycine for 5 minutes and then PBS 
containing 50% glycerol + 0.01% sodium azide was added to each well. The plate was 
then sealed with tape and stored at 4°C for not more than one week. 
2.4.3 Immunofluorescence - Single Labelling   
After fixation cells were permeabilised with 0.25% triton X-100 for 5 minutes to allow 
the antibody to bind specifically. The cells were then washed three times for 5 minutes 
with PBS before blocking with 5% BSA at room temperature for 30 minutes. The 
blocking solution was removed and the cells incubated with the primary antibody 
according to the optimised dilution (  
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Table 2.2) at 4°C overnight. 
The primary antibody was removed the next day and the cells washed three 
times for 10 minutes with PBST. The primary antibody was probed using a secondary 
antibody (biotinylated) according to the optimised dilution (  
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Table 2.2) for 1 hour at room temperature. The cells were washed three times 
with PBST for 10 minutes before being incubated with streptavidin-Texas red (1:1000) 
at room temperature for 1 hour in the dark. The cells were then counterstained with 
DAPI (1:100) for 3 minutes and washed three times with PBST for 10 minutes at room 
temperature in the dark before rinsing with PBS and mounted onto slides using 
DakoCytomation. The slides were wrapped in aluminium foil and stored at 4°C. 
2.4.4 Immunofluorescence - Double Labelling  
The same steps as for single labelling were applied up until the washing step following 
incubation with streptavidin-Texas red. The cells were washed three times with PBST 
for 10 minutes in the dark  and then incubated with the secondary antibody again for 30 
minutes to block the binding of the second primary antibody and avoid cross-reactions 
with the first primary antibody. The cells were washed three times with PBST for 10 
minutes before being incubated with the second primary antibody according to the 
optimised dilution (  
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Table 2.2) at 4°C overnight.   
The following day the primary antibody was removed and the cells washed three 
times with PBST for 10 minutes before being probed with the secondary antibody IgG-
Alexa488/IgG-FITC at room temperature in the dark. The cells were counterstained 
with DAPI (1:100) for 3 minutes and washed with PBST three times for 10 minutes. 
The cells were rinsed with PBS before being mounted onto slides using 
DakoCytomation. The slides were wrapped in aluminium foil and stored at 4 °C. 
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Table 2.2: Antibodies used in immunofluorescence 
The tertiary antibody for pax7 was streptavidin-Texas red (1:1000) 
Primary Antibody (Titre) Secondary Antibody (Titre) 
Mouse monoclonal anti-pax7 (1:500) Anti-mouse IgG biotinylated (1:1000) 
Mouse monoclonal anti-myosin (Skeletal-Fast) (1:100) Anti-mouse IgG-Alexa594 
Rabbit polyclonal anti-Akt (1:500) 
Anti-rabbit IgG-Alexa488 (1:500) 
Rabbit polyclonal anti-Akt (Phospho-Ser473) (1:200) 
Rabbit polyclonal anti-GM130 (1:200) 
Rabbit polyclonal anti-Rab11 (1:200) 
Mouse polyclonal anti-Ca2+ATPase (1:200) 
Anti-mouse IgG-FITC (1:500) Mouse polyclonal anti-CD107a (1:200) 
Mouse polyclonal Anti-KPNA2 (1:100) 
 
2.5 Protein-Protein Interaction Assay 
2.5.1 Immunoprecipitation Assay  
In this study, Pax7 and importin13 were immunoprecipitated using a protein A 
sepharose CL-4B bead slurry. KPNA2 and FLAG were immunoprecipitated using 
Dynabeads® Protein G magnetic beads. 
2.5.1.1 Protein A Sepharose CL-4B Beads Slurry Preparation 
Approximately 2.5 µg of protein A sepharose (powder form) was suspended in 50 mL 
distilled water in order to eliminate soluble stabilisation agents. The beads were spun 
down at 2500 rpm at room temperature and the supernatant discarded; this step was 
repeated 2 more times. The beads were then suspended in 20% ethanol to avoid them 
drying out. 
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2.5.1.2 Immunoprecipitation using a Protein A Sepharose CL-4B Beads Slurry 
Approximately 100 µg of cell lysate was diluted with lysis buffer and about 20 µL of 
the protein A sepharose CL-4B beads slurry added to the lysate. The mixture was 
subjected to centrifugation at 2500 rpm for 1 minute, and the pellet discarded. 
Approximately 1 µg of antibody was added to the supernatant (pre-cleared lysate) and 
incubated at 4 °C for 2 hours on a rotator. Next, 30 µL of the protein A Sepharose CL-
4B beads slurry was added into the antibody-protein complex and incubated at 4 °C 
overnight. 
The mixture containing the complex-bound beads was subjected to 
centrifugation at 2500 rpm for 1 minute. The supernatant was discarded and the pellet 
washed with 30 µL TBS (50 mM Tris-HCl; 150 mM NaCl pH7.4). The centrifugation 
step was repeated and the pellet resuspended in 20 µL sample buffer and heat-denatured 
at 95 °C for 7 minutes. The mixture was subjected to centrifugation at 13000 rpm for 1 
minute and the supernatant used in Western blot analysis. 
2.5.1.3 Dynabeads® Protein G Magnetic Beads   
Dynabeads® Protein G magnetic beads were vortexed for about 30 seconds and 
approximately 50 µL of Dynabeads transferred to a new tube and placed on a magnet 
to separate the beads from the solution. The supernatant was removed and antibody 
diluted in 200 µL PBST (PBS containing 0.02% Tween20) added, before being were 
incubated with rotation at room temperature for 10 minutes. The tube was placed on a 
magnet for bead separation and washed with 400 µL PBST. Approximately 500 µg cell 
lysate was added to the beads and the mixture incubated with rotation for 30 minutes at 
room temperature. Next, the tube was placed on a magnet and the supernatant discarded 
before washing the beads three times with ice-cold PBST. About 20 µL of sample buffer 
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was added to the cleaned beads which were resuspended before being boiled at 95°C 
for 7 minutes. 
2.5.2 Antibody Crosslinking  
Antibody crosslinking was performed to avoid non-specific binding of antibodies raised 
is the same host. The crosslinking step was performed at the beginning of 
immunoprecipitation procedure. After the Dynabeads had been incubated with the 
antibody for 10 minutes, the tube was placed on a magnet for bead-solution separation. 
The supernatant was discarded and the beads washed with PBST, followed by two 
washes in washing buffer (0.2 M triethanolamine, TEA; Sigma-Aldrich, UK, in PBS). 
The antibody-bound beads were resuspended in crosslinking buffer (20 mM dimethyl 
pimelidate dihydrochloride (DMP; Sigma-Aldrich, UK, in wash buffer) and incubated 
at room temperature for 30 minutes on a rotator. The tube was placed on a magnet for 
bead-solution separation and the supernatant discarded. The beads were washed three 
times with quenching buffer (0.05 M tris-HCl pH7.5) for 15 minutes on a rotator before 
approximately 500 µg of cell lysate (diluted in lysis buffer up to 1 mL) was added, and 
then incubated at room temperature for 30 minutes on a rotator. The tube containing the 
Dynabeads-Ab-antigen complex was washed three times with ice-cold PBS  and the 
complex resuspended in sample buffer and boiled for 7 minutes at 95 °C prior to 
Western blot analysis. 
2.6 Protein Assay  
2.6.1 Total Protein Extraction 
Protein was extracted from cells cultured in a 10 cm dish. The medium was removed 
and the cells washed twice with PBS  before adding approximately 300 µL of lysis 
buffer (0.5% triton X-100, 0.5% deoxycholic acid; 0.15 M NaCL; 0.02 M Tris; 0.01 M 
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EDTA, pH 7.5) containing a protease inhibitor (complete ULTRA tablets, EDTA-free, 
protease inhibitor cocktail, Roche, UK). The cells were scraped and collected into a 
tube before being subjected to centrifugation at 14000 rpm for 15 minutes at 4 °C. The 
pellet was discarded and the supernatant transferred to a new tube and stored at -20 °C. 
2.6.2 Protein Sub-Fractionation  
The rapid efficient and practical (REAP) protocol was used for protein sub-fractionation 
(Suzuki et al. 2010). All reagents were chilled and kept on ice all times. The medium 
was removed and the cells washed three times with PBS before adding approximately 
1 mL of ice-cold PBS. The cells were scraped and collected into a new tube and pop-
spun for 10 seconds and the supernatant discarded. The pellet was  resuspended in  900 
µL of ice-cold PBS containing 0.1% nonyl-phenoxypolyethoxylethanol (NP-40)  and 
approximately 300 µL was removed to a new tube labelled as whole cell lysate (WCL). 
The remaining cells were pop-spun for 10 seconds and approximately 300 µL was 
transferred to a new tube labelled as the cytosolic fraction, while the remainder of the 
supernatant was discarded. The pellet was washed with 1 mL of PBS  containing 0.1% 
NP-40) and pop-spun for 10 seconds; this step was repeated 2 to 5 times to eliminate 
the cytosolic fraction. After washing was completed this was considered to be the 
nuclear fraction. The cytosolic fraction was also pop-spun 3 times to separate the 
remaining nuclear fraction. Both the WCL and nuclear fraction were sonicated three 
times for 10 seconds and boiled for 1 minute. 
2.6.3 Determination of the Protein Yield 
While working with protein it was placed on ice at all times to avoid sample 
denaturation and to maintain protein stability. To determine the protein yield, unknown 
samples were diluted and compared with serial dilutions of bovine serum albumin 
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standards (BSA; Pierce, UK). BSA standards were diluted in sterile distilled water to 
obtain concentrations of 1, 2, 5, 10, 15 and 25 µg/mL, while the unknown samples were 
diluted in sterile distilled water at the ratios 1:100 and 1:400. Approximately 100 µL of 
the standards and samples were added to a 96-well plate (Nunc plasticware, UK) in 
triplicate. An equal volume of Coomassie Protein assay reagent (Pierce, UK) was added 
to each well and mixed thoroughly with the protein samples. The plate was read at 
λ=595 nm on microplate reader. The samples were stored in aliquots of 40 µL to avoid 
freeze-thawing which could damage them. 
2.7 Western Blot Analysis 
2.7.1 SDS-Poly-Acrylamide Gel Electrophoresis  
For specific protein detection, sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) was used for whole protein separation based on size 
through the use of different percentages of acrylamide within the gel. SDS with a net 
negative charge binds to polypeptide changes and is proportional to the molecular mass 
of the protein. It also destroys most of the complex structure of a protein. The percentage 
of acrylamide used depends on the size of the protein of interest (Table 2.3).  
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Table 2.3: Percentage of acrylamide in SDS-PAGE gels based on protein size 
Percentage of acrylamide (%) Range of protein separation (kDa) 
6 180> 
8 43 - 180 
10 26 - 72 
12 10 - 55 
15 10 - 34 
 
2.7.1.1 Electrophoresis 
Before preparing the SDS-PAGE mixture, the Bio-Rad electrophoresis gel apparatus 
was set up. Both gel casts were cleaned using 70% ethanol and the spacers inserted 
between two gel casts which were clipped together using the clipper. The resolving gel 
mixture contained 3.24 mL of dH2O, 1.84 mL of 30% acrylamide (Protogel, Geneflow, 
UK), 1.75 mL of 1.5 M Tris-HCl (pH8.8), 70 µL of 10% SDS, 70 µL of 10% sodium 
persulphate, and 7 µL of TEMED, which was thoroughly mixed and poured into the gel 
cast until three quarters full and left for 30 minutes until it polymerised. Onto the set 
resolving gel, the stacking gel was poured and a comb inserted into the gel. The 
resolving gel contained 1.4 mL of dH2O, 0.33 mL of 30% acrylamide (Protogel, 
Geneflow, UK), 0.25 mL of 1.5 M Tris-HCl (pH8.8), 20 µL of 10% SDS, 20 µL of 10% 
sodium persulphate, and 8.5 µL of TEMED, which was thoroughly mixed and left to 
polymerise for 30 minutes.  
Meanwhile the protein samples were prepared, and approximately 20 µg of each 
protein extract and 15 µg of embryonic samples were loaded into each well. The 
samples were mixed with 2.5 µL of 6X sample buffer and dH2O was added to make up 
the final volume to 15 µL. The samples were boiled at 100°C for 5 minutes and placed 
on ice. The comb was slowly removed from the gel to avoid tearing the wells and the 
gel holder unclipped. The gel was placed in the middle of the electrophoresis tank with 
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the plastic plates slipped next to it, and the tank fully filled with SDS running buffer. 
Both the samples and pre-stained protein markers (New England Biolabs, Ltd, UK) 
were loaded using a pipette. The gel was run at 70V until the dye front reached the end 
of the gel. 
2.7.2 Transfer Blotting using the Trans-Blot® Turbo™ Blotting System 
After the samples had been separated on the gel, the glass plates were removed from 
the tank, the plates separated and the stacking gel removed using a scalpel. Distilled 
water was used while handling the gel as the running buffer contained detergent which 
made the gel slippery. The Trans-Blot TurboTM Transfer System was then used to 
transfer the separated proteins from the gel onto a nitrocellulose membrane.  
2.7.3 Hybridisation, Detection and Analysis 
The nitrocellulose membrane with the transferred proteins were blocked with blocking 
buffer (TBS, non-fat milk, Tween20) for 1 hour at room temperature on a shaker before 
incubating the membrane with primary antibody and sealed into a plastic bag at 4°C 
overnight on a shaker. The following day the membrane was washed three times with 
washing buffer (TBS with 0.1% Tween20) for 10 minutes. The membrane was probed 
with a biotinylated secondary antibody for 1 hour at room temperature on a shaker with 
vigorous agitation before washing three times with TBS for 10 minutes. The membrane 
was probed with the detection labelling agent streptavidin-conjugated DyLight 800 for 
30 minutes at room temperature whilst protected from light and after three times 
washes, was ready to be examined using an Odyssey infrared imaging system (Li-Cor 
Biotech, UK). A list of the antibodies used with specific titre details is provided in Table 
2.4. 
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Table 2.4: Antibodies used in Western blotting analysis 
The tertiary antibody for all was DyLight(TM) 800 Conjugates-Streptavidin (1:20,000) 
Primary Antibody (Titre) 
Secondary 
Antibody (Titre) 
Mouse monoclonal anti-pax7 (1:500) 
Anti-mouse IgG 
biotinylated 
(1:10,000)  
Mouse monoclonal anti-myosin (Skeletal-Fast) (1:1000) 
Mouse polyclonal Anti-Desmin (1:500) 
Monoclonal Anti-α-Tubulin antibody produced in mouse (1:10,000) 
CHOP monoclonal antibody produced in mouse (1:500) 
Mouse anti-PKC-ε (1:1000) 
Mouse monoclonal anti-ATF6 (1:1000) 
Rabbit polyclonal anti-PKC-ε (phospho-S729) (1:1000) 
Anti-rabbit IgG 
biotinylated 
(1:10,000) 
Rabbit polyclonal anti-PTEN (1:1000) 
Rabbit polyclonal anti-PI3K p85 (1:1000) 
Rabbit polyclonal anti-PI3K p85 (phospho-Tyr458) (1:1000) 
Rabbit polyclonal anti-Akt (1:1000) 
Rabbit polyclonal anti-Akt (phospho-Ser473) (1:1000) 
Rabbit polyclonal anti-Akt (phospho-Thr308) (1:1000) 
Rabbit monoclonal anti-Rictor (1:1000) 
Rabbit monoclonal anti-Rictor (phospho-Thr1135) (1:1000) 
Rabbit polyclonal anti-mTOR (1:1000) 
Rabbit polyclonal anti-mTOR (phospho-Ser2448) (1:1000) 
Rabbit polyclonal anti-p70S6K (phospho-Thr389) (1:1000) 
Rabbit polyclonal anti-p70S6K (1:1000) 
Rabbit monoclonal anti-FoxO3a (1:1000) 
Rabbit monoclonal anti-Beclin1 (1:1000) 
Rabbit monoclonal anti-Atg5 (1:1000) 
Rabbit monoclonal anti-Atg7 (1:1000) 
Rabbit monoclonal anti-LC3A/B (1:1000) 
Rabbit monoclonal anti-PLCγ1 (1:1000) 
Rabbit monoclonal PLC-γ1 (phospho-1248) (1:1000) 
Rabbit polyclonal anti-PKC-α/βII (phospho-Thr638/Thr641) (1:1000) 
Rabbit polyclonal anti-PKC-βII (pan) (phospho-Ser660) (1:1000) 
Rabbit polyclonal anti-ERK1/2 (1:1000) 
Rabbit polyclonal anti-Phospho-ERK1/2 (phospho-Thr202/Tyr204) (1:1000) 
Rabbit monoclonal anti-eIF2α (phospho-Ser51) (1:1000) 
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2.8 Autophagy Assay - Live Cell Analysis by Flow Cytometry 
2.8.1 Cell Labelling 
An autophagy assay was performed using a CYTO-ID Autophagy Detection Kit (Enzo 
Life Science, Switzerland) and 1 x 105/mL myoblasts were added to every well in a 24-
well plate and maintained via standard tissue culture practice. Cells were grown in a 
humidified incubator at 37 °C and 5% CO2; cells were not allowed to become over-
crowded and the density should not exceed 1 x 106 /mL. In this experiment 60 mM of 
chloroquine was used as positive control, while unstained cells were utilised as a 
negative control. Myoblasts were treated with chloroquine for 4 hours in a humidified 
incubator at 37 °C and 5% CO2. At the end of the treatment cells were trypsinised and 
collected into a fresh 1.5 mL microtube. Cells were subjected to centrifugation for 5 
minutes at 1000 rpm at room temperature and washed by re-suspending in 1x assay 
buffer and the centrifugation step repeated. Each cell pellet was then re-suspended in 
250 µL of 1x assay buffer. Approximately 250 µL of the diluted CYTO-ID Green stain 
solution was added to all the cells except the negative control, and incubated for 30 
minutes at room temperature in the dark. The cells were collected by centrifugation, 
washed with 1x assay buffer, and the pelleted cells re-suspended in 500 µL of 1x assay 
buffer. The samples were analysed using the green (FL1) channel of a flow cytometer. 
2.8.2 Flow Cytometer 
Experiments were performed using a FACS Analyser CyAn B (Beckman Coulter, USA) 
at the Institute of Biomedical Research, University of Birmingham. Samples were run 
using Summit V4.3 software and all data were saved in the fcs format developed by the 
Society of Analytical Cytology, thereby allowing further analysis using other software 
packages. Data were analysed using the software FCS Express 6 Plus (De Novo 
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Software, USA) for  three parameters; side scatter (SS), forward scatter (FS) and 
Fluorescein Isothiocyanate (FITC). Gating was performed based on the size and 
complexity of the myoblasts as illustrated in density plots. Gated data were further 
analysed to count myoblasts labelled with FITC and the results presented in a histogram 
format. 
2.9 Statistical Analysis 
All Western blots were repeated at least three times for different protein samples 
obtained at different times/experiment. Statistical analyses were carried out using the 
student t-test (Microsoft Excel) and differences were considered significant at p<0.05 
and p<0.01. Standard error was obtained using analysis of variance (ANOVA) in 
Microsoft excel. 
2.10 Microscopy 
Images were taken using a confocal microscope (Nikon A1R) under 60x magnification 
and were analysed/edited using the NIS element software provided by Nikon 
Corporation. The images were analysed using NIS-elements provided by Nikon® 
Instruments using object based overlap analysis (ROI). The image was first selected 
using ROI properties and then separated into a monochrome image and converted into 
a binary image prior to the threshold. Each binary image was processed using a binary 
operation to create binary overlays that only exist when the green and red channel 
signals overlap. Each analysis was repeated at least three times for different samples 
obtained at different times/experiment. 
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Chapter 3 - Mislocalisation of Pax7 and its Interaction with 
Importin-Α1 (KPNA2) in Dystrophin-Deficient Myoblasts  
3.1 Introduction 
Earlier, our group has reported that Pax7 cell is attenuated in the mdx embryo during 
gestation. Pax7 cell fragments have also been found in dystrophic muscle, indicating 
that the cells are undergoing apoptosis. Immunoblot analysis of whole embryos showed 
that Pax7 expression was also substantially reduced with age (Merrick et al. 2009). This 
finding has led to the suggestion that dysregulation of Pax7 takes place in MD as early 
as during the embryonic stages. Therefore, in this study the Pax7 expression pattern has 
been further examined during the postnatal/juvenile stage in Pax7 myoblasts isolated 
from a 5-week old mdx mouse. 
As a transcription factor, Pax7 is mainly found in the nucleus of myoblasts, but 
surprisingly, it has been found not only in the nucleus, but also found in cytoplasmic 
region (i.e. organelles) of dystrophin-deficient myoblasts. However, there are a lack of 
studies to show what actually happens to Pax7 in dystrophin-deficient myoblasts. There 
may be a problem in protein trafficking in or out of the nucleus which involves the 
importin and exportin mediated pathway, or there could be an alteration in the NLS 
which causes the failure of Pax7 to bind to importins. This could be the cause of the 
failure of these cells to be differentiated into mature myotubes prior to the development 
of muscle tissue.  
Initially, the capacity of dystrophin-deficient myoblast differentiation was 
investigated. Analysis of myotube formation was performed by examining the 
morphology of myotubes and the expression of specific MyHC as a terminal 
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differentiation marker. The expression of Pax7 upon differentiation was determined. 
Furthermore, the cytoplasmic-Pax7 subcellular localisation, i.e. endoplasmic reticulum, 
golgi, recycling endosome and lysosome, for protein synthesis and degradation was 
examined using subcellular markers. Finally, protein prediction tools were utilised 
which suggested that a Pax7-karyopherin protein interaction is responsible for nuclear 
localisation.  
3.2 Results  
3.2.1 Dystrophin-Deficient Myoblasts Do Not Achieve Terminal 
Differentiation 
In vitro differentiation of myoblasts can be induced in culture through the use of a low 
mitogen medium (2% horse serum) for a few days. In this study, both C2C12 (non-
dystrophic) and dfd13 (dystrophin-deficient) myoblasts were cultured in low mitogen 
medium (differentiation medium; DM) for 10 days prior to determining their terminal 
differentiation capacity. Immunofluorescence analyses (Figure 3.1) showed both non-
differentiated and differentiated myoblasts. Multinucleated myotube formation can be 
clearly seen on day 10 of differentiation in C2C12 (Figure 3.1A) myoblasts but is 
hardly/rarely found in dfd13 myoblasts where less multinucleated cells were observed 
(Figure 3.1B). This indicates that dfd13 differentiation capacity is impaired; however, 
the differentiating dfd13 myoblasts can be seen to be aligned and seem to be ready for 
cell fusion to become myotubes.  
Myotube formation was determined by counting the myonuclei present in a 
myotube that expressed MyHC (fast-type II, F-MyHC) and then normalised against 
total nuclei. F-MyHC, also called ‘fast-twitch’ fibres, were chosen as the terminal 
differentiation marker based on the existence of a spectrum of fibre types, with type II 
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being the most developed form of myosin: type 1 ↔ 1/2A ↔ 2A ↔ 2A/2X ↔ 2X ↔ 
2X/2B ↔ 2B (Schiaffino and Reggiani 2011). The number of myonuclei in C2C12 
myotubes was 9-fold higher compared to myonuclei in differentiating dfd13 myoblasts 
(p<0.01; p = 2.9x10-3). The percentage of myonuclei per total nuclei was 80.2% ± 8.2 
in C2C12 myotubes and 8.2% ± 6.6 in differentiating dfd13 myoblasts (Figure 3.1C) 
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Figure 3.1: Dystrophin-deficient myoblasts formed less myotubes  
Approximately 1.5 x 104 of both C2C12 (non-dystrophic) and dfd13 (dystrophin-deficient) 
myoblasts were cultured in GM before being transferred to DM and allowed to differentiate for 
10 days in a 48-well plate (on acid-etched cover slip). On day 10 cells were fixed in 4% PFA 
and stained with an anti F-MyHC antibody, while DAPI was used as a nuclear counterstain. 
Immunofluorescence analysis of F-MyHC in (A) C2C12 and (B) dfd13 cells during the non-
differentiated stage and after 10 days of differentiation. (C) Percentage myotube formation was 
calculated by counting the nuclei present in myotubes (myonuclei) per total nuclei from 10 
random microscope fields. ND: non-differentiated; significant different: ** (p<0.01) compared 
to C2C12 myoblasts; GM: growth medium (DMEM + 10% FCS); DM: differentiation medium 
(DMEM + 2% horse serum); n=3. 
Immunoblotting for F-MyHC, pan-myosin and desmin was performed on days 4, 7 and 
10 of differentiation (Figure 3.2A). Generally, F-MyHC expression was increased upon 
differentiation in C2C12 myoblasts but none of the differentiating dfd13 myoblasts 
showed any expression (Figure 3.2B). However, pan-myosin was expressed at day 10 
in dfd13 myoblasts (Figure 3.2C), and there was a significant difference in expression 
(p<0.01; p = 7.78 x 10-3) when compared to C2C12 myoblasts. Desmin expression in 
both myoblasts was also examined and was found to be drastically increased upon 
differentiation, in C2C12 myoblasts. In differentiating dfd13 myoblasts, desmin 
expression gradually increased over the 10 days and was significantly higher (p<0.01; 
p = 2.24 x 10-3) in comparison to levels in C2C12 myotubes (day 10) (Figure 3.2D). 
Desmin was used as an intermediate differentiation marker and is a muscle specific type 
 ** 
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II intermediate filament that integrates the sarcolemma, Z-disk and nuclear membrane 
in myoblasts. An in vivo study by Smythe et al. (2001) indicated that desmin expression 
is up-regulated during myogenesis and demonstrated that desmin(-/-) showed delays in 
myotube regeneration 5 days after  transplantation when compared to the control where 
desmin was detected (Smythe et al. 2001). Desmin also has been reported overexpressed 
at molecular level in DMD patient (Haslett et al. 2002). 
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Figure 3.2: Dystrophin-deficient myoblasts do not express fast-myosin heavy chain 
during differentiation 
Both C2C12 and dfd13 myoblasts were seeded in 10-cm dishes and cultured in GM until 80-
90% confluent. The myoblasts were washed twice with PBS and then cultured in DM for 10 
days, which was changed every 2 days. Total protein was extracted at the indicated time points 
and immunoblotted with antibodies recognising the proteins F-MyHC, pan-myosin (MF-20) 
and desmin. (A) Representative immunoblot of the proteins during myoblast differentiation 
with α-tubulin expression as a loading control. Densitometry analyses of (B) F-MyHC (MY-
32), (C) pan-myosin (MF20) and (D) desmin expression. The graphs represent an average of 
three repeats from different samples. ND: non-differentiated; **: significantly different 
(p<0.01) compared to dfd13 myoblasts. GM: growth medium (DMEM + 10% FCS); DM: 
differentiation medium (DMEM + 2% horse serum); n=3. 
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3.2.2 Pax7 Expression Remains Higher in Differentiating Dystrophin-
Deficient Myoblasts 
As Pax7 cells and Pax7 expression was found to be attenuated in mdx embryos, its 
expression in the postnatal/juvenile stage was investigated. C2C12 and dfd13 myoblasts 
were initially cultured in GM overnight or until they reached 90% confluence before 
being replaced with DM. The cells were harvested and subjected to whole protein 
extraction for ND (non-differentiated) and after 4, 7 and 10 days of differentiation. Each 
sample was immunoblotted with an anti-Pax7 antibody to examine the level of Pax7 
expression throughout the 10 days of differentiation.  
Immunoblotting (Figure 3.3) showed that Pax7 is highly expressed in both types 
of undifferentiated myoblasts, although slightly lower in dfd13 myoblasts. 
Densitometry analysis showed that the level of Pax7 expression in differentiating dfd13 
myoblasts was higher than in differentiating C2C12 myoblasts throughout the 10 days 
of differentiation. The level of Pax7 showed a significant reduction at day 4 (p<0.01; 
p= 4.85x10-3) and day 7 (p<0.05; p= 2.81x10-2) and was slightly increased at day 10 
(p<0.05; p=4.64x10-2) in the myogenic differentiation of C2C12 cells when compared 
to the non-differentiated state. However, Pax7 expression in differentiating dfd13 
myoblasts remained high until day 7 and had decreased by day 10 (p<0.05; p= 4.17x10-
2). There was a significant difference in Pax7 expression between both the 
differentiating C2C12 and dfd13 myoblasts on day 7 (p<0.05; p= 1.75 x 10-2). 
Pax7 is a transcription factor that plays role in gene regulation/activation during 
myogenesis. It has been reported that Pax7 directly regulates Myf5 (McKinnell et al. 
2008; Günther et al. 2013) however, up-regulation of Pax7 expression inhibits 
myogenic differentiation due to the down-regulation of myogenin (Olguin et al. 2007; 
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Olguín and Pisconti 2011), and differentiation onset is delayed. In this study, Pax7 
remained at a high level of expression 7 days after differentiation commenced, 
indicating that differentiation may be delayed in dfd13 myoblasts. However, there was 
a significant reduction in Pax7 on day 10 in dfd13 myoblasts, suggesting that dfd13 
myoblasts are prone to apoptosis. Pax7 acts as a survival factor in myotubes (Olguin et 
al. 2007; Olguín and Pisconti 2011), thus down-regulation of Pax7 may cause apoptosis.  
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Figure 3.3: Pax7 expression remains high in differentiating myoblasts 
Both C2C12 and dfd13 myoblasts were cultured in GM overnight. After reaching 90% 
confluence, myoblasts were washed with PBS and cultured for 10 days in DM which was 
changed every two days. Myoblasts were harvested at days 4, 7 and 10 and subjected to protein 
extraction prior to immunoblotting with an antibody recognising Pax7, with α-tubulin used as a 
loading control. (A) Representative immunoblot of Pax7 and α-tubulin expression. (B) 
Densitometry analysis of Pax7 expression. The graph represents an average of three repeats 
from different samples. ND: non-differentiated; Significant different: * (p<0.05) compared to 
C2C12 myoblasts. GM: growth medium (DMEM + 10% FCS); DM: differentiation medium 
(DMEM + 2% horse serum); PBS: phosphate-buffered saline; n=3. 
3.2.3 Pax7 is Mislocalised in Proliferating Dystrophin-Deficient Myoblasts  
To further examine the Pax7 expression pattern, both types of myoblasts were subjected 
to immunofluorescence and sub-fractionation analyses. Again there is a lack of studies 
on Pax7 regulation in myoblasts in terms of the post-translational modifications, i.e. 
phosphorylation events, as well as protein distribution. In this study, Pax7 expression 
 * 
α-tubulin 
Pax7 
C2C12 dfd13 
ND  
  
D4 D10 D7 ND D4 D10 D7 
A 
B 
 71 
and its distribution was assessed in dystrophin-deficient myoblasts, with C2C12 
myoblasts used as a control. 
In line with the role of Pax7 as a transcription factor, the immunofluorescence 
data showed the localisation of Pax7 within the nucleus of both types of myoblasts 
(Figure 3.4). However, it also showed that Pax7 was localised outside the nucleus, 
within the cytoplasm compartment. The pattern of Pax7 distribution was mostly 
perinuclear, and in the dfd13 myoblasts it  could also be found scattered within the 
cytoplasm (Figure 3.4). Pax7 was labelled with AlexaFlour®594 dye (red) in both types 
of myoblasts and counterstained with DAPI. The images were taken using a confocal 
microscope (Nikon A1R) and were analysed/edited using the NIS element software 
provided by Nikon Corporation. However, this analysis was not able to provide the 
exact amount of Pax7 expression in both compartments, thus immunoblotting analysis 
was performed.  
Cellular fractionation was performed for both types of myoblast during the 
proliferative stage. For protein yield validation, specific markers were used, including 
the structure-specific recognition protein-1 (SSRP-1) and α-tubulin for nuclear and 
cytoplasmic fractions, respectively. Immunoblots showed that SSRP-1 was not present 
in the cytoplasmic fraction and α-tubulin was completely absent from the nuclear 
fraction, indicated that these fractions were not contaminated with each other (Figure 
3.5A).  
Immunoblot analysis on the subfractionated myoblasts showed that about 27.5% 
of Pax7 in C2C12 cells was localised to the nucleus, while only 11.1% of Pax7 in dfd13 
myoblasts was localised to the nucleus (Figure 3.5B). Nuclear-Pax7 expression was 
normalised with SSRP-1, while cytoplasmic-Pax7 was normalised with α-tubulin. The 
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immunoblot data revealed that most Pax7 was found in the cytoplasm of both types 
myoblast (Figure 3.5B). The specific localisation distribution generally indicates that 
Pax7 is heading to an unknown protein event. For example, perinuclear Pax7 in C2C12 
cells could be due to Pax7 being abundantly synthesised in the cytoplasm and then 
retained in the cell during the undifferentiated stage where it is maintained by cell 
proliferation.  
Pax7 expression was found to be scattered throughout the cytoplasm of dfd13 
myoblasts. This observation shows that Pax7 is extensively mislocalised in dfd13 
myoblasts, suggesting that Pax7 is misregulated during the proliferative stage. 
Unpublished data from Chen (2013), showed that Pax7 was expressed at slightly higher 
levels in undifferentiated dfd13 myoblasts compared to undifferentiated C2C12 
myoblasts. However, there no data has previously reported on the level of Pax7 
expression in the nucleus and cytoplasm of myoblasts separately. Further examination 
of cytoplasmic-Pax7 in subcellular fraction was undertaken via co-localisation analysis.  
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Figure 3.4: Pax7 is more widely scattered in the cytoplasm of dystrophin-deficient 
myoblasts 
Approximately 1.5 x 104 C2C12 and dfd13 myoblasts were cultured in GM until 60-70% 
confluent in a 48-well plate. Both types of myoblast were fixed in 4% PFA and subjected to 
immunofluorescence labelling. Pax7 was labelled with AlexaFlour594 and the myoblasts were 
counterstained with DAPI. Immunofluorescence of Pax7 in C2C12 and dfd13 images were 
taken using a confocal microscope (Nikon A1R) and were analysed/edited using the NIS 
element software provided by Nikon Corporation. GM: growth medium (DMEM + 10% FCS);  
n=3. 
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Figure 3.5: Pax7 expression within the subcellular compartments of myoblasts 
Both C2C12 and dfd13 myoblasts were cultured in GM and when ~70% confluent were 
harvested and subjected to sub-fractionation prior to immunoblotting with an anti-Pax7 
antibody. SSRP-1 and α-tubulin were used as nuclear and cytoplasmic fraction control markers, 
respectively. (A) Immunoblot for Pax7 expression. (B) Densitometry analysis of Pax7 
expression in both types of myoblasts. WCL: whole cell lysate; Cyto: cytoplasmic; Nuc: 
nuclear; n=3. 
3.2.4 Pax7 May Undergo Protein Modification and Be Recycled in 
Proliferating Dystrophin-Deficient Myoblasts 
As indicated in Figure 3.4 and Figure 3.5, Pax7 was found to be expressed and more 
localised to the cytoplasm of dfd13 myoblasts compared to C2C12 myoblasts. To 
examine the exact location of Pax7 and identify the event that cytoplasmic-Pax7 might 
be involved in within proliferating dfd13 myoblasts, co-localisation of Pax7 with 
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subcellular components, i.e. endoplasmic reticulum, golgi, recycling endosome and 
lysosome, was performed. Co-localisation analysis via immunofluorescence double 
labelling using specific markers for each location was undertaken and the subcellular 
markers utilised are listed in Table 3.1. 
Table 3.1: Subcellular markers utilised 
Subcellular Marker Functions 
Ca2+ATPase: Endoplasmic 
reticulum 
Protein is synthesised and prepared for sending to the 
Golgi prior to integral modification, sorting and 
packaging. 
Golgi Matrix protein-130kDa 
(GM130): Golgi 
Involved in maintaining the cis-Golgi structure. Protein is 
ready to be dispatched to other parts of the cell. 
Rab11: Recycling endosome Transporting protein within the tubular network. 
CD107a: Lysosome 
Also known as lysosomal-associated membrane protein-1 
(LAMP1), involved in the protein degradation pathway. 
 
3.2.4.1 Cytoplasmic-Pax7 of Both Types of Proliferating Myoblasts are Co-
Localised with Markers for the Endoplasmic Reticulum and Golgi  
As depicted in Figure 3.6, Pax7 was labelled with Texas red (red) while the Ca2+ATPase 
(ER) and GM130 (Golgi) markers were labelled with AlexaFlour®488 (green). From 
the images taken, it can be seen that Pax7 co-localised with Ca2+ATPase and GM130 in 
both proliferating C2C12 and dfd13 myoblasts (Figure 3.6).  
Based on the statistical co-localisation analysis, Pax7 was found to be co-
localised with the ER and Golgi markers in proliferating C2C12 myoblasts and dfd13 
myoblasts. The co-localisation of Pax7 with Ca2+ATPase demonstrates that Pax7 is 
synthesised abundantly in proliferative C2C12 myoblasts in line with the expression 
levels detected previously (Figure 3.3A). Ca2+ATPase is localised to the ER membrane 
and involved in transporting calcium ions from the cytosol into the ER. Co-localisation 
of Pax7 to Ca2+ATPase corresponds to the current location of Pax7. It has been reported 
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that Pax7 expression is crucial for the maintenance and self-renewal of myoblasts 
(Kuang et al. 2006; Lepper, Conway, and Fan 2009). Maintaining Pax7 expression 
retains the transcriptional regulation of Pax7 for myogenesis and for down-regulation 
at the onset of muscle differentiation.  
GM130 is a protein localised specifically at the cis-Golgi, where it faces the ER 
in order to receive biosynthetic output from the ER. Co-localisation of Pax7 with 
GM130 suggests two possible events. Pax7 which is not used may be packaged and 
ready to be despatched to the final destination, most probably to lysosomes for 
digestion. Alternatively, Pax7 may be ready to be despatched back to the ER and to be 
translocated to the nucleus for transcription purposes. As GM130 has been found to be 
involved in signal transduction regulating migration and cell polarisation via kinases 
(Preisinger et al. 2004; Millarte and Farhan 2012), it could be suggested that Pax7 is 
also involved in these events. Further analysis is therefore needed into the co-
localisation of Pax7 with recycling endosomes and lysosomes. 
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Figure 3.6: Cytoplasmic-Pax7 is co-localised in the ER and Golgi in both proliferating 
C2C12 and dfd13 myoblasts 
Approximately 1.5 x 104 C2C12 (non-dystrophic) and dfd13 (dystrophin-deficient) myoblasts 
were cultured in GM until 60-70% confluent in a 48-well plate. Both types of myoblast were 
fixed in 4% PFA prior to double immunolabelling for Ca2+ATPase or GM130 (green) and Pax7  
(red). DAPI was used as a nuclear counterstain. Images were taken using a Nikon A1 confocal 
microscope and co-localisation analysis was performed using NIS element software provided 
by Nikon. GM: growth medium (DMEM + 10% FCS); n=3  
10µm 
10µm 
10µm 
10µm 
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3.2.4.2 Cytoplasmic-Pax7 in Proliferating Dystrophin-Deficient Myoblast is Co-
Localised with Recycling Endosomes and Not Lysosomes 
Cytoplasmic-Pax7 in both proliferative C2C12 and dfd13 myoblasts has been shown to 
localise to the Golgi, suggesting that Pax7 might be processed, packaged and ready to 
be translocated to another myoblast compartment. It was hypothesised that Pax7 would 
be digested/lysed rather than secreted for an external use as it plays a role as a 
transcription factor within the nucleus. In addition, Pax7 does not possess a signal 
peptide directing it towards a secretory pathway. To test this hypothesis, co-localisation 
of Pax7 within cells components, i.e. recycling endosome and lysosome, was explored. 
Rab11 and CD107a markers were used for recycling endosomes and lyososomes, 
respectively.  
C2C12 myoblasts with cytoplasmic-Pax7 expression were chosen for this 
analysis. Co-localisation of Pax7 with recycling endosomes (Rab11) could be clearly 
seen in both proliferative C2C12 and dfd13 myoblasts (Figure 3.7). Rab11 is a small 
Ras-like GTPase regulatory protein which has a regulatory role in most membrane-
transport steps, i.e. recycling of perinuclear proteins, the plasma membrane and golgi 
compartment endosomes.  It is localised to the endocytic recycling compartment and 
trans-Golgi network. As Pax7 was found to co-localise with Rab11 in the perinuclear 
region, it can be suggested that here it is in the process of being transported from the 
Golgi to the ER following modification. 
The co-localisation of Pax7 with lysosomes (CD107a) gave a lower score in 
both types of myoblasts (Table 3.2). CD107a, also known as lysosomal-associated 
membrane protein-1 (LAMP-1), is a type I transmembrane protein that has been widely 
used as a lysosome marker. As Pax7 was not co-localised with CD107a, this suggests 
that degradation of Pax7 may not occur to a significant extent. This result suggests that 
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cytoplasmic-Pax7 in both proliferative C2C12 and dfd13 myoblasts is active within 
recycling endosomes but not purposely for degradation.  
 
Figure 3.7: Cytoplasmic-Pax7 co-localises with recycling endosomes in both proliferating 
myoblasts 
Approximately 1.5 x 104 C2C12 (non-dystrophic) and dfd13 (dystrophin-deficient) myoblasts 
were cultured in GM until 60-70% confluent in a 48-well plate. The myoblasts were fixed in 
4% PFA prior to double immunolabelling for Rab11 or CD107a (green) and Pax7 (red). DAPI 
was used as a nuclear counterstain. Images were taken using a Nikon A1 confocal microscope 
and co-localisation analysis was performed using NIS element software provided by Nikon. 
GM: growth medium (DMEM + 10% FCS); n=3. 
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Table 3.2: Analysis of Pax7 co-localisation with subcellular markers 
Stage/State of 
Myoblasts 
Protein events with respect 
Subcellular markers C2C12 myoblasts 
 dystrophin-
deficient 
myoblasts 
Proliferating 
Protein synthesis/modification 
• Endoplasmic reticulum 
(Ca2+ATPase) 
• Golgi (GM130) 
 
Co-localised 
 
Co-localised 
 
Co-localised 
 
Co-localised 
Protein transportation/degradation 
• Recycling endosome (Rab11) 
 
• Lysosome (CD107a) 
 
Co-localised 
 
Not co-localised 
 
Co-localised* 
(p=2.62x10-2) 
Not co-localised 
* Significantly higher (p<0.05) when compared to C2C12; (n=3). 
3.2.5 Identification of the Nuclear Localisation of Pax7-KPNA2 Interaction 
Synthesised protein that needs to be translocated into the nucleus needs a importin-α 
and importin-β recognition sequence within its NLS in order to form a complex. 
However, it remains unknown as to which protein adaptor is involved in shuttling Pax7 
through the nuclear membrane.   
3.2.5.1 In silico Inspection of the Pax7 Sequence  
A) NES analysis 
Based on the previous results, cytoplasmic-Pax7 has been found to be localised at higher 
levels in dfd13 myoblasts compared to C2C12 myoblasts. It appears that cytoplasmic-
Pax7 is either from the nucleus or remains in the cytoplasm following translation 
process. It was therefore hypothesised that there must be an impairment in the nuclear-
cytoplasmic transportation for Pax7 or other associated-proteins. The Pax7 protein 
sequence was obtained from the UniProt database (www.uniprot.org) and analysed to 
ascertain whether a NLS and/or nuclear export signal (NES) was present.  
The NetNES 1.1 server developed by the Center for Biological Sequence 
Analysis (CBS), Technical University of Denmark 
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(http://www.cbs.dtu.dk/services/NetNES/) was used to predict the NES sequence in 
Pax7. The server predicts leucine-rich NES in eukaryotic proteins using combination of 
Hidden Markov Model (HMM) and Artificial Neural Network (ANN) scores in the 
prediction algorithm and verify the method on the most recently discovered NES 
(Figure 3.8) with 0.5 as a threshold. However, as the NES score was below the 
threshold, no residue is expected to participate in a NES.  
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Figure 3.8: NES analysis of the Pax7 sequence 
Pax7 has no potential sequence for exportin to bind to for its export out of the nucleus to the 
cytoplasm. (A) Graphic of the NES analysis showing that no residue scored over the threshold. 
(B) Some of the residues analysed by the NetNES 1.1 server.  
B) NLS analysis 
The cNLS mapper is software for NLS predictions in protein sequences and was 
developed by Kasugi et al. (2009) to recognise specific NLS for the importin αβ 
pathway by calculating NLS scores (levels of NLS activities) (Kosugi et al. 2009). In 
this study, it was used to analyse the NLS residues in the Pax7 sequence. The Pax7 
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sequence was obtained from the UniProt database (www.uniprot.org) and loaded into 
the software with a cut-off score of 5.0 selected. The cut-off score indicates the strength 
of NLS activity, with higher activities at 10.0 and lower activities at 1.0, based on an 
experiment where the GUS-GFP reporter protein was fused to an NLS. Searching for a 
bipartite NLS with a long linker in the protein sequence was also performed by selecting 
the ‘within terminal 60-amino-acids region’ option, as this would help to identify a 
structure-dependent bipartite NLS which may be located close to each other in the 
tertiary structure (http://nls-mapper.iab.keio.ac.jp/). The analysis showed that a 
predicted bipartite NLS was present in the Pax7 sequence, starting at position 134 until 
residue 220, shown in red text in Figure 3.9A. The scores were 5.8, 5.5 and 5.1, which 
means that Pax7 has intermediate NLS activities, indicating it could be localised within 
both the nucleus and cytoplasm.  
Analysis of phosphorylation sites was achieved using the NetPhos 2.0 server 
developed by the Center for Biological Sequence Analysis (CBS), Technical University 
of Denmark (http://www.cbs.dtu.dk/services/NetNES/). This server produces 
predictions for serine, threonine and tyrosine phosphorylation sites in eukaryotic 
proteins. The analysis shows that there are seven predicted serine phosphorylation sites 
within the NLS sequence, but no threonine or tyrosine phosphorylation sites were found 
(Figure 3.9B). These sites indicate the positions that have the highest probability for 
importin binding via a phosphorylation event.   
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Figure 3.9: NLS analysis of the Pax7 sequence 
(A) Pax7 has NLS residues from 134 to 220 that are a potential site for importin to bind to,  
indicating that Pax7 is a nuclear protein that is translocated into the nucleus. (B) The NLS 
sequence highlighting the predicted residues for phosphorylation as analysed using the NetPhos 
2.0 server.  
3.2.5.2 Prediction of Importin-α1 and Importin13 as Pax7 Translocator in 
Myoblasts 
There is a lack of studies on the interactions of Pax7 with proteins involved in it 
translocation to the nucleus. Since Pax7 was found to be more localised within the 
cytoplasm of dfd13 myoblasts, it was hypothesised that the translocation of Pax7 into 
the nucleus is impaired, resulting in more cytoplasmic-Pax7 in these myoblasts. Two 
B B 
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candidate proteins were chosen that may form a complex with Pax7, karyopherin-α 
(KPNA2) and karyopherin-β or importin13 (IPO13).   
Karyopherin α1 has been shown to be involved in myoblast proliferation and 
differentiation, as a knockdown via siRNA targeting KPNA2 reduced both events (Hall 
et al. 2011). A study by Kovac et al. (2000) confirmed that importin α1 interacts with 
Pax5 via a NLS located at amino acids 195-201 within the central domain (Kovac et al. 
2000). Therefore, it was hypothesised that importin α1 could also be the Pax7 escort 
protein enabling its translocation into the nucleus. The Pax5 and Pax7 sequences were 
aligned, revealing that 4 out of the 8 residues were similar within the binding site, 
suggesting that importin α1 could potentially interact with Pax7 (Figure 3.10). The NLS 
of both Pax7 and Pax5 was also analysed using NucPred by Brameier et al. (2007), 
which showed that both have a similar predicted NLS, suggesting that both proteins 
have a nuclear role (Figure 3.11) (Brameier, Krings, and MacCallum 2007). 
Based on the STRING (Search Tool for the Retrieval of Interacting 
Genes/Proteins) database, no study has reported Pax7 (Mus musculus) protein 
interactions. However, it has been reported that Pax6 and Pax3 interact with IPO13, 
indicating that these are potential cargo proteins for IPO13 (Ploski, Shamsher, and Radu 
2004). Thus, it was hypothesised that IPO13 may also play a role as a translocator for 
Pax7.  
 
  
 86 
 
Figure 3.10: Alignment of Pax5 and Pax7 sequences 
The alignment shows that only 4 out of 8 Pax7 residues are similar to the Pax5 residue binding 
site. Alignment of the two sequences was performed using blastp algorithm from the BLAST 
website.  
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Figure 3.11: NLS analysis of the Pax7 sequence compared to the Pax5 sequence  
Analysis of the NLS using NucPred by Brameier et al., 2007. The ‘S’ (serine) and ‘T’ 
(Threonine) are residue which are expected to be phosphorylated based on the prediction 
phosphorylation analysis using NetPhos2.0. 
(https://www.sbc.su.se/~maccallr/nucpred/cgi-bin/single.cgi)   
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3.2.5.3 Endogenous Pax7 is Associated with Importin-α1 (KPNA2) But Not 
Importin13 (IPO13) in Myoblasts  
The data has shown that cytoplasmic-Pax7 was found localised in the Golgi and 
recycling endosomes  not in lysosomes. This provides evidence that high level 
expression of Pax7 in differentiating dfd13 myoblasts is recycled and not degraded, 
retaining its function during this stage. Therefore, it was suspected that Pax7 
transportation regulation is impaired during proliferation and differentiation of dfd13 
myoblasts. Further investigations were carried out to determine the functional 
interaction of Pax7 with importin-α1 (KPNA2) in myoblasts.  
There is no data relating to the Pax7 nuclear transport protein (karyopherin) 
available; however, based on the analysis presented, it is predicted that Pax7 possesses 
a NLS that importin could bind to. Analysis of importin candidates could be a Pax7 
protein partner, identified IPO13 and KPNA2. Co-immunoprecipitation analysis 
showed that only KPNA2 associates with Pax7 (Figure 3.12). Therefore to confirm this 
interaction, co-localisation analysis was undertaken. Co-localisation analysis also 
showed that Pax7 and KPNA2 are associated, suggesting that these proteins are 
interacting (Figure3.13). 
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Figure 3.12: Endogenous Pax7 associates with KPNA2  
Approximately 500 µg of whole cell lysates of C2C12 and dfd13 myoblasts were used for 
immunoprecipitation analysis. Endogenous Pax7 was pulled down using a protein A sepharose 
CL-4B bead slurry, and KPNA2 was pulled down using Dynabeads Protein G magnetic beads. 
Both purified proteins were blotted with anti-Pax7, KPNA2 and IPO13 antibodies. Whole cell 
lysate was used as a positive control and rabbit IgG (with sample buffer) as the negative control. 
WCL: whole cell lysate; n=3 
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Figure 3.13: Endogenous Pax7 co-localises with KPNA2 
Approximately 1.5 x 104 C2C12 and dfd13 myoblasts were cultured in GM in a 48-well plate 
overnight. The myoblasts were fixed in 4% paraformaldehyde prior to immunolabelling with 
for Pax7 and KPNA2. DAPI was used as a nuclear counterstain. The images were captured 
using a confocal microscope Nikon 1AR. Co-localisation analysis has performed using NIS 
element software provided by Nikon. GM: growth medium (DMEM + 10% FCS); n=3. 
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3.2.6 KPNA2 Expression Fluctuates in Differentiating Dystrophin-
Deficient Myoblasts 
It has been shown that KPNA2 knockdown decreases myoblast proliferation, indicating 
that KPNA2 plays a role in myoblast proliferation (Hall et al. 2011). Furthermore, it has 
also been suggested that KPNA2 may have a specific role in the nucleo-cytoplasmic 
import of cNLS proteins required for the positive regulation of myoblast proliferation. 
The results of further investigations in this study indicated that KPNA2 interacts with 
Pax7 and plays the role of the Pax7-transport protein.  
Figure 3.14A presents an immunoblot demonstrating KPNA2 expression in non-
differentiated and differentiated myoblasts. Generally, KPNA2 expression is decreased 
upon differentiation when compared to non-differentiated myoblasts. At day 10 of 
differentiation, KPNA2 has accumulated but is still lower than in non-differentiated 
C2C12 cells (Figure 3.14B). Densitometry analysis showed that there is a significant 
difference in expression (p<0.05; p = 3.27 x 10-2) on day 7 between the two types of 
myoblasts.  
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Figure 3.14: KPNA2 expression fluctuates in differentiating dystrophin-deficient 
myoblasts 
Both C2C12 and dfd13 myoblasts were cultured in GM until 80-90% confluent before replacing 
with DM and cultured for 10 days, with the medium changed every two days. Total protein 
extraction was performed at the indicated time points prior to immunoblotting with antibodies 
recognising KPNA2 and α-tubulin protein. (A) Immunoblot of KPNA2 expression during 
differentiation with α-tubulin as a loading control. (B) Densitometry analysis of KPNA2 
expression normalised against α-tubulin. The graph represents an average of three repeats from 
different samples. ND: non-differentiated; Significant different: * (p<0.05) compared to dfd13 
myoblasts; GM: growth medium (DMEM + 10% FCS); DM: differentiation medium (DMEM 
+ 2% horse serum); n=3. 
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3.3 Discussion 
3.3.1 Dystrophin-Deficient Myoblasts Do Not Achieve Terminal 
Differentiation 
In this chapter it has been established that dystrophin-deficient myoblast differentiation 
is impaired when in low mitogen medium for 10 days based on morphological analysis 
(Figure 3.1) and the detection of F-MyHC expression (Figure 3.2). Differentiation 
analyses showed that less myotubes were formed, and no/less F-MyHC expression was 
detected. However, pan-myosin was only expressed at the end of differentiation on day 
10 in dfd13 myoblasts. Desmin expression levels were found to be higher at the end of 
the differentiation period. Desmin is a marker for newly formed fibres and is a class-III 
intermediate filament found in muscle cells that connect myofibrils to each other, as 
well as to the plasma membrane of myofibres. In this study, it can be suggested that the 
integrative element in myofibres was generated/developed earlier than myotube 
formation in the differentiating dystrophin-deficient myoblasts, although full/terminal 
differentiation was not achieved. 
During myogenesis, proliferating myoblasts withdraw from the cell cycle and 
differentiate into myotubes. Cyclin-dependent Kinase (CDK) inhibitor p21 and 
retinoblastoma protein (Rb) have been shown to play a critical role in establishing the 
post-mitotic state by permitting the transcription of the S-phase promoting gene during 
myogenesis (Blagosklonny and Pardee 2002). Most mitogens have been shown to 
promote myoblast proliferation. In contrast, insulin-like growth factors (Igf-1 and Igf-
2) trigger myoblast differentiation. It is unknown how Igf-2 is controlled during the 
initiation of differentiation. A previous study showed that Igf-2 up-regulates its own 
gene expression via the Akt/PKB pathway (Duan, Liimatta, and Bottum 1999). 
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Elevation of Igf-2 mRNA was found in C2 myoblasts after 24 hours’ culture in 
differentiation medium containing 2-10% horse serum (Tollefsen et al. 1989), while 
Erbay et al. (2003) suggested that mTOR regulates Igf-2 production at the 
transcriptional level when cultured under low mitogen conditions (Erbay et al. 2003). 
There has also been a study suggesting that myoblasts under low mitogen conditions 
have elevated levels of IGFBP5, which helps concentrate IGF-2 to a threshold level 
which triggers the IGF-1R pathway leading to differentiation (James et al. 1993; Florini, 
Ewton, and Coolican 1996). However, in this study levels of Igf-1/2 could not be 
examined in the culture system utilised, i.e. Igf-1/2 secreted/present in the media. 
Therefore, further study needs to be undertaken to examine this aspect. a previous study 
by Chen (2013) showed that Igf-2 induction promotes dystrophin-deficient myoblast 
differentiation for 4 days, and differentiation was greater when induced by a 
combination of Igf-1/Igf-2/LIF factors (Hung-chih 2013).   
3.3.2 Pax7 Mislocalisation/Misregulation May Affect Terminal 
Differentiation Achievement in Dystrophin-Deficient Myoblasts 
The localisation of specific proteins, particularly transcription factors can be used to 
elucidate their specific functions and enable characterisation. Therefore, determinating 
the localisation of Pax7 was crucial to distinguishing and identifying whether this 
protein was functioning. As depicted in Figure 3.3, Pax7 levels remain highly expressed 
upon differentiation in dystrophin-deficient myoblasts. A previous study reported that 
overexpression of Pax7 inhibits myoblast differentiation by down-regulating MyoD, 
thus preventing myogenin induction (Olguin and Olwin 2004).  Therefore, further 
analysis of Pax7 localisation and subcellular-localisation during the proliferating and 
differentiating state was performed. As depicted in Figure 3.4 and Figure 3.5, Pax7 
distribution analysis revealed that it is in the ER, golgi and recycling endosome of 
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dystrophin-deficient myoblasts. However, only ROI analysis of the co-localisation of 
Pax7 with rab11 showed that co-localisation was significantly higher (p = 2.6x10-2) in 
dfd13 myoblasts compared to C2C12 myoblasts (Table 3.2). This indicates that Pax7 is 
actively transported across the cytoplasm, thus explaining the extensive dispersion 
expression within the cytoplasm of dystrophin-deficient myoblasts. Significant co-
localisation was defined as the percentage of Pax7 co-localised with rab11 in dfd13 
myoblasts compared to C2C12 myoblasts via a binary overlay. 
3.3.3 Association of Pax7 with KPNA2 as a Complex Suggests a Nuclear 
Localisation Vehicle 
As Pax7 was found in ER, golgi and recycling endosomes of dystrophin-deficient 
myoblasts, it was hypothesised that the protein translocator karyopherin may be 
impaired. To date, no study has reported on karyopherin complexing with Pax7 for 
translocation into the nucleus. It was identified in this study that KPNA2 interacts with 
Pax7 in both types of myoblasts examined. However, there was no impairment in terms 
of Pax7 binding to KPNA2. Figure 3.5 and Figure 3.6 showed that endogenous Pax7 is 
associated with KPNA2 in both types of myoblast. 
KPNA2 is a member of the karyopherin-α family of proteins which function as 
protein transporters to the nucleus. A study by Hall et al. (2011) demonstrated that 
KPNA2 is important for myoblast proliferation (Hall et al. 2011). Therefore, it can be 
suggested that high expression levels of KPNA2 reflect Pax7 levels, since the co-
immunoprecipitation analysis showed that both proteins interact and are associated. 
KPNA2 expression (Figure 3.14) has the same pattern as Pax7 (Figure 3.3), thereby 
supporting the association between Pax7 and KPNA2. High level expression of Pax7 
may also reflect high binding to β-catenin, which inhibits myoblast differentiation 
 96 
(Zhuang et al. 2014). From the data obtained, it can be seen that F-MyHC appeared on 
day 4 and increased upon differentiation, while Pax7 and KPNA2 expression was 
decreased until day 7, but then  had accumulated by day 10. Such an accumulation may 
be due to their function as survival factors for myotubes (Olguín and Pisconti 2011) 
however their regulation was found to be impaired in dfd13 myoblasts. 
3.4 Conclusions 
In this chapter, it has been demonstrated that Pax7 is misregulated/mislocalised in 
dystrophin-deficient myoblasts. For the first time, it has been established that KPNA2 
is the karyopherin-α that may be responsible for Pax7 translocation to the nucleus. 
Key finding(s): 
• Pax7 is localised in ER, golgi and rab11 of dystrophin-deficient myoblasts. 
• Pax7 associates with KPNA2 to form a translocation complex.  
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Chapter 4 - The PTEN-PI3K/Akt Signalling Pathway is 
Perturbed in Dystrophin-Deficient Myoblasts 
4.1 Introduction 
The absence of dystrophin has a massive impact on myotube as well as myofibre 
structure. The destabilisation of the plasma membrane in dystrophin-deficient 
myoblasts from an mdx mouse affects transmembrane protein stability, as well as the 
protein-anchored cytoplasmic layer of the cell membrane thus changing signalling. One 
of the conserved signalling pathways for skeletal muscle differentiation is the 
PI3K/Akt/mTOR pathway. The regulation is via insulin-like growth factor-1 receptor 
(IGF-1R) activation following IGF1 binding. IGF-1R plays a major role in the 
regulation of skeletal muscle growth and many researchers have reported on the 
impairment of the Igf-1 pathway and changed its downstream protein regulation in MD. 
However, PTEN expression and regulation is rarely studied since this protein is 
negatively regulated in the Igf-1 pathway. In this chapter, the elevation of PTEN 
perturbed PI3K/Akt/mTOR signalling is reported which causes protein translation 
deactivation, excessive activation of autophagy related genes via FoxO3, and 
subsequently a reduction in autophagic flux in dystrophin-deficient myoblasts (Chapter 
5).  
The PTEN-PI3K/Akt signalling pathway regulates multiple biological 
processes, such as cell proliferation, differentiation, autophagy and apoptosis. A 
disruption in this pathway can cause impairments to these processes, as can occur in 
cancers due to an increase in Akt activity caused by the down-regulation of PTEN 
expression which is affected by PI3K activation. However, there is a different scenario 
in dystrophin-deficient myoblasts where PTEN expression is significantly higher and 
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extensively expressed upon differentiation. PTEN, also known as a tumour suppressor, 
is mutated within cancer cells. PTEN acts as a lipid phosphatase and hydrolyses 
phosphates in the 3′ position of phosphoinositides. Previous studies have found that 
PTEN mRNA is elevated in the muscle of mdx mice (Dogra et al. 2006; Haslett et al. 
2003). The elevation of PTEN expression and its activity due to the deregulation of the 
PI3K/Akt signalling pathway in dystrophin-deficient dog muscle has also been shown 
in the GRMD dog (Feron et al., 2009).  
In this study the protein responsible for the conversion of PIP2 and PIP3 is 
examined via the synergistic function of PI3K and PTEN. The conversion of 
phosphoinositides is important in regulating Akt signalling and the downstream proteins 
which are responsible for the regulation of proliferation, differentiation and cell 
survival, especially in myoblasts. To understand the impaired regulation of PTEN-
PI3K/Akt in dystrophin-deficient myoblasts, the downstream protein profiling of this 
pathway was investigated as this ultimately changes autophagy modulation and 
activation, as will be shown in Chapter 5. An overview of this chapter is illustrated in 
Figure 4.1. 
 99 
 
 
 
 
Figure 4.1: Chapter overview: perturbation of the PTEN-PI3K/Akt signalling pathway in dystrophin-deficient myoblasts 
PTEN was found to be highly expressed in dystrophin-deficient myoblasts which leads to the reduction of activation of PI3K.  Surprisingly, Akt was found not 
to be activated due to the inactivation of Rictor-mTORC2. Furthermore, downstream of Akt, i.e. p70S6K and FoxO3, there was defective activation. Activation 
of p70S6K was reduced, indicating that protein synthesis regulation is impaired. FoxO3 (unphosphorylated) expression accumulated thus increased FoxO3 
nuclear translocation. Therefore, it can be implied that PI3K/Akt and downstream protein signalling is perturbed in dystrophin-deficient myoblasts. 
PI3K 
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4.2 Results 
It was shown in Chapter 3 that the differentiation capacity of dystrophin-deficient 
(dfd13) myoblasts is diminished. The data showed that dfd13 myoblasts are unable to 
achieve terminal differentiation after culture in low-mitogen (2% horse serum) media 
for 10 days. In this chapter, the regulation of PTEN-PI3K is examined, as this is 
responsible for myoblast differentiation. PI3K/Akt regulation and regulation of the 
downstream protein pathway in myoblasts during differentiation is also investigated. 
4.2.1 PTEN-PI3K Regulation is Perturbed in Differentiating Dystrophin-
Deficient Myoblasts 
Generally, PTEN expression was increased upon differentiation in both types of 
myoblasts. However, the accumulation of PTEN was found to be higher in 
differentiating dfd13 myoblasts compared to C2C12 myoblasts ( 
Figure 4.2A). The accumulation of PTEN throughout differentiation was not significant 
in C2C12 myoblasts but there were significant increases on day 7 (p<0.05; p = 4.30x10-
2) and day 10 (p<0.05; p = 4.88x10-2) when compared to non-differentiated cells. 
Densitometry analysis showed that PTEN expression in differentiating dfd13 myoblasts 
were significantly higher compared to the differentiating C2C12 myoblasts (p<0.01; p 
= 4.81x10-3) on day 4, (p<0.05), day 7 (p = 1.29x10-2) and day 10 (p = 1.95x10-2) ( 
Figure 4.2B).  
PTEN has a negative effect on PI3K, as it concomitantly affects PI3K 
regulation. PI3K expression and its activity in both types of myoblasts was therefore 
examined. Generally, total PI3K expression was increased in dfd13 myoblasts 
throughout the differentiation period. However, significant accumulation of PI3K could 
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be seen by day 7 (p<0.01; p = 1.04x10-3) and day 10 (p<0.01; p = 1.65x10-3) when 
compared to the non-differentiated dfd13 myoblasts. There was a significant difference 
in total PI3K expression in C2C12 myoblasts on days 7 and 10 compared to non-
differentiated myoblasts. Densitometry analysis showed that there were significant 
differences in total PI3K expression in dfd13 myoblasts on day 4 (p<0.05; p = 1.70x10-
2), day 7 (p<0.01; p = 2.08x10-3), and day 10 (p = 1.42x10-3) when compared to 
differentiating C2C12 myoblasts ( 
Figure 4.2C). As illustrated in  
Figure 4.2D, densitometry analysis on relative PI3K activity was higher in dfd13 
myoblasts at the non-differentiated stage (p<0.01; p = 9.89x10-3), day 4 (p<0.01; p = 
1.69x10-3) and reduced at day 10 of differentiation (p<0.05; p = 3.25x10-2) when 
compared to C2C12 myoblasts. However, the actual activity of PI3K is increased 
(Figure 4.2E). 
In this study, phosphorylation of PI3K-p85 (regulatory subunit) was examined 
in order to observe PI3K activation. When cells are stimulated by the receptor, intrinsic 
tyrosine kinase phosphorylates p85 at Tyr458, causing a conformational change to p110 
(the catalytic subunit) which increases its enzymatic activity for PIP2. From this data, it 
seems that high PTEN expression decreased PI3K activity, thus affecting its 
downstream protein activation. 
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Figure 4.2: PTEN expression is higher while PI3K activation is decreased in dystrophin-
deficient myoblasts 
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and 
culturing in DM for 10 days with the media being changed every 2 days.  Total protein 
extraction was performed at the indicated time points prior to immunoblot analysis. (A) 
Immunoblot analysis of PTEN, phospho-PI3K (p85) and total PI3K during myoblasts 
differentiation with α-tubulin expression as a loading control. Densitometry analysis of (B) 
PTEN expression, (C) total PI3K expression, and (C) PI3K activity. The graphs represent an 
average of three repeats from different samples. ND: non-differentiated; Significant different: 
* (p<0.05) and ** (p<0.01) compared to C2C12 myoblasts. GM: growth medium (DMEM + 
10% FCS); DM: differentiation medium (DMEM + 2% horse serum); n=3. 
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4.2.2 Akt Is inactivated in Dystrophin-Deficient Myoblasts 
As PTEN has been shown to be highly expressed in dfd13 myoblasts, it is predicted that 
Akt is inactivated, as PTEN has previously been reported to modulate Akt activation in 
rhabdomyosarcomas cells; skeletal muscle cancer (Wan and Helman 2003). In this 
study phosphorylation of Akt was  not detected at Ser473 or Thr308 in dfd13 myoblasts 
during differentiation (Figure 4.3A). It has been reported that phosphorylation of Akt 
by PDK1 at Thr308 partially activates Akt while full activation requires 
phosphorylation of Ser473 which can be catalysed by multiple protiens including rictor-
mTORC2 (Sarbassov et al. 2005). These activation is responsible for myoblast 
proliferation as well as differentiation.  
As depicted in Figure 4.3B, total Akt expression increased in both types of 
myoblast during differentiation, with slightly higher levels present in dfd13 myoblasts 
(not significantly different). Densitometry analysis of Akt activation via 
phosphorylation at Ser473 (Figure 4.3C) showed a significant difference when 
compared to C2C12 myoblast at all stages (non-differentiated p<0.05; p = 3.90x10-2, 
day 4 p<0.05; p = 1.17x10-2, day 7 p<0.05; p = 1.25x10-2 and day 10 p<0.01; p = 
1.39x10-3). There was also a significant difference in Akt activation at Ser473 in C2C12 
myoblasts when compared to the non-differentiated stage (day 4 p<0.05; p = 2.06x10-
2, day 7 p<0.05; p = 3.31x10-2 and  day 10 p<0.01; p = 1.41x10-3). 
Akt is a downstream protein of PI3K. Its plays an important role and is 
recognised as one of the most critical pathways in the regulation of cell viability and 
maintenance in skeletal muscle mass (Egerman and Glass 2014). Therefore, its 
expression pattern in dystrophin-deficient myoblasts was investigated, as previously 
dfd13 myoblasts have been reported to undergo apoptosis when cultured in DM (Chen 
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2013). As expected, the immunoblot data showed that Akt was inactivated in 
differentiating dfd13 myoblasts. Surprisingly, it was found that Akt was only activated 
by phosphorylation at Ser473 in C2C12 myoblasts. Akt was not phosphorylated at 
Thr308 in either type of myoblasts and consequently mouse embryonic fibroblast 
(MEF) cells were used as a positive control (gift from Adil Rashid, University of 
Birmingham) for this activation site (Figure 4.3A). 
Immunofluorescence analysis was performed to localise Akt phosphorylated at 
Ser473 in myoblasts during differentiation. As illustrated in Figure 4.4, phosphorylated-
Akt can be observed on the membrane of both non-differentiated myoblasts and 
myotubes. However, less phospho-Akt was found in non-differentiated dfd13 
myoblasts and some was localised on the membrane at day10 of differentiation.  
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Figure 4.3: Akt is inactivated in dystrophin-deficient myoblasts  
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and 
culturing in DM for 10 days with the media being changed every 2 days. Untreated- and PDGF-
treated MEF cells were used as a control for Akt phosphorylation at both Ser473 and Thr308. 
Total protein was extracted at the indicated time points prior to immunoblotting with antibodies 
recognising Akt, phospho-Akt (Ser473) and phospho-Akt (Thr308). (A) Immunoblot analysis 
during myoblast differentiation with α-tubulin expression as a loading control. Densitometry 
analysis of (B) Akt expression and (C) Akt activation at Ser473. The graphs represent an 
average of three repeats from different samples. ND: non-differentiated; +: PDGF-treated; -: 
non-treated; *: significantly different (p<0.05) compared to C2C12 myoblasts. GM: growth 
medium (DMEM + 10% FCS); DM: differentiation medium (DMEM + 2% horse serum); n=3. 
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Figure 4.4: Phosphorylated-Akt is not localised to the membrane in dystrophin-deficient 
myoblasts 
Approximately 1.5 x 104 non-dystrophic and dystrophin-deficient myoblasts were cultured in 
GM before differentiated for 10 days in DM in a 48-well plate. Myoblasts (undifferentiated) 
and myotubes (Day10) were fixed in 4% PFA and blocked with 5% BSA for 30 minutes before 
staining with anti-phospho-Akt (Ser473) antibody. DAPI was used as a nuclear counterstain. 
Immunofluorescence analysis of (A) phospho-Akt (ser473) in C2C12 myoblasts and (B) dfd13 
myoblasts at the non-differentiated stage and day 10 of differentiation. Yellow arrow showed 
phospho-Akt(Ser473) on membrane. GM: growth medium (DMEM + 10% FCS); DM: 
differentiation medium (DMEM + 2% horse serum); n=3. 
4.2.3 Rictor-mTORC2 is inactivated in Dystrophin-Deficient Myoblasts 
A previous study reported that mTORC2 is essential for terminal myogenic 
differentiation (Shu and Houghton 2009). It was also reported that it participates in actin 
cytoskeleton arrangements, which might be involved in dystrophin functionality in 
myoblasts. Therefore, it was hypothesised that Akt inactivation is affected by rictor, a 
subunit of mTORC2, upstream of Akt and responsible for Ser473 phosphorylation. 
However, the upstream protein that regulates rictor-mTORC2 remains unclear. In this 
study both total rictor and mTOR expression was examined as well as its activation. 
However, it was impossible to classify the specific complexes of mTOR activity as 
phosphorylation at Ser2448 can cause the binding to both raptor and rictor (Rosner et 
al. 2010). 
As depicted in  Figure 4.5A, immunoblot analysis of total rictor, mTOR and 
their  phosphorylated forms was performed. Phosphorylated-rictor at Thr1135 was 
virtually not detected in dfd13 myoblasts throughout the differentiation period. 
However, rictor expression was increased upon differentiation in both types of 
myoblasts. Densitometry analysis showed that there was no significance difference in 
its accumulation in the two types of myoblasts (Figure 4.5B). Rictor expression only 
showed a significant increase (p<0.05; p = 2.75x10-2) in dfd13 myoblasts at day 10 
compared to non-differentiated dfd13 myoblasts. Densitometry analysis of rictor 
 109 
activation by phosphorylation at Thr1135 (Figure 4.5C) showed a significant difference 
in C2C12 myoblasts compared to dfd13 myoblasts at all stages; non-differentiated 
p<0.05; p = 2.22x10-2, day 4 p<0.05; p = 3.52x10-2, day 7 p<0.05; p = 1.01x10-2 and 
day 10 p<0.01; p = 3.23x10-3).  
Figure 4.5D shows that total mTOR expression was increased in dfd13 
myoblasts during differentiation but remained the same in C2C12 myoblasts. A 
significant accumulation was seen in dfd13 myoblasts on day 4 (p<0.05; p = 2.93x10-
2), day 7 (p<0.05; p = 1.23x10-2), and day 10 (p<0.01; p = 8.55x10-3) when compared 
to C2C12 myoblasts. Relative mTOR activity was significantly higher in non-
differentiated dfd13 myoblasts when compared to non-differentiated C2C12 myoblasts 
(p<0.05; p = 4.15x10-2). Relative activity showed a significant reduction upon 
differentiation in dfd13 myoblasts while C2C12 myoblasts showed a significant 
accumulation when compared to dfd13 myoblasts on day4 (p<0.05; p = 2.23x10-2), day 
7 (p<0.01; p = 6.78x10-3) and day 10 (p<0.05; p = 1.29x10-2) (Figure 4.5E). The actual 
of mTOR activity in dfd13 myoblast also showed reduction throughout differentiation 
day (Figure 4.5F). 
From these results it can be suggested that inactivation of Akt is caused by the 
inactivation of rictor in dfd13 myoblasts. This impairment is thought to affect other 
kinases, such as protein kinase C (PKC) (Chapter 6) and focal adhesion proteins, such 
as  integrin-linked-kinase (ILK). Alterations to these kinases have been reported as one 
of the factors that causes MD. Expression and activation of mTOR was considered to 
represent endogenous levels of mTOR within both complexes i.e. mTORC1 or 
mTORC2, where distinct activation occurred. Phosphorylation of mTOR at Ser2448 
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makes it a major target for p70S6 kinase activation and is also an important event for 
raptor and rictor binding (Rosner et al., 2010).  
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Figure 4.5: Rictor-mTORC2 activation is lower in dystrophin-deficient myoblasts  
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and 
culturing in DM for 10 days with the media being changed every 2 days. Total protein was 
extracted at the indicated time points prior to immunoblotting with antibodies recognising 
phospho-rictor (Thr1135), rictor, phospho-mTOR (Ser2448) and mTOR proteins. (A) 
Immunoblot analysis during myoblast differentiation with α-tubulin expression as a loading 
control. Densitometry analyses of (B) total rictor expression (C) rictor activity (D) total mTOR 
expression, and (E) mTOR activity. The graphs represent an average of three repeats from 
different samples. ND: non-differentiated; *: significantly different (p<0.05) compared to dfd13 
myoblasts. GM: growth medium (DMEM + 10% FCS); DM: differentiation medium (DMEM 
+ 2% horse serum); n=3. 
4.2.4 p70S6 Kinase Activity Is Completely Reduced in Differentiating 
Dystrophin-Deficient Myoblasts  
Rictor has been shown inactivated in undifferentiated and differentiating dfd13 
myoblasts. Following the mTORC2 impairment, mTORC1 activity was investigated 
through the analysis of the downstream protein, pS6 kinase. pS6 kinase has two 
isoforms; p70S6K  and p85S6K. Expression and activation of both isoforms in 
undifferentiated and differentiated myoblasts were examined.  
As depicted in Figure 4.6A, an immunoblot panel showed that phospho-p70S6K 
(Thr389) and p70S6K was detected in both types of myoblasts. The phopsho-kinase 
blot also detected endogenous levels of p85S6K when phosphorylated at the analogous 
site (Thr412) (Figure 4.6A). Densitometry analysis showed that both p85 and p70 S6 
kinase expression remained the same throughout the differentiation period in C2C12 
myoblasts, but in contrast, both kinases were significantly increased in dfd13 myoblasts. 
p70S6K was significantly increased in dfd13 myoblasts compared to C2C12 myoblasts 
on day 4  (p<0.05; p = 4.74x10-2), day 7 (p<0.05; p = 1.29x10-2), and day 10 (p<0.05; p 
= 1.01x10-2 and p<0.05; p = 2.45x10-2) (Figure 4.6B). Similarly, p85S6K was 
significantly increased in dfd13 myoblasts compared to C2C12 myoblasts on day 4  
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(p<0.05; p = 4.84x10-2), day 7 (p<0.05; p = 3.36x10-2), and day 10 (p<0.05; p = 1.01x10-
2 and p<0.05; p = 2.21x10-2) (Figure 4.6C). 
Figure 4.6D shows p70S6K activation when phosphorylated at Thr389, which 
can be seen to have increased significantly (p<0.05; p = 4.69x10-2) on day 4 in C2C12 
myoblasts compared to dfd13 myoblasts. This activity was found to be reduced on day 
7 (p<0.05; p = 4.49x10-2) and day 10 (p<0.05; p = 4.70x10-2) of differentiation, but 
remained higher when compared to dfd13 myoblasts. In contrast, p70S6K activation 
was only found in non-differentiated dfd13 myoblasts and decreased over the 
differentiation period (Figure 4.6D). Phosphorylated-p85S6Kwas not detected in either 
type of myoblasts.  
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Figure 4.6: p70S6 kinase activation is reduced in differentiating dystrophin-deficient 
myoblasts  
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and 
culturing in DM for 10 days with the media being changed every 2 days. Total protein was 
extracted at the indicated time points prior to immunoblotting with antibodies recognising 
phosho-p70S6K, p70S6K and p85S6K protein. (A) Immunoblot of the proteins during myoblast 
differentiation with α-tubulin expression as a loading control. Densitometry analysis 
representing (B) p70S6K expression, (C) p85S6K, and (D) phospho-p70S6K (Thr389) 
activation. The graphs represent an average of three repeats from different samples. ND: non-
differentiated; *: significantly different (p<0.05) compared to dfd13 myoblasts. GM: growth 
medium (DMEM + 10% FCS); DM: differentiation medium (DMEM + 2% horse serum); n=3. 
4.2.5 FoxO3 Expression Is Highly Increased in Differentiating Dystrophin-
Deficient Myoblasts 
Besides p70S6K, inactivation of Akt also had an effect on another downstream protein, 
FoxO3 (Forkhead box O3), which is a target protein of Akt. FoxO3 is a transcription 
factor responsible for the activation of autophagy genes involved in the autophagy 
machinery. A previous study showed that FoxO3 controls autophagy in skeletal muscle 
in vivo and induced multiple autophagy genes, including LC3B transcription in skeletal 
muscle (Mammucari et al. 2007). In this study, FoxO3 expression in myoblasts was 
examined.  
Immunoblot analyses (Figure 4.7A) showed that FoxO3 expression was 
increased in both types of myoblasts during differentiation. However, there was only a 
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slight increase in FoxO3 in C2C12 myoblasts on day 4, and it remained at the same 
level until day 10. In non-differentiated dfd13 myoblasts FoxO3 levels were found to 
be significantly lower (p<0.01; p = 6.63x10-3) compared to C2C12 myoblasts. FoxO3 
then increased throughout the differentiation period and there was a significant 
difference in dfd13 myoblasts (p<0.01; p = 4.45x10-3) on day 10 compared to C2C12 
myoblasts (Figure 4.7B). 
Akt plays a role in inhibiting FoxO3 through phosphorylation at Thr24, Ser256 
and Ser319, which leads to nuclear exclusion and activation. As Akt is inactive in dfd13 
myoblasts, it is thought that FoxO3 is not phosphorylated. Therefore, the non-
phosphorylated FoxO3 is translocated to the nucleus and activates the gene involved in 
autophagy i.e., Becn1, Atg5 and Atg7.  
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Figure 4.7: FoxO3a is highly increased in differentiating dystrophin-deficient myoblasts  
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and 
culturing in DM for 10 days with the media being changed every 2 days. Total protein was 
extracted at the indicated time points prior to immunoblotting with antibodies recognising 
FoxO3a. (A) Immunoblot analysis of proteins during myoblast differentiation with α-tubulin 
expression as a loading control. Densitometry analysis representing (B) FoxO3a expression. 
The graph represents an average of three repeats from different samples. ND: non-
differentiated; *: significantly different (p<0.05) compared to dfd13 myoblasts. GM: growth 
medium (DMEM + 10% FCS); DM: differentiation medium (DMEM + 2% horse serum); n=3. 
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4.3 Discussion 
4.3.1 Elevation of PTEN Affects PI3K/Akt Regulation in Dystrophin-
Deficient Myoblasts 
The PI3K/Akt pathway is a highly-conserved pathway for the regulation of skeletal 
muscle growth and is activated by the binding of Igf-1 to its receptor, Igf1-r. This 
binding leads to intrinsic tyrosine kinase activation, as well as auto-phosphorylation, 
which can generate a docking site for IRS. Phosphorylated-IRS then becomes a docking 
site for PI3K, thus activating PI3K/Akt signalling for myoblast differentiation via a 
series of phosphorylation events. This signalling is negatively regulated by PTEN. 
In this study PTEN was shown to be elevated in dfd13 myoblasts, which might 
affect PI3K activity upon PIP3 production, as it was found to be decreased during 
differentiation ( 
Figure 4.2), indicating that PI3K regulation is altered in dfd13 myoblasts. PTEN 
acts as lipid phosphatase and plays a role in removing the phosphate group present on 
the inositol ring of PIP3 to produce PIP2. In contrast, PI3K reverses this event by 
phosphorylating PIP2 to become PIP3.  
PI3K exists as a heterodimer consisting of two subunits (p85 and p110) 
regulatory and catalytic. When cells are stimulated, p85 binds to tyrosine-
phosphorylated IRS, and phosphorylated-p85 changes the conformation of p110 and 
thus mediates the p110 subunit to translocate to the membrane and increases its 
enzymatic activity such as PIP2 phosphorylation. PIP3 helps to recruit Akt by binding 
the plekstrin homolog (PH) domain at the N-terminal of Akt to the cell membrane. 
PTEN in turn acts as a negative regulator by dephosphorylating PIP3 to form PIP2, and 
thereby reduces the available docking sites for Akt to bind to prior to activation. PTEN 
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is mainly found in the cytosol and nucleus. The N-terminal possess a PIP2-binding motif 
while the C-terminal contains a serine/threonine phosphorylation, Ser380, which 
regulates its stability and activity, as well as membrane recruitment. The main C2 
domain, contains basic residues that are essential for membrane binding. 
Phosphorylation of PTEN is considered result in a closed conformation which is the 
inactive form. In this conformation it has been proposed that the phosphorylated C-
terminal interacts with the positively charged C2 domain and remains in the cytoplasm 
(Vazquez et al. 2006).   
Feron and colleagues (2009) reported that increased PTEN expression caused 
deregulation of the PI3K/Akt pathway in dystrophin-deficient muscle present in GRMD 
dogs. This was also observed in muscle sections from 3- to 36-month old animals and 
indicates that the PI3K/Akt pathway is a long-term alteration. A more recent study by 
Alexander et al. (2014) proposed that overexpression of micro-RNA-486 improved 
muscle physiology and performance in dystrophin-deficient mice. Micro-RNA-486 is a 
muscle-enriched micro-RNA that is markedly reduced in the muscle of dystrophin-
deficient mice and DMD patient muscles (Eisenberg et al. 2007; Alexander et al. 2011). 
Micro-RNA-486 targets DOCK3 (dedicator of cytokinesis 3) which modulates 
PTEN/Akt signalling in skeletal muscle. As DOCK3 was increased in dystrophic 
muscle (Alexander et al. 2014), it is suggested that high PTEN activation also occurred 
in dystrophin-defieicent myoblasts. 
4.3.2 Inactivation of Akt is Caused By Impaired Rictor-mTORC2 in 
Dystrophin-Deficient Myoblasts 
In this study it was found that Akt is inactivated in dfd13 myoblasts, as phosphorylation 
at Ser473 or Thr308 was not detected. However, in C2C12 myoblasts Akt was 
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phosphorylated at Ser473 and the activated form accumulated upon differentiation. 
Immunofluorescence analysis showed that phosphorylated-Akt (Ser473) is localised to 
the membrane of C2C12 myotubes  but found less often in dfd13 myoblasts. During 
biosynthesis, nascent Akt is phosphorylated at Thr450 within the turn motif site and 
localised to the cytosol when in its inactive conformation. In the presence of signals via 
PI3K activation, Akt is recruited to the membrane through the binding of plekstrin 
homolog (PH) to PIP3. Once bound, the conformation is changed and this event 
unmasks two residues for phosphorylation, Ser473 and Thr308. In this study, less Akt-
phosphorylated at Ser473 was detected in dystrophin-deficient myoblasts, indicating 
that Akt is inactivated. According to Sarbassov et al. (2005), PDK1 has a better target 
on Akt phosphorylated at Ser473 than non-phosphorylated Akt. In line with the results 
shown in  
Figure 4.2, there is no Thr308 phosphorylation if Ser473 phosphorylation does not 
occur. However, the expression of total Akt did not show any significant difference 
when compared between both types of myoblast.  
Since Akt was found to only be phosphorylated at Ser473 the protein responsible 
for this phosphorylation event was investigated. It is known that mTORC2, specifically, 
rictor, can directly phosphorylate Akt at Ser473 in vitro and this facilitated Thr308 
phosphorylation by PDK1 in Drosophila (Sarbassov et al., 2005). In this study it was 
found that rictor is inactivated in both undifferentiated and differentiated dfd13 cells, 
which explains the absence of phosphorylated-Akt (Ser473) observed; however, the 
regulator for rictor activation in myoblasts remains unknown. Rictor phosphorylation 
has been shown to require mTORC1-activated p70S6K in MEF, HEK293 and HeLa 
cells (Julien et al. 2010). Recently, it has been showed that PTEN negatively regulates 
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mTORC2 signalling in glioma (Bhattacharya, Maiti, and Mandal 2016). As PTEN was 
found to be highly expressed in dfd13 myoblasts, inactivation of rictor can be seen as a 
consequence of this event and presumably represents the same scenario as in myoblasts. 
4.3.3 Reduction of p70S6 Kinase Activation Indicates Less mTORC1 
Activation and Suggests Inactivation of Akt in Dystrophin-Deficient 
Myoblasts 
Akt is not activated in dystrophin-deficient myoblasts which alters downstream protein 
regulation, as Akt is a key regulator of a diverse array of cellular functions, such as cell 
proliferation, differentiation, apoptosis and metabolism. One of the downstream 
proteins it regulates is p70S6K, which together with 4E-BP1 is responsible for protein 
synthesis. This is the best characterised substrate of mTORC1 kinase activity. Akt 
controls mTORC1 activation via a series of other protein activations i.e. PRASS40, and 
protein inhibitions, i.e. TSC1/2-RHEB complexes. 
The data showed that phosphorylated-p70S6K at Thr389 is decreased in dfd13 
myoblasts after differentiation. This indicates that mTORC1 is inactivated, in line with 
the inactivation of Akt (Figure 4.3), and there is less phosphorylated-mTOR at Ser2448 
Figure 4.4 upon differentiation. This suggests that protein synthesis regulation is 
disturbed thus impairing myoblast differentiation regulation. As p70S6K showed a 
decrease in activation, it can be suggested that rictor phosphorylation is mTORC1-
activated p70S6K dependent within myoblasts, which is in line with what occurs in 
reports for other cells (Julien et al., 2010). To the best of our knowledge, this is the first 
report describing the inactivation of Akt which is mTORC1-activated p70S6K 
dependent in dystrophin-deficient myoblasts and could be one of the causes for 
dystrophin-deficient myoblasts not achieving terminal differentiation. 
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4.4 Conclusions 
PTEN-PI3K/Akt and its downstream proteins are perturbed in dystrophin-deficient 
myoblasts.  
Key finding(s): 
• PTEN overexpression impairs PI3K/Akt signalling. 
• Activation of Akt (Ser473) is mTORC1-activated p70S6K dependent. 
• Protein synthesis and FoxO3 regulation is defective. 
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Chapter 5 - Autophagy is Defective in Dystrophin-Deficient 
Myoblasts 
5.1 Introduction 
It is known that the transcription factor FoxO3 controls autophagy in skeletal muscle; 
however, it remains unknown how autophagy is modulated in the mdx mouse as well as 
in DMD humans. In this study, dystrophin-deficient myoblasts were used to reveal the 
mechanism for this event. In Chapter 4 it was reported that PI3K/Akt and its 
downstream proteins are impaired in differentiating dystrophin-deficient myoblasts, 
and FoxO3 expression was shown to increase in dfd13 myoblasts after 10 days of 
differentiation.  
A previous study has demonstrated that in carcinoma cells an increase in Akt 
activity promotes nuclear exclusion of FoxO thus preventing FoxO-DNA binding and 
transcriptional activity (Brunet et al. 1999). Similarly, in colon and renal cancer cells 
which do not express PTEN, the accumulation of FoxO3 in the cytoplasm results in 
arrest in the G1 phase of the cell cycle (Nakamura et al., 2000). However, the situation 
may be different in dystrophin-deficient myoblasts where PTEN is excessively 
expressed upon differentiation. It has also been reported that autophagy is defective in 
mdx mice but can be rescued by long-term exposure to a low-protein diet (Clara De 
Palma et al. 2014).  
To further understand the impaired regulation of autophagy in dystrophin-
deficient myoblasts, the protein profiling of this pathway has been determined which 
provides information on autophagy modulation and activation.  An overview of this 
chapter is presented in Figure 5.1. 
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Figure 5.1: Chapter overview: accumulation of nuclear-FoxO3 increases autophagosome formation but exhibits an autophagy flux reduction in 
dystrophin-deficient myoblasts 
Accumulation of translocated-FoxO3 to the nucleus increases the expression autophagy related proteins, i.e. Atg5, Atg7, Beclin1. As a result, phagophore 
formation is increased and the maturation of autophagosome by Atgs; however, autophagic flux is reduced. The perturbation of PI3K/Akt increases nuclear-
FoxO3, thus modulating excessive autophagosome formation while reducing autophagic flux in dystrophin-deficient myoblasts. 
Decreased Increased 
No 
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5.2 Results 
5.2.1 FoxO3 Is Predominantly Localised in the Nucleus of Differentiating 
Dystrophin-Deficient Myoblasts 
Akt represses FoxO3 via phosphorylation resulting in nuclear exclusion. As Akt is not 
activated in dfd13 myoblasts,  it was speculated that unphosphorylted-FoxO3 
translocates into the nucleus and binds to the promoter, thus up-regulating autophagy 
related genes such as LC3B, Atg5 and Atg7. Therefore, FoxO3 expression and 
localisation needed to be examined within subcellular fractions, i.e. the nucleus and 
cytoplasm. 
 FoxO3 was found to be localised more to the nucleus of dfd13 myoblasts (Figure 
5.2A), with approximately 81.6% of FoxO3 present in the nucleus of dfd13 myoblasts 
compared to only ~47.6% in C2C12 myoblasts during the undifferentiated stage. 
Surprisingly, on day 10 of differentiation, levels in the nucleus had accumulated in both 
types of myoblast; C2C12 ~78.2%,  and dfd13 ~94.4%.  
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Figure 5.2: FoxO3a is predominantly localised in the nucleus of differentiating 
dystrophin-deficient myoblasts  
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and 
culturing in DM for 10 days with the media being changed every 2 days.  Subcellular protein 
extraction was performed at the indicated time points using the REAP protocol prior to 
immunoblotting with an antibody which recognises FoxO3a. (A) Immunoblot of the proteins 
during myoblast differentiation with α-tubulin and SSRP1 expression as loading controls. 
Densitometry analysis representing (B) FoxO3a expression in the cytoplasm and nucleus. ND: 
non-differentiated; GM: growth medium (DMEM + 10% FCS); DM: differentiation medium 
(DMEM + 2% horse serum); W: whole cell lysate; C: cytoplasm; N: nucleus; n=3. 
5.2.2 Autophagy Related Proteins Are Highly Increased in Differentiating 
Dystrophin-Deficient Myoblasts 
It has been shown that FoxO3 is highly expressed and primarily localised to the nucleus 
of differentiating dfd13 myoblasts. Within the nucleus, FoxO3 acts as a transcriptional 
activator that can recognise and bind to DNA sequences resulting in the activation of 
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genes involved in autophagy, such as those for Beclin1 and Atgs. It was hypothesised 
that autophagy is highly activated in differentiating dystrophin-deficient myoblasts. 
Figure 5.3 presents immunoblot and densitometry analyses of autophagy related 
proteins involved in autophagosome formation. Beclin1 expression was slightly 
increased in C2C12 myoblasts and highly increased in dfd13 myoblasts upon 
differentiation (Figure 5.3A). Densitometry analysis of Beclin1 expression showed 
significant accumulation on day 4 (p<0.05; p = 2.07x10-2), day 7 (p<0.05; p = 1.56x10-
2) and day 10 (p<0.01; p = 5.70x10-3) in dfd13 myoblasts compared to C2C12 myoblasts 
(Figure 5.3B).  
Atg5 was found to be expressed at low levels in C2C12 myoblasts (Figure 5.3A). 
It can be seen that Atg5 expression was increased upon differentiation in dfd13 
myoblasts, and expression was significantly increased on day 4 (p<0.01; p = 6.36x10-
3), day 7 (p<0.01; p = 6.13x10-4) and day 10 (p<0.01; p = 1.96x10-3) compared to the 
non-differentiated stage. Densitometry analysis also showed significant differences 
(p<0.01) for dfd13 myoblasts at every time point compared to C2C12 myoblasts (Figure 
5.3C).  
Densitometry analysis of Atg7 expression in dfd13 myoblasts showed its 
accumulation throughout the differentiation period; however, there was no significant 
difference in expression when compared to the non-differentiated stage in C2C12 
myoblasts. Expression showed a significant increase in dfd13 myoblasts when 
compared to the non-differentiated stage and also significant on day 4 (p<0.05; p = 
1.43x10-2), day 7 (p<0.05; p = 4.54x10-2) and day 10 (p<0.05; p = 2.74x10-2) compared 
to C2C12 myoblasts (Figure 5.3D).  
 128 
Autophagy is responsible for the removal of unfolded protein as well as 
dysfunctioning organelles, and has been reported to be constantly active within skeletal 
muscle (De Palma et al., 2014). Beclin1 is the protein responsible for the initiation of 
autophagosome formation and is also known as phagophore, while Atg5 and Atg7 are 
ubiquitin-like enzymes involved in the autophagosome elongation process. In this 
study, Beclin1, Atg5 and Atg7 showed enhanced expression in dfd13 myoblasts. 
However, in C2C12 myoblasts there was only a slight increase in the expression of 
Beclin1 and Atg7 which persisted throughout the differentiation period. Consequently, 
autophagosome formation (maturation) and autophagic flux during myoblast 
differentiation were investigated via immunoblotting and flow cytometry analysis, 
respectively. 
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Figure 5.3: Expression of autophagy related proteins is highly increased in 
differentiating dystrophin-deficient myoblasts 
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and 
culturing in DM for 10 days with the media being changed every 2 days. Protein extraction was 
performed at the indicated time points. (A) Immunoblot analysis of Beclin1, Atg5 and Atg7 
expression with α-tubulin expression as a loading control. Densitometry analysis representing 
(B) Beclin1, (C) Atg5, and (D) Atg7 expression. The graphs represent an average of four repeats 
from different samples. ND: non-differentiated; Significantly different: * (p<0.05) and ** 
(p<0.01) compared to C2C12 myoblasts; n=4.  
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5.2.3 Microtubule-Associated Light Chain-3B Conversion Is Increased in 
Differentiating Dystrophin-Deficient Myoblasts  
Autophagy related genes had been shown to be highly activated, and the next step was 
to determine whether a double-membraned vesicle, known as autophagosome, had been 
formed. The conversion of Light Chain-3B (LC3B-I) to LC3B-II can be considered to 
represent total autophagosome formation in myoblasts during differentiation.  
As shown in Figure 5.4A, expression of LC3B-I and LC3B-II is increased in 
both differentiating C2C12 and dfd13 myoblasts when compared to the respective non-
differentiated myoblasts. LC3B-I expression in differentiated dfd13 myoblasts was 
significantly higher (p<0.01; p = 3.41x10-3) at day 10 when compared to differentiated 
C2C12 myoblasts (Figure 5.4B). LC3B-II was found to accumulate upon differentiation 
in both types of myoblasts, but was higher in dfd13 myoblasts, with a  significant 
difference on day 10 (p<0.05; p = 1.69x10-2) when compared with to C2C12 myoblasts 
(Figure 5.4C). However, the LC3B-II/LC3B-I ratio showed a reduction in dfd13 
myoblasts compared to C2C12 myoblasts upon differentiation, and was significantly 
different (p<0.05; p = 5.33x10-2) (Figure 5.4D).  
LC3B-II levels correlate with the number of autophagosomes formed; however, 
this could indicate either the up-regulation of autophagosome formation or a blockage 
in autophagic degradation. In addition, it does not conclusively indicate autophagic 
degradation. Therefore, further analysis was performed to determine autophagic flux, 
with a lysosome inhibitor used as a positive control. 
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Figure 5.4: LC3B-II expression is decreased in differentiating dystrophin-deficient 
myoblasts 
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and 
culturing in DM for 10 days with the media being changed every 2 days. Total protein was 
extracted at the indicated time points prior to immunoblotting with an antibody recognising 
LC3B with α-tubulin expression as a loading control. Densitometry analysis of (B) LC3B-I 
expression, (C) LC3B-II expression, and (D) the ratio of LC3B-II/LC3B-I. The graphs represent 
an average of four repeats from different samples. ND: non-differentiated; significantly 
different: * (p<0.05) and ** (p<0.01) compared to C2C12 myoblasts; n=4.  
5.2.4 Autophagic Flux Is Decreased During Dystrophin-Deficient Myoblast 
Differentiation 
In order to accurately determine autophagic activity, measuring the increase in the 
number of autophagosomes is required.  Previous data showed that LC3B conversion 
was increased in C2C12 but reduced in dfd13 myoblasts upon differentiation; however, 
the results from measuring LC3B conversion alone could be inappropriately interpreted. 
LC3B-II itself has been reported to be degraded by autophagy and also tends to be more 
sensitive than LC3B-I during immunoblotting analysis (Mizushima and Yoshimori 
2007). Autophagosome formation is an intermediate stage of autophagy, and there could 
be either the generation of autophagosomes or the blocked conversion of 
autolysosomes. Therefore, the accurate measurement of autophagic flux is required. In 
this study a Cyto-ID autophagy detection kit was utilised which selectively labelled 
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autophagic vacuoles independent of the LC3B protein, thus eliminating the need for 
transfection. This detection kit employs a 488nm-exitable green-emitting fluorescent 
probe to highlight various vacuolar components of autophagy. Chloroquine was used as 
a control as it passively diffuses into lysosomes and increases the pH, thus inhibiting 
lysosome function and blocking fusion with autophagosomes to become an 
autolysosome. 
Figure 5.5 presents the density plots (A-D) and histograms (E-H) from flow 
cytometry-based profiling for both C2C12 and dfd13 myoblasts in the non-
differentiated and differentiated state. From the density plot images, the size and 
complexity of each myoblasts can be determined. When the laser beam strikes the 
stream, a photon passes through unobstructed, but when it  strikes a cell there are two 
different sizes of angle produced. When a photon strikes the cytoplasm, which is less 
dense and translucent, a small angle of reflection is generated and which can be detected 
by the forward scatter detector. In contrast, when a photon strikes an organelle such as 
nucleus or ER (denser), then a wide angle of reflection is generated which is detected 
by side scatter detector. The forward scatter (FS: X-axis) is proportional to the size, 
meaning that the bigger a cell the more light that will be scattered and a higher signal 
will be detected. The side scatter (SS: Y-axis) is proportional to the complexity of the 
myoblasts.  
Based on the density plot images, it can be seen that the dfd13 myoblasts (Figure 
5.5B) are smaller and less complex than C2C12 myoblasts (Figure 5.5A), although the 
differences between these cells are not obvious. After differentiation it can be seen that 
C2C12 cells become more complex (Figure 5.5C) while dfd13 cells remain the same 
(Figure 5.5D). As both myoblasts were labelled with FITC (green fluorescence), this 
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analysis was taken beyond the basic characteristics of myoblasts, as the specific protein 
behaviour of the antibody-tagged protein can be accurately measured. The signal was 
collected and measured/read by using a specific filter/channel based on the size of the 
emission and excitation of the fluorochrome used. 
A Cyto-ID autophagy detection kit and FITC was utilised to label/stain 
autophagosomes. The collected data was gated and analyses were performed based on 
the myoblasts in the gated region. Histograms were then plotted, as shown in Figure 
5.5E-H; the black line indicates the unstained myoblasts (negative control), the blue line 
stained myoblasts, and the red line stained myoblasts treated with chloroquine (positive 
control). From the histograms data were gated based on the intensity (101-103) (X-axis) 
and then the percentage obtained. 
Generally, both treated and non-treated myoblasts showed a reduction in 
autophagosome counts after 10 days of differentiation. Non-treated myoblasts had less 
autophagosomes when compared to treated myoblasts, which is due to chloroquine 
acting as a lysosome inhibitor, preventing autophagosome from fusing with lysosomes 
and causing the accumulation of autophagosomes. As illustrated in Figure 5.5I, the 
number of autophagosomes was significantly decreased after 10 days of differentiation 
in both non-treated C2C12 myoblasts (p= 1.98x10-2) and dfd13 myoblasts (p= 1.59x10-
2) when compared to non-differentiated stage. It was also significantly decreased in 
treated C2C12 myoblasts (p= 2.34x10-3) and dfd13 myoblasts (p= 3.44x10-3) after 10 
days of differentiation. There was a significant reduction in autophagosomes in dfd13 
myoblasts when compared to C2C12 myoblasts at the equivalent stages and treatment. 
From these results autophagy flux can be determined. Autophagic flux can be 
calculated by subtracting the chloroquine-treated from the untreated myoblasts, which 
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enables the total number of non-fused autophagosomes to be measured and also the total 
number of autophagosomes formed. As depicted in Figure 5.5J, autophagic flux was 
increased in C2C12 myoblasts after 10 days of differentiation, whereas it was reduced 
in dfd13 myoblasts. When compared to non-differentiated C2C12 myoblasts, the 
number of autophagosomes in dfd13 myoblasts was significantly higher (p= 3.64x10-2) 
and was slightly higher in differentiated dfd13 myoblasts compared to differentiated 
C2C12 myoblasts.   
Overall, autophagy activity was decreased upon differentiation in dystrophin-
deficient myoblasts. Based on the flow cytometry analysis, autophagic flux was 
decreased, as the total number of autophagosomes detected was higher in dfd13 
myoblasts (both non-differentiated and differentiated) when compared to C2C12 
myoblasts. In addition,  autophagy was 2-fold higher in non-differentiated myoblasts 
(proliferation state) compared to the differentiated state.  
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Figure 5.5: Autophagic flux is reduced in differentiating dystrophin-deficient myoblasts 
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and 
culturing in DM for 10 days with the media being changed every 2 days.. Three different 
conditions were set up for each stage: 1) unstained cells (negative control); 2) stained cells; and 
3) stained cells with chloroquine treatment (positive control). Chloroquine treatment was 
consisted of 3 hours’ incubation at 37°C.  Cells were trypsinised and incubated with Cyto-ID 
Green stain solution prior to analysis using the FITC channel of a CyAn B flow cytometer 
(Beckman Coulter, USA). Data analysis was  performed using FCS Express 6 Plus Research 
Edition De Novo Software, USA). The density plot images represent non-differentiated (A) 
C2C12 myoblasts, (B) dfd13 myoblasts; day10 differentiation (C) C2C12 myoblasts and(D) 
dfd13 myoblasts. The histogram overlays (E-H) represent each neighbouring dot plot. (I) The 
percentage of autophagosomes detected in myoblasts and (J) percentage of autophagic flux 
within myoblasts. All bar graphs represent an average of three repeats from different samples. 
DM: differentiation medium; ND: non-differentiated; * (p<0.05) significantly difference when 
compared to C2C12 myoblasts. # (p<0.05) when compared with ND; § (p<0.05) when 
compared to DM+CLQ; n=3. 
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5.3 Discussion 
5.3.1 Excessive Formation of Autophagosome in Dystrophin-Deficient 
Myoblast via FoxO3-Mediated Regulation  
In skeletal muscle, autophagy is transiently activated and continues for only a few days 
(Mizushima 2004; Clara De Palma et al. 2014) it is regulated via FoxO3. Generally, it 
can be seen that autophagosomes are formed in both types of myoblast during 
differentiation, as the autophagy related protein involved in the initiation and elongation 
process was found to be increased (Figure 5.3). The ratio of LC3B-I converted to LC3B-
II also reflected the formation of autophagosomes during differentiation (Figure 5.4).  
The data presented here suggest that autophagosome formation is modulated via 
FoxO3 in dfd13 myoblasts. Inactivation of Akt allowed the active-form of FoxO3 
(unphosphorylated) to translocate into the nucleus and trigger the expression of 
autophagy related genes. FoxO3 is required for the transcriptional regulation of LC3B. 
and also for transcriptional regulation of MAFbx and MuRF1. This transcriptional 
regulation leads to protein degradation via the autophagy-lysosome pathway and 
ubiquitin-proteosome pathway, respectively. However, autophagy in C2C12 myoblasts 
seems to be only partially FoxO3-mediated, as subsequent activation of Akt inhibited 
FoxO3 and suppressed its translocation to the nucleus and the targeting of autophagy-
related gene activation. Activated-Akt, through phosphorylation at Ser473 by rictor-
mTORC2, also contributes to autophagy activation during C2C12 myoblast 
differentiation (Shu and Houghton 2009; Ge and Chen 2012). 
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5.3.2 Modulation of Atg5-Dependent Autophagy During Differentiation of 
Dystrophin-Deficient Myoblasts 
Autophagy is responsible for removing unfolded proteins as well as dysfunctioning 
organelles, and has been reported to be constantly active within skeletal muscle. 
Recently, increased autophagy has been reported to protect differentiating myoblasts 
from apoptotic cell death (McMillan and Quadrilatero 2014). Several autophagy related 
genes are known to be involved in the formation of autophagosomes, and FoxO3 has 
been shown to induce multiple autophagy related genes, including LC3B transcription 
in skeletal muscle (Mammucari et al., 2007). LC3B is an isoform of LC3 which plays a 
critical role in autophagy via post-translational modification.  
LC3B is a subunit of microtubule-associated protein 1 (MAP1LC3B), and LC3 
is cleaved by Atg4 to become cytosolic LC3B-I. LC3B-I is then converted to lipidated-
LC3B-II through the conjugation of membrane lipid phosphatidylethanoleamine (PE), 
which involves the E1-like enzyme ubiquitin, Atg7 and the E2-like enzyme, Atg10. 
LC3B-II then binds to the isolation membrane and mediates membrane elongation until 
the edges fuse to form an autophagosome. The isolation membrane appears when cells 
are placed under starvation conditions. Atg7 also conjugate Atg5 to Atg12 to form the 
Atg5-Atg12 complex and then bind to the isolation membrane with Atg16. This 
complex binding is necessary for autophagosome formation. 
In this study, the results showed that LC3B-I was increased in both types of 
myoblast due to the up-regulation of Beclin1 by nuclear-FoxO3, which is increased in 
dystrophin-deficient myoblasts (Figure 5.3). Beclin1 forms a complex with Vsp34 and 
becomes a core component during the pre-autophagosome stage. This complex then 
binds to the ULK1/Atg13/FIP200/Atg101 complex before entering the elongation stage, 
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when  Atg7 catalyses the ligation of Atg5 to Atg12 to become the Atg5-Atg12 complex. 
With the aid of the Atg5-Atg12 complex, Atg7 catalyses the transfer of PE to LC3B-I, 
converting it to LC3B-II, resulting in the accumulation of LC3B-II within dfd13 
myoblasts (Figure 5.4). Therefore, autophagosomes can be formed even when Atg5 is 
not present and so it can be suggested that Atg5 plays a booster role for autophagosome 
formation in dfd13 myoblasts. Autophagy in C2C12 myoblasts might also activated via 
PERK-mediated CHOP (Matsumoto et al., 2013), which is investigated in Chapter 6. 
Although the expression of both LC3B-I and LC3B-II in differentiating dfd13 
myoblasts accumulates until day 10, the conversion ratio of LC3B-I to LC3B-II was 
reduced in dystrophin-deficient myoblasts, indicating that autophagy regulation is 
impaired (Figure 5.5).  
It has been reported that autophagy is induced upon myoblast differentiation in 
order to eliminate pre-existing structures and proteins. This elimination occurs 
concomitantly with the myoblast fusion process prior to the formation of multinucleated 
myotubes. Based on the results presented, autophagy is activated in both types of 
myoblasts; however, over expression of Atg7 and Atg5 in dystrophin-deficient 
myoblasts suggests that the ubiquitin-like system is impaired. This could affect cascade 
activation which in turn will affect autophagosome formation, as well as autophagic 
flux in dystrophin-deficient myoblasts. 
5.3.3 Reduction in Autophagic Flux suggests there is Defective Autophagy 
in Dystrophin-Deficient Myoblasts   
From the data obtained the increased expression of autophagy related genes (Atg5, Atg7 
& Beclin1) demonstrates excessive autophagosome formation in dfd13 myoblasts 
during differentiation; however, the conversion ratio of LC3B-I to LC3B-II was reduced 
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in dystrophin-deficient myoblasts. Furthermore, although activation was higher, 
autophagic flux analysis showed a reduction upon differentiation and revealed that 
autophagy activity is decreased upon differentiation in dfd13 myoblasts. Therefore, it 
was suggested that after excessive autophagosome formation in non-differentiated 
dfd13 myoblasts could potentially undergo apoptosis during differentiation. Previously, 
our group has shown that the ratio of cleaved caspase-3 to uncleaved caspase-3 is 
increased in a derivative of dfd13 myoblasts, PD50A when cultured in DM (Chen, 
2013). This finding fits with the current data obtained and in the next chapter it is shown 
that dystrophin-deficient myoblasts are prone to apoptosis via PERK-mediated CHOP 
under ER stress conditions. 
DMD is mostly characterised by ~2 years of age and it progresses until the early 
30s. Therefore, the applicability of this finding to the understating of DMD patients may 
fit with the actual scenario. During the early stage of life (new born to below 2 years),  
deficient myoblasts survive as most cells are actively proliferating and high levels of 
autophagy activation is able to prevent apoptosis. As age increases (>2 years old), most 
of the deficient myoblasts have been triggered for differentiation as the body develops 
and muscle size and functionality increases, but now autophagy starts to decrease and 
apoptosis begins. This is the most common period for when DMD is diagnosed. At the 
later stage (~10 years-old), there is progressive disruption to the muscle due to 
loss/damage and support (wheelchair) is needed for mobility and undertaking daily life 
tasks. This state will worsen and patients will eventually die, commonly as a 
complication of respiratory muscle damage and cardiomyopathy (Figure 5.6) 
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Figure 5.6: Proposed sequence of autophagy events in DMD patients 
5.4 Conclusions 
From the data obtained, dystrophin-deficient myoblasts exhibit the high expression of 
autophagy related proteins. However, a reduction in autophagy activity, as well as 
autophagy flux upon differentiation, indicates that autophagy is defective. This finding 
suggests the reduction of autophagy in dystrophin-deficient myoblasts. The perturbation 
of the PTEN-PI3K/Akt pathway initially triggers excessive autophagosome formation, 
and subsequently there is a reduction in autophagic flux within dystrophin-deficient 
myoblasts. 
Key finding: 
• Autophagy regulation is defective in differentiating dystrophin-deficient 
myoblasts.  
Newborn to <2 years-old
- Proliferation/quiescent 
state of dystrophin-deficent 
myoblasts.
- Active autophagy event for 
dystrophin-deficent myoblast 
survival.
- Prevent/less apoptosis.
>2-10 years-old
- Most dystrophin-deficent 
myoblasts are triggered/ 
induced to be differentiated
- Reduction in autophagy
- Apoptosis begins
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Chapter 6 - Unfolded Protein Response is Impaired in 
Differentiating Dystrophin-Deficient Myoblasts 
6.1 Introduction 
During muscle fibre development there are series of myoblast conversions, i.e. 
alignment and fusion, before the formation of multinucleated fibres called myotubes. 
Myotubes re-organised and form muscle fibres which spontaneously contract once 
maturation is achieved. Each series of conversions is coordinated by the activation of 
various signalling pathways. For instance, during myoblast fusion to form 
multinucleated myotubes, cell surface proteins, as well as intracellular proteins, require 
the activation of signalling pathways, which then modulate membrane changes and 
cytoskeletal rearrangements. In addition to the fusion event, unfolded or misfolded 
proteins accumulate in the ER (Nakanishi, Dohmae, and Morishima 2007), which is 
known as ER stress and is essential for successful myotube formation. Therefore, a 
dynamic unfolded protein response needs to be achieved in order to maintain ER 
homeostasis. 
ER stress has been reported to be involved during myotube formation 
(Nakanishi et al., 2007) and been proven to be required during myoblast differentiation 
(Rayavarapu, Coley, and Nagaraju 2012; Screen et al. 2014). ER stress is triggered due 
to the loss of homeostasis in ER lumen during the transition when myoblasts become 
multinucleated. Under these circumstances myoblasts exhibit two types of response 
which lead to survival and/or apoptosis. The ER is a storage location for Ca2+ which 
plays a role as a second messenger in regulating several cellular functions. The correct 
concentration of this ion is extremely important, especially for the formation of 
disulphide bonds and correct protein folding, together with maintaining protein 
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regulation during differentiation. This is finely regulated by a complex machinery, 
including plasma membrane Ca2+ATPase (PMCA), Na+/Ca2+ exchanger (NCX), 
inositol 1,4,5-triphospate receptor (InsP3R) and sarcoplasmic reticulum Ca
2+ATPase 
(SERCA). In this study, it is suggested that Ca2+ leaks via InsP3R into the cytosolic 
space which is affected by high PLC-γ1 activation in dystrophin-deficient myoblasts. 
The absence of dystrophin has also been thought to affect this myoblast fusion 
via PIP2 regulation on the membrane; however, the signalling cascade that modulates 
this process remains unclear although inositide regulation/signalling is also thought to 
be disturbed/impaired during differentiation. In Chapter 4 it was reported that PTEN is 
highly expressed in differentiating dystrophin-deficient myoblasts, which causes the 
abundant production of PIP2 which is a substrate for PLC. PLC catalyses the hydrolysis 
of PIP2 to diacyl glycerol (DAG) and IP3, with the latter triggering SERCA to open 
allowing Ca2+ to be released into the cytoplasmic compartment. This change to the ER 
stress level stimulates the activation of the unfolded protein response (UPR). 
Meanwhile, DAG binds to PKC, and binding of Ca2+ will also change PKC regulation.  
Therefore, it was hypothesised that high PLC activation disturbs the ER stress 
level subsequently affected UPR activation at the same time disturbs PKC regulation 
and thus impairs dystrophin-deficient myoblast differentiation. In this chapter how the 
elevation of PTEN conveys a signal to C/EBP homolog protein (CHOP) via UPR 
regulation during myoblast differentiation in vitro is investigated. These mechanisms 
could support and explain the elevation of Ca2+ in mdx mice and in DMD human fibres, 
as has been reported (Mallouk, Jacquemond, and Allard 2000; Han, Grounds, and 
Bakker 2006). An overview of the chapter is presented in Figure 6.1. 
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Figure 6.1: Chapter overview: elevation of PTEN expression contributes to the perturbation of PLC and PKC signalling and subsequently changes 
UPR modulation in dystrophin-deficient myoblasts 
PTEN overexpression increases PLC-γ1 activation which causes a reduction in the ER stress level. Subsequently, modulation of UPR is changed and activation 
of CHOP tends to results in the activation of apoptosis rather than ERAD machinery activation. Meanwhile, phosphorylated-PKC levels are altered, which 
effects downstream protein activation, i.e. ERK1/2. From this chapter, it can be concluded that dystrophin-deficient myoblasts show a tendency for apoptosis 
modulated by PERK-mediated CHOP. ERAD: ER-associated degradation 
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6.2 Results 
6.2.1 Phospholipase C Gamma-1 Activation Is Increased in Differentiating 
Dystrophin-Deficient Myoblasts 
A study by Valdes et al. (2013) demonstrated that PI3K also regulates PLC-γ1 
activation when myoblast was induced by Igf-1 (Valdés et al. 2013). In Chapter 4 it was 
shown that PTEN is highly expressed in dystrophin-deficient myoblasts during 
differentiation, which leads to an abundance of PIP2 and triggers the high level 
activation of PLC signalling. There are different subfamilies/isotypes of PLC, known 
such as beta, gamma, delta, epsilon, eta and zeta. However, in this study, PLC-γ1 is the 
only isotype that is examined because its activator is known to be either a non-receptor 
or protein receptor tyrosine kinase which is involved in myoblast differentiation. 
The activity of PLC, specifically subunit γ1, was measured, as this has 
previously been reported to be activated during myoblast differentiation (Gaboardi et 
al. 2010; Valdés et al. 2013). Figure 6.2A shows an immunoblot of PLC-γ1 expression 
and its phosphorylated form at Tyr783. Figure 6.2B and Figure 6.2C show the 
densitometry analysis of PLC-γ1 expression and activity, respectively. Total PLC-γ1 
was constantly expressed in C2C12 myoblasts compared to the non-differentiated state. 
However, in dfd13 myoblasts there was a significant accumulation on day 7 (p<0.05; p 
= 4.67 x 10-2) and day 10 (p<0.05; p = 4.52 x 10-2) compared to non-differentiated dfd13 
myoblasts. 
In C2C12 myoblasts it can be clearly seen that PLC-γ1 activity remains constant 
in both non-differentiated and differentiated cells throughout the differentiation period. 
However, in dfd13 myoblasts PLC-γ1 activity was accumulated following 
differentiation, and a significant increase in activation was noted on day 7 (p = 1.44 x 
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10-2) and day 10 (p = 2.27 x 10-2) compared to the non-differentiated state. PLC-γ1 
activation in dfd13 myoblasts also showed a significant increase after differentiation on 
day 4 (p<0.01; p = 4.52 x 10-3), day 7 (p<0.01; p = 4.82 x 10-5) and day 10 (p<0.01; p 
= 9.49 x 10-3) compared to C2C12 myoblasts.  
The elevation of PLC-γ1 activation was thought to be due to the conversion of 
PIP2 produced by elevated PTEN levels. PIP2 is a minor membrane component that is 
exclusively located in the cytoplasmic leaflet of the plasma membrane. PLC hydrolyses 
PIP2 into IP3 and DAG, which subsequently activate IP3R and PKC, respectively.  
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Figure 6.2: PLC-γ1 is highly activated in differentiating dystrophin-deficient myoblasts  
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and 
culturing in DM for 10 days with the media being changed every 2 days.   Total protein was 
extracted at the indicated time points prior to immunoblotting with antibodies recognising 
phospho-PLC-γ1 and PLC-γ1. (A) Immunoblot analysis during myoblast differentiation with 
α-tubulin expression as a loading control. Densitometry analysis of (B) PLC-γ1 expression and 
(C) PLC-γ1 activity. The graphs represent an average of three repeats from different samples. 
ND: non-differentiated; *: significantly different (p<0.05) compared to dfd13 myoblasts. **: 
significantly different (p<0.01) compared to dfd13 myoblasts; GM: growth medium (DMEM + 
10% FCS); DM: differentiation medium (DMEM + 2% horse serum); n=3. 
6.2.2 CHOP Expression is Reduced in Early Differentiating Dystrophin-
Deficient Myoblasts 
Previous studies have shown that ER stress occurs during myoblast differentiation 
(Nakanishi et al., 2007; Rayavarapu et al., 2012); consequently, the UPR is activated. 
During ER stress, unfolded and misfolded proteins accumulate in the ER lumen and in 
the short term, the UPR inhibits protein synthesis, whereas in the longer term, the UPR 
leads to adaptive changes, such as an increase in ER protein folding chaperones; if this 
is not sufficient to alleviate the stress, then apoptosis will occur. It was hypothesised 
that UPR regulation is impaired in dystrophin-deficient myoblasts. Therefore, CHOP 
expression together with the activation of transmembrane receptor markers, i.e. 
phospho-eIF2α and ATF6, were examined throughout the myoblast differentiation 
period. 
C 
 * 
 * 
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A control experiment was performed to determine CHOP expression following 
induction with 10 µg/mL of tunicamycin (Figure 6.3). Tunicamycin is an antibiotic that 
inhibits glycoprotein synthesis (inhibitor of N-glycosylation) and subsequently causes 
ER stress. Generally, both types of myoblast showed the accumulation of CHOP 
following 8 hours of tunicamycin treatment (Figure 6.3A). However, there was higher 
expression in C2C12 myoblasts after 4 hours (p<0.05; p = 4.42x10-2) and the highest 
level of CHOP expression was observed after 8 hours (p<0.05; p = 2.95x10-2) of 
tunicamycin treatment (Figure 6.3B). Expression was decreased in C2C12 myoblasts 
after 16 hours, but remained the same in dfd13 myoblasts. After 24 hours of tunicamycin 
treatment both types of myoblast were observed to detach from the plate surface (not 
shown). From this control experiment it can be suggested that dfd13 myoblasts 
exhibited lower ER stress after treated with tunicamycin, indicating that UPR regulation 
may be impaired. 
Immunoblot analysis (Figure 6.4A) showed an elevation in CHOP expression 
upon differentiation in both C2C12 and dfd13 myoblasts compared to their respective 
non-differentiated myoblasts. However, there was a non-identified band present on the 
blot, with a size of ~25 kDa. Densitometry analysis (Figure 6.4B) showed that CHOP 
expression was significantly increased (p<0.05; p = 4.39x10-2) on day 4 and even more 
so on day7 (p = 8.81x10-4) and day10 (p = 1.43x10-2) in differentiating C2C12 
myoblasts compared to non-differentiated myoblasts. However, in differentiating dfd13 
myoblasts, the accumulation of CHOP expression only showed a significant increase 
on day 7 (p<0.01; p = 1.44x10-3) which continued to increase until day 10 (p<0.01; p = 
3.45x10-4) compared to non-differentiated myoblasts. There was a significant difference 
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(p<0.05; p = 2.74x10-2) in CHOP expression in C2C12 myoblasts compared to dfd13 
myoblasts on day 4 of differentiation.  
Generally, the pattern of CHOP expression seems to be different between the 
two types of differentiating myoblasts. CHOP expression remained stable in 
differentiating C2C12 myoblasts, was slightly decreased on day 10 of differentiation, 
and was expected to decrease further over time. In contrast, CHOP expression in 
differentiating dfd13 myoblasts increased continuously until day 10 of differentiation 
and was expected to be increased further over time. Therefore, the next step is to 
investigate UPR markers in order to reveal which receptor is activated and conveys the 
signal. 
 151 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: Dystrophin-deficient myoblasts have reduced CHOP expression following 
tunicamycin treatment 
Myoblasts were cultured in GM until 80 to 90% confluent and then treated with 10µg/mL of 
tunicamycin (LKT laboratories, UK). Total protein was extracted at the indicated time points 
prior to immunoblotting with an antibody which recognises CHOP. (A) Immunoblot analysis 
of CHOP expression in myoblasts during tunicamycin treatment/induction with α-tubulin 
expression as a loading control. (B) Densitometry analysis of CHOP expression. The graph 
represents an average of three repeats from different samples. NT: Non-treated; *: significantly 
different (p<0.05) compared to dfd13 myoblasts. GM: growth medium (DMEM + 10% FCS); 
n=3. 
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Figure 6.4: CHOP expression is lower in early differentiating dystrophin-deficient 
myoblasts 
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and 
culturing in DM for 10 days with the media being changed every 2 days.  Total protein was 
extracted at the indicated time points prior to immunoblotting with antibodies which recognise 
CHOP and α-tubulin. (A) Immunoblot analysis of CHOP expression during differentiation with 
α-tubulin as a loading control. (B) Densitometry analysis of CHOP expression. The graph 
represents an average of four repeats from different samples. ND: non-differentiated; 
Significant different: * (p<0.05) compared to dfd13 myoblasts; GM: growth medium (DMEM 
+ 10% FCS); DM: differentiation medium (DMEM + 2% horse serum); n=3. 
6.2.3 ER Stress Activates the Phosphorylation of eIF2α via PERK Receptor 
and Deactivates ATF6 Transmission in Differentiating Dystrophin-
Deficient Myoblasts 
ER stress signalling has been reported to be transmitted through the activation of 
transcription factor-6 (ATF6) in C2C12 myoblasts during differentiation (Nakanishi, 
Sudo, and Morishima 2005). It can also be transmitted via the protein kinase RNA-like 
endoplasmic reticulum kinase (PERK) receptor, with subsequent phosphorylation of 
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eukaryotic initiation factor 2-α (eIF2α) prior to the attenuation of the translational 
process and cell cycle arrest at the G1 phase. However, some ATF4 triggers CHOP 
production and it can therefore be used as a marker of ER stress. 
CHOP expression has been shown to be lower in dfd13 myoblasts,  suggesting 
that transmission activation may be impaired. Immunoblot analysis (Figure 6.5A) 
showed that phospho-eIF2α is increased in differentiating dfd13 myoblasts compared 
to C2C12 myoblasts, where it remains the same. There was a significantly lower level 
(p<0.01; p = 4.26x10-4) in non-differentiated dfd13 myoblasts compared to non-
differentiated C2C12 myoblasts. Phosphorylated-eIF2α increased significantly 
throughout the differentiation period and there was a significant difference in  
expression in dfd13 myoblasts on day 4 (p<0.01; p = 9.73x10-3), day 7 (p<0.01; p = 
1.55x10-2) and day 10 (p<0.01; p = 6.56x10-3) compared C2C12 myoblasts (Figure 
6.5B). This indicates that PERK is less activated in proliferating dfd13 myoblasts. In 
the differentiation state it is auto-phosphorylated and subsequently phosphorylates 
eIF2α at Ser51. Higher levels of the phospho-form indicate high activation of PERK 
following ER stress induction.  
ATF6 is a unique transcription factor which is embedded in the ER and acts as 
a transmembrane protein. Activated ATF6 translocates to the Golgi and is subsequently 
cleaved by proteases to form an active 50 kDa fragment. This protein fragment activates 
the target genes for the UPR during ER stress. From the immunoblot data shown, it can 
be clearly seen that ATF6 signal activation is decreasing while eIF2α receptor activation 
increases in dfd13 myoblasts upon differentiation. ATF6 activity was measured using 
the ratio of cleaved ATF6 (50kDa) to total ATF6 (90kDa), and this showed a significant 
reduction of activation at day 4 (p = 3.49x10-3), day 7 (p = 3.74x10-2) and day 10 (p = 
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2.10x10-2) of dfd13 myoblast differentiation compared to C2C12 myoblasts (Figure 
6.5C). Although one of the receptor was turned down, a significant increase in phospho-
eIF2α can compensate for ATF6, and thus explains the high level of CHOP expression 
at the end of the differentiation period. 
From this analysis it can be suggested that ER stress in differentiating dfd13 
myoblasts switched the UPR signals for activation from ATF6 to the PERK receptor. 
During ER stress the majority of the phosphorylated-eIF2α will block ribosome 80s 
assembly, thus preventing protein translation and synthesis and causing cell cycle arrest. 
Under other conditions, phosphorylated-eIF2α can also trigger ATF4 translation, which 
in turn up-regulates CHOP. Therefore, this explains the lower CHOP expression in 
dfd13 myoblasts at day 4 of differentiation. CHOP acts as a dominant-negative inhibitor 
of DNA-binding when it is heterodimerised to another C/EBP partner.  
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Figure 6.5: ER stress activates the eIF2α receptor and deactivates the  ATF6 signal in 
differentiating dystrophin-deficient myoblasts 
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and 
culturing in DM for 10 days with the media being changed every 2 days.  Total protein was 
extracted at the indicated time points prior to immunoblotting with antibodies recognising 
phospho-eIF2α, ATF6 and α-tubulin. (A) Immunoblot analysis of phospho-eIF2α and ATF6-
90kDa and ATF6-50kDa expression during differentiation with α-tubulin as a loading control. 
(B) Densitometry analysis of phospho-eIF2α protein and (C) percentage of ATF6 according to 
fragment size. The graphs represent an average of three repeats from different samples. ND: 
non-differentiated; Significant different: * (p<0.05) and ** (p<0.01) compared to C2C12 
myoblasts; GM: growth medium (DMEM + 10% FCS); DM: differentiation medium (DMEM 
+ 2% horse serum); n=3. 
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6.2.4 Protein Kinase C Alpha Remains Activated While Protein Kinase C 
Beta II is Selectively Activated in Differentiating Dystrophin-
Deficient Myoblasts 
PKC activation requires a series of maturation steps before it can be catalytically 
function. This maturation steps consist of series of phosphorylation at the specific site 
based on type of isoform. It is thought that PKC could have high activation since PLC-
γ1 has been shown gave massive catalytic mechanism generating DAG and IP3 (Ca2+ 
released intracellularly). In order to confirm this hypothesis PKC phosphorylation was 
assessed by focussing on two different isoforms, PKC-α and PKC-β. These isoforms 
were chosen based on the report that they are involved in myoblast proliferation and 
differentiation (Capiati, Téllez-Iñón, and Boland 1999).  
Immunoblot analysis of PKC-α and PKC-βII and their phosphorylated forms is 
shown in Figure 6.6A. Densitometry analysis (Figure 6.6B-D) of both PKC isoforms 
showed that the degree of phosphorylation revealed maturation prior to being 
catalytically activated. Densitometry analysis of PKC-α phosphorylation at Thr638 
showed an increase throughout the differentiation period, with a significant increase in 
phosphorylation in C2C12 myoblasts seen after 10 day of differentiation (p<0.01; p = 
8.15 x 10-3) compared to the non-differentiated state. A significant increase  was shown 
for all time points  in dfd13 myoblasts compared to the non-differentiated state; day 4 
(p<0.05; p = 1.62 x 10-2), day 7 (p<0.05; p = 1.08 x 10-2) and day 10 (p<0.01; p = 7.77 
x 10-3) (Figure 6.6B). Both types of myoblasts showed a significant difference in 
phosphorylation throughout the differentiation period when compared to each other;  
day 4 (p<0.05; p = 1.87 x 10-2), day 7 (p<0.01; p = 6.16 x 10-3) and day 10 (p<0.05; p 
= 1.06 x 10-2) (Figure 6.6B).  
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Rapid phosphorylation of PKC-βII was observed and the activation pattern of 
the two different activation sites, Thr641 and Ser660, was assessed to confirm PKC-βII 
maturation. Densitometry analysis showed that phosphorylated-PKC-βII at Thr641 was 
decreased in C2C12 myoblasts whilst it remained the same in dfd13 myoblasts upon 
differentiation. The difference in this phosphorylation event continued to be significant 
as the C2C12 myoblasts differentiated; day 4 (p<0.05; p = 4.12 x 10-2), day 7 (p<0.01; 
p = 5.09 x 10-3) and day 10 (p<0.01; p = 7.42 x 10-5) compared to non-differentiated 
stage (Figure 6.6C). The level was significantly different in non-differentiated stage 
(p<0.01; p = 1.01x10-3) and day 4 (p<0.05; p = 2.17x10-2) of differentiation when 
compared to dfd13 myoblasts (Figure 6.6C).  
Phosphorylated-PKC-β at Ser660 was found to be significantly lower (p<0.05; 
p = 1.54x10-2) in dfd13 myoblasts compared to C2C12 myoblasts in the non-
differentiated state. Phosphorylation was increased in dfd13 myoblasts while it 
remained the same in C2C12 myoblasts upon differentiation. There was a significant 
difference in phosphorylated-PKC-βII found on day 7 (p<0.05; p = 3.33x10-2) and day 
10 (p<0.05; p = 3.69x10-2) in dfd13 myoblasts compared to C2C12 myoblasts (Figure 
6.6D). 
Generally, the physiological function of PKC can be achieved via three events, 
maturation, catalytic activation and targeting. Maturation consists of a series of 
phosphorylations at specific sites depending on the type of PKC. Catalytic activation 
occurs when DAG, Ca2+ and other substrates bind to a specific site within the C2 domain 
of PKC causing the conformational change required for its catalytic function. Then, 
activated PKC is targeted to a specific subcellular location. In this study, the maturation 
of PKC-α and PKC-ßII was determined before further DAG and Ca2+ binding. 
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Phosphorylation of the Thr638 residue in PKC-α and of Thr641 and Ser660 in PKC-βII 
was observed in both types of myoblasts. mTORC2 has been reported to target Thr638 
in PKC-α during myogenic differentiation (Jaafar et al. 2011). Inactivation of mTORC2 
(rictor-mTORC) is thought to impair the phosphorylation of PKC-α at Thr657, as it has 
been shown to not be activated in dfd13 myoblasts  (Chapter 4). Phosphorylation of 
PKC-α at Ser657 was not observed and phosphorylation of Thr500 was not assessed as 
this is a prerequisite for subsequent activation to occur. Therefore, it can also be 
suggested that non-phosphorylation of Akt at Thr308 in dfd13 myoblasts is not caused 
by a PDK1 impairment, as phosphorylation of PKC at Thr641 revealed its functionality 
(Figure 6.6C). PDK1 is responsible for phosphorylating PKC-βII at Thr500. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
0.5
1
1.5
2
2.5
3
ND Day 4 Day 7 Day 10P
h
o
p
h
o
ry
la
ti
o
n
 o
f 
P
K
C
-α
at
 T
h
r6
3
8
 
(p
P
K
C
a/
tu
b
)
Day of differentiation
C2C12
dfd13
C2C12 dfd13 
ND  
  
D4 D10 D7 ND D4 D10 D7 
Phospho-PKCα/βII 
α-tubulin 
α (Thr638) 
βII (Thr641) 
Phospho-PKCβII (Ser660) 
A 
B 
 * 
 * 
 ** 
 159 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6: PKC-α and PKC-βII regulation is impaired in differentiating dystrophin-
deficient myoblasts  
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and 
culturing in DM for 10 days with the media being changed every 2 days.  Total protein was 
extracted at the indicated time points prior to immunoblotting with antibodies recognising 
phospho-PKC-α/βII (Thr638/Thr641) and phospho-PKC-βII (Ser660). (A) Immunoblot 
analysis during myoblast differentiation with α-tubulin expression as a loading control. 
Densitometry analysis of (B) phosphorylation of PKC-α at Thr638, (C) phosphorylation of 
PKC-βII at Thr641, and (D) phosphorylation of PKC-βII at Ser660. The graphs represent an 
average of three repeats from different samples. ND: non-differentiated; *: significantly 
different (p<0.05) compared to dfd13 myoblasts. **: significantly different (p<0.01) compared 
to dfd13 myoblasts; GM: growth medium (DMEM + 10% FCS); DM: differentiation medium 
(DMEM + 2% horse serum); n=3. 
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6.2.5 Protein Kinase C Epsilon Is Highly Expressed in Differentiating 
Dystrophin-Deficient Myoblasts 
Levels of the ε-isoform of PKC were determined in order to investigate DAG-dependent 
PKC activity, since PLC-γ1 was shown to have high activity in dfd13 myoblasts. A 
study by Gaboardi et al. (2009) demonstrated that PKC-ε levels and its activity is 
increased in differentiated myoblasts after being administered via insulin. In this study, 
total PKC-ε expression was found to be increased in both types of myoblast. However, 
dfd13 myoblasts showed significantly higher expression and activity compared to 
C2C12 myoblasts; though detected at very low levels.  
Figure 6.7A presents the immunoblot analysis of the phosphorylated form of 
PKC-ε and total PKC-ε expression. Densitometry analysis of total PKC-ε expression 
(Figure 6.7B) showed the significant accumulation in dfd13 myoblasts compared to the 
C2C12 myoblasts; day 4 (p<0.01; p = 8.58x10-3), day 7 (p<0.05; p = 1.14x10-2) and day 
10 (p<0.05; p = 1.33x10-2). Expression was also significantly increased when compared 
to the non-differentiated state at day 4 (p<0.01; p = 3.31x10-3), day 7 (p<0.01; p = 
8.10x10-3) and day 10 (p<0.05; p = 6.36x10-3) (Figure 6.7B). Total PKC-ε expression 
in C2C12 myoblasts only showed a significant increase at day 10 when compared to the 
non-differentiated state (Figure 6.7B). 
The PKC-ε was found not activated in C2C12 myoblasts. PKC-ε activation 
showed a significant increase throughout the differentiation period; non-differentiated 
(p<0.05; p = 1.59x10-2), day 4 (p<0.01; p = 1.78x10-3), day 7 (p<0.01; p = 2.98x10-3) 
and day 10 (p<0.01; p = 2.66x10-4) compared to C2C12 myoblasts (Figure 6.7B). This 
data indicates the elevation of DAG from the high activity of PLC-γ1 which is a 
substrate for PKC-ε and thus activates the kinase catalytic domain. 
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Figure 6.7: PKC-ε is highly activated in differentiating dystrophin-deficient myoblasts  
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and 
culturing in DM for 10 days with the media being changed every 2 days.   Total protein was 
extracted at the indicated time points prior to immunoblotting with antibodies which recognise 
phospho-PKC-ε (Ser729) and PKC-ε. (A) Immunoblot analysis during myoblast differentiation 
with α-tubulin expression as a loading control. Densitometry analysis of (B) PKC-ε expression 
and (C) PKC-ε activity. The graphs represent an average of three repeats from different samples. 
ND: non-differentiated; *: significantly different (p<0.05) compared to dfd13 myoblasts. **: 
significantly different (p<0.01) compared to dfd13 myoblasts; GM: growth medium (DMEM + 
10% FCS); DM: differentiation medium (DMEM + 2% horse serum); n=3. 
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6.2.6 ERK1/2 Activity Is Decreased in Differentiating Dystrophin-Deficient 
Myoblasts 
ERKs have been reported to be activated when myogenesis is promoted by mitogen 
removal in C2C12 myoblasts (Gredinger et al. 1998). Activation of ERK by PKC-α via 
MEF activation is also a possible mechanism of MAPK activation in myoblasts 
(Schönwasser et al. 1998). Therefore, ERK activation was examined to determine 
whether high activation of PLC-γ1 affected ERK activation during dfd13 myoblast 
differentiation. Previous data has shown that PKC activation is disturbed in dystrophin-
deficient myoblasts. ERK consists of two similar protein kinases, known as ERK1 and 
ERK2, and phosphorylation activates kinase activity for protein translation in 
myoblasts. 
Figure 6.8 presents the analysis of ERK1/2 in both types of myoblasts during 
the non-differentiated and differentiated stages. An immunoblot of ERK1/2 expression 
and activation is shown in Figure 6.8A. Densitometry analysis (Figure 6.8B) of ERK1 
expression (approximately 44 kDa) showed its significant accumulation in both types 
of myoblasts upon differentiation compared to non-differentiated cells. There was also 
a significant difference between the two types of myoblast; ERK2 expression 
(approximately 42 kDa) was shown to accumulate in dfd13 myoblasts while expression 
remained the same in C2C12 myoblasts. A significant increase was found on day 7 
(p<0.05; p = 3.61x10-2) and day 10 (p<0.05; p = 2.31x10-2) compared to non-
differentiated dfd13 myoblasts (Figure 6.8C). A significant difference in expression on 
day 7 (p<0.05; p = 1.58x10-2) and day 10 (p<0.05; p = 1.12x10-2) was also shown in 
comparison to C2C12 myoblasts (Figure 6.8C). 
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As illustrated in Figure 6.8D, the activation of ERK1 was decreased in dfd13 
myoblasts upon differentiation, while in C2C12 myoblasts it was constantly expressed 
at the same level upon differentiation. A significant reduction was found on day 4 
(p<0.05; p = 4.03x10-2) when compared to non-differentiated dfd13 myoblasts, and a 
significant difference in the expression level was seen on day 4 (p<0.05; p = 3.82x10-2) 
day 7 (p<0.05; p = 3.44x10-2) and day 10 (p<0.05; p = 3.99x10-2) compared to C2C12 
myoblasts (Figure 6.8D). 
ERK2 activation showed a massive reduction in differentiating dfd13 myoblasts 
which was significant on day 4 (p<0.01; p = 7.39x10-3), day 7 (p<0.05; p = 1.87x10-2) 
and day 10 (p<0.05; p = 1.09x10-2) compared to the non-differentiated state (Figure 
6.8E). The significant accumulation of ERK2 activation was seen in C2C12 myoblasts 
on day 4 (p<0.05; p = 1.98x10-2) but activation was significantly reduced on day 7 
(p<0.01; p = 3.09x10-3) and day 10 (p<0.05; p = 4.42x10-2) compared to non-
differentiated C2C12 myoblasts. A significant difference in ERK2 activation was found 
on day 4 (p<0.01; p = 1.75x10-3), day 7 (p<0.01; p = 7.53x10-3) and day 10 (p<0.05; p 
= 8.28x10-2) when compared between the two types of myoblasts (Figure 6.8E). 
From the data obtained, ERK1/2 activation was reduced in dfd13 myoblasts 
during differentiation. ERK1/2 is phosphorylated by MEK at Thr202 and Thr204 in 
response to external stimuli, such as insulin. This phosphorylation is required for 
activation and conformational changes which enable interactions with substrates.  
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Figure 6.8: ERK1/2 is down-regulated in differentiating dystrophin-deficient myoblasts  
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and 
culturing in DM for 10 days with the media being changed every 2 days.  Total protein was 
extracted the indicated time points prior to immunoblotting with antibodies which recognise 
phospho-ERK1/2 and ERK1/2. (A) Immunoblot analysis during myoblast differentiation with 
α-tubulin expression as a loading control. Densitometry analysis of (B) ERK1, (C) ERK2 
expression, and (D) phospho-ERK1, (E) phopsho-ERK2 activity. The graphs represent an 
average of three repeats from different samples. ND: non-differentiated; *: significantly 
different (p<0.05) compared to dfd13 myoblasts. GM: growth medium (DMEM + 10% FCS); 
DM: differentiation medium (DMEM + 2% horse serum); n=3.  
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6.3 Discussion 
6.3.1 Increased PLC Activity Increases the Cytosolic Calcium 
Concentration which Impairs Endoplasmic Reticulum Stress in 
Differentiating Dystrophin-Deficient Myoblasts 
One of the problematic conditions faced in dystrophic muscle is the loss of membrane 
integrity causing an increase in Ca2+ permeability, known as Ca2+ leakage. Ca2+ leaks 
into the cell through the damaged membrane causes an elevation in cytosolic Ca2+ 
within muscle fibre. It also has been reported that Ca2+ leakage occurs from the ER to 
the cytosolic space, as SERCA activity is found to be reduced which suggests a 
reduction of ER stress in dystrophic muscle (Divet and Huchet-Cadiou 2002; 
Goonasekera et al. 2011). However, the mechanism/signalling/regulation of Ca2+ 
leakage from the ER to the cytosolic space through IP3R remains uncertain. In this study 
it has been shown that the reduction of ER stress might be caused by high PLC activity 
derived from the overexpression of PTEN.   
In Chapter 4 it was shown that PTEN expression is highly increased in 
differentiating dfd13 myoblasts and this has an effect on the PI3K/Akt pathway ( 
Figure 4.2). In this chapter, the regulation of PLC and PKC was examined, 
together with ER stress, which are all thought to be affected by the high expression of 
PTEN in dystrophin-deficient myoblasts. PTEN is known to be a tumour suppressor 
which plays a role in the conversion of PIP3 to PIP2 via a dephosphorylation event. As 
PTEN is highly expressed ( 
Figure 4.2), a high level of PIP2 is presumed to formed which will subsequently 
increase PLC activity. A study by Hong et al. (2001) reported that PLC plays a role in 
IGF-1 induced muscle differentiation, and the isoform PLC-γ1 has been widely reported 
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to be involved in this event. PLC-γ1 is also involved in the activation of focal adhesion 
kinase (FAK), which is required in cytoskeletal organisation as it directly interacts with 
the cytoplasmic tail of integrin-β1 (Hong et al. 2001; Choi et al. 2007). This indicates 
that the absence of dystrophin could also impair PLC regulation.  
During myoblast differentiation PI3K is activated via a series of 
phosphorylation events following Igf-1 induction. In addition to Akt activation, PI3K 
has also been shown to control the activation of the PLC-γ1/IP3 pathway, as inhibition 
of PI3K blocks PLC-γ1 activation. Valdes et al. (2013) reported that during myoblast 
differentiation, calcium is released from intracellular stores, which is mediated by the 
PLC signalling pathway. This has been coordinated dynamically such that over 
activation will cause excessive calcium to be released from the ER via the IP3R into the 
intracellular space. Since the calcium concentration has been reported to be elevated in 
mdx mice and DMD human fibres, this finding regarding the high activation of PLC 
being affected by high PTEN expression may be cause. High activation of PLC 
produces IP3 and DAG, which bind to IP3R and PKC, respectively. Once bound to IP3R, 
the channel is opened and subsequently causes calcium to be released into the 
cytoplasm. Concurrently, DAG bound to PKC will open its active site, enabling 
phosphorylation of its substrates, such as RAF. The downstream proteins of MAP 
kinase will also be affected, such as ERK1/2 expression and activation. 
Although previous studies have shown that a lack of dystrophin causes calcium 
leakage from the extracellular space into the cell through the damaged membrane, this 
study suggests that elevation of cytosolic calcium concentration due to leakage from the 
ER may also occur. Calcium homeostasis is regulated by the presence of protein 
chaperons, known as Ca2+ binding proteins. The chaperons, such as binding 
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immunoglobulin protein (BiP/Grp78) and calreticulin, function as buffers which have a 
low-affinity and large-capacity for Ca2+ binding (Kaufman and Malhotra 2014). In this 
case, released calcium will cause a reduction of Ca2+/BiP and/or Ca2+/calreticulin thus 
reducing the ER stress level (Figure 6.5). However, the actual calcium concentration in 
the ER could not be measured and instead expression of the ER stress protein marker, 
CHOP, as well as its receptor activation on the ER was assessed in order to determine 
the stress level. It was found that CHOP expression is low initially and increases upon 
differentiation in dystrophin-deficient myoblasts, indicating that ER homeostasis is 
impaired (Figure 6.5).  
6.3.2 Expression of CHOP via PERK May Leads to Dystrophin-Deficient 
Myoblasts Apoptosis 
CHOP is induced by nutrient depletion and a previous study has shown that ER stress 
occurs during myoblast differentiation (Nakanishi et al., 2005). In this study, myoblasts 
were cultures in serum-deprived medium by using a low percentage of horse serum 
which can considerably slow down proliferation and switch myoblasts to differentiate 
into multinucleated myotubes. This condition can disrupt/change ER homeostasis and 
subsequently cause ER stress. By activating the UPR mechanism, ER stress can be 
countered and ER homeostasis restored. The UPR is used to alleviate the effects of ER 
stress via receptor-based activation, but excessive activation causes apoptosis. There 
are three classic specific responses involving three ER stress sensors: 1) PERK, 2) 
ATF6 and 3) IRE1. The activation of UPR via these sensors up regulates ER stress 
proteins such as BiP/Grp78 (binding immunoglobulin protein) and CHOP (GADD153; 
growth arrest DNA damage inducible protein 153) in order to increase the protein 
folding capacity within the ER. The up-regulation of all the proteins involved will 
restore ER homeostasis. 
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In C2C12 myoblasts both receptors are constantly activated upon myoblast 
differentiation; however, dfd13 myoblasts showed a different pattern of UPR activation. 
In non-differentiated state, UPR activation is highly exhibited via the ATF6 receptor 
rather than PERK; upon differentiation, this is a switch to PERK and ATF6 shows less 
activation. This may explain the lower levels of CHOP expression observed 4 and 7 
days after differentiation. ATF6 is a transmembrane-transcription factor embedded in 
the ER membrane where Grp78/BiP binds to it. During ER stress, Grp78/BiP is 
dissociated and ATF6 become activated before being translocated to the Golgi and 
cleaved by proteases (S1P and S2P) to become a 50kDa-ATF6 (N-terminal cyclic AMP-
dependent) fragment. This fragment then translocates to the nucleus and activates the 
transcription of genes involved in the UPR. From the data (Figure 6.5), ATF6-50 kDa 
was found to be reduced in differentiated dfd13 myoblasts, suggesting that ATF6 is less 
activated. 
The elevation of UPR activation via PERK/phospho-eIF2α blocks ribosome 80s 
assembly and protein synthesis, consequently causing cell cycle arrest. This also 
explains the translational attenuation through the inactivation of p70S6K, as previously 
reported (Figure 4.6). However, some phospho-eIF2α also activates ATF4  and thus up-
regulates CHOP expression. CHOP activates GADD34 (protein phosphatase 1 
regulatory subunit 15A) which can dephosphorylate phospho-eIF2α and reversing the 
blockage of protein synthesis. This may be the cause of lower CHOP expression on day 
4 of differentiation in dfd13 myoblasts. However, the increase in CHOP expression 
upon differentiation can be explained by the increase in phospho-eIF2α expression 
which up-regulates CHOP via ATF4 activation. A previous study reported that UPR 
activation via PERK is enriched in mitochondria-associated ER membranes which 
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promotes ER-stress induced apoptosis (Verfaillie et al. 2012). As both mitochondria 
and ER regulate calcium signalling, it is possible that the same scenario occurs.  
The accumulation of CHOP expression in dfd13 myoblasts could also lead to 
prolonged ER stress and eventually could cause apoptosis. In differentiating C2C12 
myoblasts CHOP protein expression is retained throughout the differentiation period, 
suggesting that ER stress could be well-alleviated by the UPR mechanism, i.e. via ATF6 
and phospho-eIF2α regulation as shown in this study (Figure 6.6). Persistent CHOP 
expression can mediate programmed cell death by suppressing the transcription factor 
anti-apoptotic Bcl-2. The interaction of CHOP with FoxO3a has been shown to regulate 
the expression of BH3-only, i.e. BAD in neuronal cells (Ghosh 2012) and this may also 
occur in myoblasts. Therefore, it can be concluded that the accumulation of FoxO3a 
(Figure 4.7), reduction of autophagic flux (Figure 5.5) and PERK-mediated CHOP 
(Figure 6.4) suggest the dfd13 myoblasts are prone to apoptosis.  
6.3.3 Increased PKC Activation Reflects Increased PLC Activity in 
Differentiating Dystrophin-Deficient Myoblasts 
PKC is a serine/threonine kinase that is involved in cell proliferation, as well as cell 
differentiation. It consists of three subfamilies i.e. conventional/classic, novel and 
atypical. Each subfamily requires different activators for their activation and in this 
study, two isoforms from the classic PKC (cPKC) and one isoform from the novel PKC 
(nPKC) subfamilies were examined during differentiation. These isoforms were chosen 
based on the PLC products DAG and IP3, which are highly produced as a result of PTEN 
overexpression. As discussed, high IP3 could cause the release of Ca
2+ into the cytosol 
thereby increasing the Ca2+ concentration. Therefore, excessive PKC activation in 
dfd13 myoblasts could reflect the existence/production of high DAG and Ca2+ in the 
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cytosol. The binding of DAG to the C1 domain and Ca2+ binding to the C2 domain of 
cPKC, PKC-α and PKC-βII results in its catalytic activation. The nPKC, PKC-ε, only 
requires DAG binding to its C1 domain for catalytic activation.  
Before the binding of activators, phosphorylation of PKC at a specific residue 
will occur. From the data obtained,  phosphorylated PKCs increased throughout the 
differentiation period in both types of myoblast. However, one of the phosphorylation 
residues of PKCβII, Thr641, was shown to be not phosphorylated in dystrophin-
deficient myoblasts. A previous study reported that PKC-β is involved in myogenic 
differentiation and expression is increased upon differentiation. This indicates that non-
phosphorylation of one residue in PKC-β could contribute to the deterioration of 
myotube development. It could be possible that PKC-β interacts with dystrophin as its 
target location on the membrane. It has also been previously shown to be localised to 
the cytoskeleton of a T-cell (Black and Black 2012). 
This study provided information about the involvement of isoforms of PKC 
during the transition event. It can be seen that high levels of activated PKC-ε also 
reflects the accumulation of DAG in dystrophin-deficient myoblasts (Figure 6.8). In this 
case  PKC-ε is almost never activated (low level detected), even though  total PKC-ε 
expression showed a significant accumulation in C2C12 myoblasts (Figure 6.8). 
However, further analysis on Ca2+ concentration needs to be carried out prior to confirm 
PKC activation. A study by Gaboardi et al. (2009) reported that not only was PKC-ε 
expression increased but also activation following culture in a serum-free medium 
supplemented with insulin. In this case, it can be assumed that PKC-ε is also activated 
in C2C12 myoblasts but at lower levels which might be increased under insulin-induced 
conditions.  
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6.3.4 Reduced Activation of PKC-βII Contributes to the Instability of Its 
Catalytic Domain in Dystrophin-Deficient Myoblasts 
The newly translated PKC-βII is associated with the cytoskeleton, and once 
phosphorylated, it starts to mature and is ready to act as a kinase. The regulation of 
PKC-βII involves two distinct phosphorylation events: 1) trans-phosphorylation at 
Thr500 to provide catalytic competency, via PDK1; and 2) auto-phosphorylation at C-
terminus Thr641 which stabilises the catalytic conformation and auto-phosphorylation 
at Ser660, which releases PKC into the cytosol. However, this conformation remains 
inactive as the pseudo-substrate position is still occupied within the substrate-binding 
cavity. DAG and Ca2+ binding will release the pseudo-substrate and provide the open-
formed catalytic site ready for substrate binding (substrate phosphorylation). 
There is a lack of study regarding the involvement of PKC in myogenic 
differentiation. From the data obtained (Figure 6.6), PKC-βII has been shown to be 
selectively activated during myoblast differentiation. In this study the phosphorylation 
of PKC-βII at Thr641 was decreased but was increased at Ser660, suggesting that there 
is different regulation of these phosphorylation sites during differentiation of C2C12 
myoblasts (Figure 6.6). Both phosphorylation sites occur within the C-terminus of the 
PKC-βII kinase domain; however, regulation is disturbed in dystrophin-deficient 
myoblasts. Phosphorylation of PKC-βII at Ser660 is found to be highly increased while 
phosphorylation at Thr641 is far less in dfd13 myoblasts throughout the differentiation 
period (Figure 6.6).  
This phosphorylation event takes place at a hydrophobic motif and plays role in 
stabilising the catalytic competent conformation of PKC-βII before being released into 
the cytosol. As Thr641 is found to be less activated in dystrophin-deficient myoblasts, 
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it can be proposed that the released PKC-βII has an unstable catalytic component which 
impairs its role as a protein kinase. It also can be proposed that unphosphorylated 
Thr641 may disturb DAG and Ca2+ binding to the C1 and C2 domains, respectively, 
and subsequently alter the conformation change for the release of the pseudo-substrate 
prior to its kinase activity. This also impairs the stability of the PKC-membrane binding 
due to the high phosphorylation at the Ser660 site.  
The phosphorylation of PKC-α at Thr638 corresponds to phosphorylation of 
PKC-βII at Thr641 in the turn motif of the catalytic region. Surprisingly, this 
phosphorylation showed a massive accumulation in dystrophin-deficient myoblasts, 
indicating that its regulation is impaired. Another suggestion that may support the 
reduced activation at Thr641 is the inactivation of rictor-mTORC2 as reported in 
Chapter 4, which may not be able to phosphorylate PKC-βII. It has been reported that 
mTORC2 may be responsible for both phosphorylation sites; however, it is unknown 
whether it is directly or indirectly involved (Alexandre and Thrower, 2012).  
A previous study has shown that down-regulation of PKC-α inhibits myoblast 
proliferation. In contrast, PKC-β expression is increased during myoblast 
differentiation. From this study, again it can be implied that the accumulation of PKC-
α activation and reduction in PKC activation are necessary during myoblast 
differentiation. In proliferating chick embryo myoblasts treatment with a PKC activator, 
TPA (phorbol ester), inhibited DNA synthesis and down-regulated PKC expression, 
suggesting that PKC-α plays a role in myoblast proliferation (Capiati et al., 1999). A 
study by Komati et al. (2004) demonstrated that TPA also can induce myogenic 
differentiation at nano molar concentrations (Komati et al. 2004). PKC can promote cell 
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growth by phosphorylating and activating RAF1, which mediates the activation of the 
MAPK/ERK signalling cascade. 
6.3.5 Instability of PKC Reduces ERK1/2 Activation in Dystrophin-
Deficient Myoblasts 
According to the immunoblot analysis of PKC activation in dfd13 myoblasts, it can be 
suggested that the phosphorylated-form reflects the high release of DAG and Ca2+. 
PKC-ε also showed the same effects which was caused by high levels of DAG being 
produced from the conversion of PLC-γ1. However, PKC-βII activity is down-regulated 
than in C2C12 myoblasts, suggesting that PKC-βII is not regulated/activated by high 
DAG and Ca2+. It can also be suggested that low/down-regulated of PKC-βII activity is 
caused by impaired rictor-mTORC2 (Chapter 4) as a previous study showed that this 
complex regulates PKC in myoblasts. As ERK1/2 is also a downstream protein for PKC, 
ERK1/2 activity is thought to also be impaired.  
Phosphorylation of PKC-βII at Thr641 stabilises the catalytic conformation 
while phosphorylation at Ser660 releases PKC from a detergent-insoluble fraction into 
the cytosol. In this study, the results showed a lack of phosphorylation at Thr641 (in 
PKC-βII) in differentiating dfd13 myoblasts potentially disturbed the stability of the 
kinase catalytic domain at the C-terminus, although it was released into the cytosol 
following phosphorylation at Ser660. This impairs the catalytic activity/kinase activity 
(phosphorylation) of its downstream protein. It has been reported that PKC controls 
RAF-1 activation, thus activating the MAPK cascade. In this study it was shown that 
the ERK1/2 expression, as well activation, is down-regulated in dystrophin-deficient 
myoblasts. Down-regulation of ERK1/2 also contributes to the down-regulation of 
protein translation. This in line with the impairment of p70S6K activity, as reported in 
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Chapter 4. ERK1/2 is a serine/threonine kinase that participates in the Raf/Ras/MEK 
cascade, and plays a role in catalysing the phosphorylation of various substrates, such 
as transcription factors during protein translation. Therefore, it is important to examine 
its phosphorylation level for effective functionality.  
6.4 Conclusions 
Elevation of PLC activation contributes to a reduction in the ER stress level and 
subsequently changes the UPR in differentiating dystrophin-deficient myoblasts. 
Key finding(s): 
• PTEN overexpression triggers high PLC activation and PKC regulation and 
disturbs the ER stress level in dystrophin-deficient myoblasts.  
• A disturbed ER stress level alters activation of the UPR and leads to apoptosis 
via PERK-mediated CHOP. 
• PKC maturation is disturbed thus reduced ERK1/2 activation in dystrophin-
deficient myoblasts.  
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Chapter 7 - Minidystrophin∆H2-R19 Partly Improved Protein 
Signalling in Dystrophin-Deficient Myoblasts 
7.1 Introduction 
The gene encoding dystrophin is one of the largest genes, and results in a rod-shaped 
dystrophin protein that is responsible for connecting the cytoskeleton to the extracellular 
matrix. The absence of full-length dystrophin in DMD has previously been shown 
causes impaired PTEN/PI3K/Akt (Chapter 4), which  alters autophagy modulation 
(Chapter 5) and PLC/PKC signalling (Chapter 6), as well as causing a reduction is ER 
stress; therefore, the restoration of this protein is hoped to compensate for these effects. 
However, full-length dystrophin restoration is extremely difficult due to the large size 
of the dystrophin protein, and consequently mini-dystrophin has been utilised. 
In this study, stable minidystrophin-eGFP tagged transfected myoblasts were 
used. Both C2C12 (non-dystrophic) and dfd13 (dystrophin-deficient) myoblasts were 
transfected with pCR3.1 eGFP-mini dystrophin (pMDysE), which is  ~5.8 kb and kindly 
provided by Jacque P. Tremblay (Faculté of Médecine, Université Laval, Quebec, 
Canada). Minidystrophin lacks exons 17-48 of full-length dystrophin, which is ~220 
kDa. A schematic of  minidystrophin compared to full-length dystrophin is depicted in 
Figure 7.1, and stable transfectants are presented in Figure 7.2. An overview of the 
chapter is presented in Figure 7.3. 
. 
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Figure 7.1: Schematic of full-length dystrophin and mini-dystrophin ∆H2-R19  
Dystrophin begins with an actin-binding domain (ABD1) that binds to actin filaments. The 
central domain consists of long rod spectrin repeats, which are interspersed with hinge regions, 
and is followed by a cysteine-rich domain (CR) for dystroglycan binding. The C terminus (CT) 
domain binds members of the syntrophin and dystrobrevin protein families.  
 
Figure 7.2: Minidystrophin-eGFP expression in C2C12 and dfd13 myoblasts   
Human minidystrophin tagged with eGFP was introduced into C2C12 and dfd13 myoblasts. 
Stable clones were selected with geniticin for use in differentiation studies. 
Immunofluorescence and immunoblot analyses were performed prior to determining the 
capacity of both myoblasts to be terminally differentiated. Immunofluorescence analysis 
showed that minidystrophin∆H2-R19 had been successfully introduced in C2C12 and dfd13 
myoblasts. The eGFP plasmid was used as a control. Transfection of myoblasts with 
minidystrophin-eGFP was undertaken by Dr. Chen Hung-Chih during his doctoral research in 
Dr. Janet Smith’s Lab (Chen, 2013).  
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Figure 7.3: Chapter overview: mini-dystrophin∆H2-R19 partly improves proteins signalling in dystrophin-deficient myoblasts. 
In this chapter, minidystrophin transfected myoblasts resulted in improvements to protein signalling. The accumulation of Akt was shown during the non-
differentiated stage, with increased p70S6K activation throughout the differentiation period. Autophagy activation also increased as the LC3B conversion ratio 
was increased; however FoxO3 expression was decreased. 
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7.2 Results 
7.2.1 dfd13 Minidystrophin∆H2-R19 Myoblasts Did Not Achieve Terminal 
Differentiation 
In Chapter 3 it was shown that dfd13 myoblasts failed to achieve terminal 
differentiation. Unfortunately, the introduction of minidystrophin into dfd13 myoblasts 
also showed the same pattern,  and MyHC and MF-20 were expressed late compared to 
C2C12-eGFP myoblasts. Immunoblot analysis (Figure 7.4A) showed that both proteins 
were expressed at day 7 in C2C12-minidystrophin myoblasts, whereas in C2C12-eGFP 
myoblasts expression commences as early as day 4 of differentiation. Based on the 
densitometry analysis (Figure 7.4B), there were significant differences in MyHC 
expression between C2C12-minidystrophin and C2C12-eGFP myoblasts on day 7 
(p<0.01; p = 5.00 x 10-3), and day 10 (p<0.01; p = 2.34 x 10-3). 
As shown in Figure 7.4C, MF-20 was also expressed later in C2C12-
minidystrophin myoblasts. Densitometry analysis showed that MF-20 was expressed 
significant lower than in C2C12-eGFP myoblasts on day 7 (p<0.01; p = 7.64 x 10-4), 
and day 10 (p<0.01; p = 7.39 x 10-3). From this analysis, it can be seen that 
minidystrophin delayed C2C12 myoblast terminal differentiation. It is also showed that 
minidystrophin is unable to rescue dfd13 myoblasts to achieve terminal differentiation. 
Therefore, potentially full-length of dystrophin may be required to improve 
differentiation in dystrophin-deficient myoblasts.  
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Figure 7.4: Myosin heavy chain is expressed later in C2C12 minidystrophin∆H2-R19 
myoblasts 
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and 
culturing in DM for 10 days with the media being changed every 2 days.   Total protein was 
extracted at the indicated time points prior to immunoblotting with antibodies recognising-
MyHC and pan-myosin (MF20).  (A) Immunoblot analysis during myoblast differentiation with 
α-tubulin expression as a loading control. Densitometry analysis of (B) F-MyHC and (C) pan-
myosin (MF20) expression. The graphs represent an average of three repeats from different 
samples. ND: non-differentiated; Significantly different: § (p<0.01) compared to C2C12-eGFP 
myoblasts. GM: growth medium (DMEM + 10% FCS); DM: differentiation medium (DMEM 
+ 2% horse serum). 
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7.2.2 Minidystrophin∆H2-R19 Improves Akt Expression During the 
Undifferentiated Stage and Increases p70S6 Kinase Activation 
During Dystrophin-Deficient Myoblasts Differentiation  
In Chapter 4 it was shown that the PTEN-PI3K/Akt pathway is impaired in dfd13 
myoblasts where the downstream proteins, i.e. p70S6K, FoxO3a, were affected. In 
dfd13-minidystrophin myoblasts PTEN expression was found to be reduced upon 
differentiation. Akt was found to be highly activated at the undifferentiated stage, while 
p70S6K showed activation upon differentiation. Immunoblot analysis of protein 
expression in minidystrophin-transfected myoblasts is shown in Figure 7.5A .  
Densitometry analysis of PTEN expression showed significant accumulation of 
PTEN in C2C12-minidystrophin myoblasts when compared to C2C12-eGFP 
myoblasts; ND (p<0.01; p = 1.20 x 10-3) and day 4 (p<0.01; p = 4.81 x 10-4). In contrast, 
PTEN expression was found to be significantly reduced on day 7 (p<0.01; p = 9.81 x 
10-4) and day 10 (p<0.01; p = 7.37 x 10-3) in dfd13-minidystrophin myoblasts when 
compared to dfd13-eGFP myoblasts. Rictor was inactivate in dfd13 myoblasts before 
and after the introduction of minidystrophin, but rictor expression and activity remained 
increased in C2C12-minidystrophin myoblasts upon differentiation.  
mTOR expression was found significantly increased in minidystrophin-
myoblasts when compared to eGFP-myoblasts; day 4 (p<0.05; p = 2.08 x 10-2) and day 
7 (p<0.05; p = 1.36 x 10-2) (Figure7.5E). However, mTOR activity was showed a 
massive reduction in C2C12-minidystrophin when compared to C2C12-eGFP; ND 
(p<0.01; p = 4.59 x 10-3), on day 4 (p<0.01; p = 1.41 x 10-4), day 7 (p<0.01; p = 6.24 x 
10-3), and day 10 (p<0.01; p = 5.38 x 10-3). Whilst, mTOR activity remained the same 
in dfd13-minidystrophin with slightly increased on day 10.  
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Akt activation was found to be significantly increased (p<0.01; p = 6.73 x 10-4) 
in undifferentiated dfd13-minidystrophin myoblasts compared to dfd13-eGFP 
myoblasts. However, its expression was found reduced upon differentiation to levels 
comparable with dfd13-eGFP myoblasts. Significant accumulation of Akt activity was 
found in C2C12-minidystrophin myoblasts compared to C2C12-eGFP myoblasts; ND 
(p<0.01; p = 7.98 x 10-4), on day 4 (p<0.01; p = 3.46 x 10-4), day 7 (p<0.01; p = 1.66 x 
10-4), and day 10 (p<0.01; p = 3.51 x 10-3).  
Surprisingly, p70S6K showed significant massive activation in dfd13-
minidystrophin myoblasts compared to dfd13-eGFP myoblasts. Although the total 
expression reduced, it remained active in dfd13-minidystrophin myoblasts upon 
differentiation. There was a significant level of activation throughout the differentiation 
period compared to dfd13-eGFP myoblasts; day 4 (p<0.05; p = 1.36 x 10-2), day 7 
(p<0.05; p = 2.26 x 10-2), and day 10 (p<0.01; p = 3.45 x 10-3). C2C12-minidystrophin 
also showed the same pattern where the p70S6K activity showed significant increased 
when compared to C2C12-eGFP; day 4 (p<0.01; p = 7.71 x 10-3), day 7 (p<0.01; p = 
2.64 x 10-3), and day 10 (p<0.01; p = 9.84 x 10-4).      
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Figure 7.5: Minidystrophin∆H2-R19 improved Akt at undifferentiated stage and increases the p70S6 Kinase activation of dystrophin-deficient 
myoblasts during differentiation 
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and culturing in DM for 10 days with the media being changed 
every 2 days.   Total protein was extracted at the indicated time points prior to immunoblot analysis.  (A) Immunoblot analysis of PTEN, phospho-Rictor, 
Rictor, phospho-Akt (Ser473), Akt, phospho-p70S6K and p70S6K expression during myoblast differentiation with α-tubulin expression as a loading control. 
Densitometry analysis of (B) PTEN expression, (C) Rictor expression, (D) Rictor activity, (E) mTOR expression, (F) mTOR activity, (G) Akt expression, 
(H) Akt activity, (I) p70S6K expression and (J) p70S6K activation. The graphs represent an average of three repeats from different samples. ND: non-
differentiated; Significantly different: § (p<0.01) compared to C2C12-eGFP myoblasts; * (p<0.01) compared to dfd13-eGFP myoblasts; GM: growth medium 
(DMEM + 10% FCS); DM: differentiation medium (DMEM + 2% horse serum) 
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7.2.3 Autophagosome Formation Increases in dfd13 Minidystrophin∆H2-R19  
Myoblasts 
As previously reported in Chapter 5, the conversion of the LC3B ratio correlates with 
the autophagy flux in dfd13 myoblasts during differentiation. Therefore, 
immunoblotting analysis was performed to determine the effects of minidystrophin in 
dfd13 myoblasts as well as in C2C12 myoblasts. Figure 7.6A shows the immunoblot 
analysis of FoxO3, Becn1 and LCB expression, and Figure 7.6B-F shows the  
densitometry analysis for the expression of each protein.  
Surprisingly, FoxO3a was highly expressed in C2C12-minidystrophin 
myoblasts compared to dfd13-minidystrophin myoblasts, and there was a significant 
difference in the expression level; ND (p<0.01; p = 2.01 x 10-3), on day 4 (p<0.01; p = 
1.16 x 10-3), day 7 (p<0.01; p = 2.73 x 10-3), and day 10 (p<0.01; p = 5.16 x 10-3). The 
data also showed that FoxO3a expression in dfd13-minidystrophin myoblasts was 
reduced in dfd13-eGFP myoblasts. This indicates that the presence of minidystrophin 
had a massive impact on FoxO3a expression (unphosphorylated form). Beclin1 also 
showed higher expression in C2C12-minidystrophin myoblasts compared to C2C12-
eGFP myoblasts. There was also an accumulation of expression in dfd13-
minidystrophin myoblasts, although this was significantly lower at day 10 (p<0.01; p = 
1.04 x 10-3) compared to dfd13-eGFP myoblasts.  
Figure 7.6D & E show the densitometry analysis for LC3B-I and LC3B-II 
expression, respectively. LC3B-I was highly expressed in C2C12-minidystrophin 
myoblasts throughout the differentiation period compared to C2C12-eGFP myoblasts 
and dfd13-minidystrophin myoblasts. This is in line with the high expression level of 
Beclin1 and FoxO3a noted previously. LC3B-I expression was increased in dfd13-
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minidystrophin myoblasts but still lower than in dfd13-eGFP myoblasts and 
proportional to the low FoxO3a expression level described. Densitometry analysis of 
the LC3B conversion ration showed a reduction in conversion in C2C12-
minidystrophin myoblasts. In contrast, dfd13-minidystrophin myoblasts showed 
increased LC3B conversion, indicating that autophagosome formation actively 
increased upon differentiation. It can also be seen that the LC3B conversion ratio was 
altered in both control myoblasts (eGFP-transfectants), where there was a reduction in 
conversion, indicating that autophagosome formation is reduced upon differentiation. 
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Figure 7.6: Minidystrophin∆H2-R19 reduces the FoxO3a expression and increases the LC3B conversion ratio in dfd13 during differentiation. 
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and culturing in DM for 10 days with the media being changed 
every 2 days.   Total protein was extracted at the indicated time points prior to immunoblot analysis.  (A) Immunoblot analysis of FoxO3a, Beclin1 and LC3B 
expression during myoblasts differentiation with α-tubulin expression as a loading control. Densitometry analysis of (B) FoxO3a expression, (C) Beclin1 
expression, (D) LC3B-I expression, (E) LC3B-II formation, (F) Ratio of LC3B conversion. The graphs represent an average of three repeats from different 
samples. ND: non-differentiated; Significantly different: § (p<0.01) compared to C2C12-eGFP myoblasts; * (p<0.01) compared to dfd13-eGFP myoblasts; 
GM: growth medium (DMEM + 10% FCS); DM: differentiation medium (DMEM + 2% horse serum); n=3 
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7.2.4 Minidystrophin∆H2-R19 Reduces PLC Activation and Changes the ER 
Stress Level 
In Chapter 6 it was suggested that PLC-γ1 activation is affected by PTEN expression, 
as well as PI3K activity in myoblasts. Previously, (Figure 7.5), PTEN has been shown 
to be expressed at a lower level in dfd13-minidystrophin myoblasts than in dfd13-eGFP 
myoblasts. As predicted, even though there is increased activation of PLC-γ1 in dfd13-
minidystrophin myoblasts, this is less than in dfd13-eGFP myoblasts upon 
differentiation, with a significant difference observed at day 10 (p<0.05; p = 4.44 x 10-
2) (Figure 7.7B and C).  
Surprisingly, CHOP was expressed at a low level in dfd13-minidystrophin 
myoblasts and even lower (almost not expressed) in C2C12-minidystrophin myoblasts 
(Figure 7.7). There was a significant difference in expression between the two types of 
myoblast during differentiation; day 4 (p<0.01; p = 5.91 x 10-4), day 7 (p<0.01; p = 4.21 
x 10-3), and day 10 (p<0.01; p = 2.35 x 10-3).  The level of CHOP expression showed a 
significant reduction (p<0.01; p = 1.04 x 10-3) in dfd13-eGFP myoblasts when 
compared to C2C12-eGFP myoblasts at day 7. This showed that the introduction of the 
eGFP-plasmid changed the ER stress level, as well as CHOP expression. It can be seen 
that the non-specific band sized approximately 25 kDa was also reduced, but this could 
not be identified. Furthermore, level of phospho-eIF2α was found significantly reduced 
in dfd13-minidystrophin day 7 (p<0.05; p = 1.77 x 10-2), and day 10 (p<0.01; p = 3.48 
x 10-3). 
The ATF6 cleavage ratio was examined since it is a downstream protein that is 
up-regulated by phospho-eIF2α. Figure 7.7F shows the percentage of ATF6 based on 
the 90 kDa and 50 kDa fragments. Fragmented/cleaved ATF6 represents the level of 
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ATF6 activation following cleavage in the Golgi during differentiation. As reported in 
Chapter 6, ATF6 is less activated in differentiating dfd13 myoblasts in line with the 
control dfd13-eGFP myoblasts. Interestingly, dfd13-minidystrophin myoblasts showed 
significantly higher activation of ATF6 compared to dfd13-eGFP myoblasts during 
differentiation; day 4 (p<0.01; p = 1.13 x 10-4) and day 10 (p<0.01; p = 9.15 x 10-4). In 
C2C12-minidystrophin myoblasts ATF6 showed a slight reduction in activation 
compared to C2C12-eGFP myoblasts but there was no significant difference. 
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Figure 7.7: PLC activation and ER stress were reduced in dfd13-minidystrophin during differentiation 
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and culturing in DM for 10 days with the media being changed 
every 2 days.   Total protein was extracted at the indicated time points prior to immunoblot analysis.  (A) Immunoblot analysis of phospho-PLC-γ1, PLC-γ1, 
CHOP, ATF6 expression during myoblasts differentiation with α-tubulin expression as a loading control. Densitometry analysis of (B) PLC-γ1 expression, 
(C) PLC-γ1 activity, (D) CHOP expression, (E) phospho-eIF2α (F) ATF6 fragmented percentage. The graphs represent an average of three repeats from 
different samples. ND: non-differentiated; Significantly different: § (p<0.01) compared to C2C12-eGFP myoblasts; * (p<0.01) compared to dfd13-eGFP 
myoblasts; GM: growth medium (DMEM + 10% FCS); DM: differentiation medium (DMEM + 2% horse serum); n=3. 
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7.2.5 Minidystrophin∆H2-R19 Changes PKC and ERK1/2 Signalling  
Previously, PKC and ERK1/2 have been shown to be impaired in dfd13 myoblasts 
(Chapter 5). PKC and ERK1/2 signalling was therefore examined in mindystrophin-
transfected myoblasts. Figure 7.8A shows the immunoblot analysis for the expression 
of each protein in minidystrophin- and eGFP-transfected myoblasts. Densitometry 
analysis (Figure 7.8B) for the phosphorylation of PKC-α at Thr638 was found to be 
high during the non-differentiated state of C2C12-minidystrophin myoblasts compared 
to C2C12-eGFP myoblasts (p<0.05; p = 1.26 x 10-2). Expression was accumulated upon 
differentiation in both minidystrophin myoblasts and was even greater in eGFP 
myoblasts. 
PKC-βII phosphorylation at Thr641 showed a reduction in C2C12-
minidystrophin myoblasts and no expression in dfd13-minidystrophin myoblasts during 
differentiation. There was a significant reduction in the phosphorylation level in 
C2C12-minidystrophin myoblasts compared to C2C12-eGFP myoblasts; ND (p<0.01; 
p = 9.78 x 10-4), day 4 (p<0.01; p = 2.20 x 10-4), day 7 (p<0.01; p = 5.49 x 105), and day 
10 (p<0.01; p = 4.20 x 10-3) (Figure 7.8C).  Phosphorylation of PKC-βII at Ser660 
increased in minidystrophin myoblasts and showed the same pattern of expression as in 
both eGFP-myoblasts at a lower level. 
As depicted in Figure 7.8E-H, ERK1/2 was also affected by minidystrophin. 
ERK1 is highly expressed in both C2C12-minidystrophin myoblasts and dfd13-
minidystrophin myoblasts and showed the same expression pattern in eGFP-myoblasts. 
However, ERK1 activation could only be seen in C2C12-eGFP myoblasts with a 
reduction upon differentiation. ERK2 expression also showed the same pattern as in 
eGFP-myoblasts but at a higher level (Figure 7.8G); however, its activation was only 
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significantly higher (p<0.01; p = 1.40 x 10-3) in dfd13-minidystrophin myoblasts during 
the non-differentiated stage compared to C2C12-minidystrophin myoblasts. Upon 
differentiation, ERK2 was found to be less activated in dfd13-minidystrophin myoblasts 
compared to C2C12-minidystrophin myoblasts; day 4 (p<0.01; p = 7.12 x 10-4), day 7 
(p<0.01; p = 8.34 x 104), and day 10 (p<0.01; p = 2.63 x 10-4) (Figure 7.8H).   
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Figure 7.8: Minidystrophin∆H2-R19 changed PKC and ERK1/2 activation in myoblasts during differentiation. 
Myoblasts were cultured in GM until 80 to 90% confluent before washing twice with PBS and culturing in DM for 10 days with the media being changed 
every 2 days.   Total protein was extracted at the indicated time points prior to immunoblot analysis.  (A) Immunoblot analysis of phospho-PKCα/βII 
(Thr638/Thr641), phospho-PKCβII (Ser660), phospho-ERK1/2 and ERK1/2 expression during myoblasts differentiation with α-tubulin expression as a 
loading control. Densitometry analysis of (B) phospho-PKCα (Thr638) expression, (C) phospho-PKC-βII (Thr641), (D) phospho-PKCβII (Ser660), (E) 
ERK1 expression, (F) ERK1 activation, (G) ERK2 expression and (H) ERK2 activity. The graphs represent an average of three repeats from different 
samples. ND: non-differentiated; Significantly different: § (p<0.01) compared to C2C12-eGFP myoblasts; * (p<0.01) compared to dfd13-eGFP myoblasts; 
GM: growth medium (DMEM + 10% FCS); DM: differentiation medium (DMEM + 2% horse serum); n=3. 
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7.3 Discussion 
7.3.1 Minidystrophin∆H2-R19 Ameliorates Protein Synthesis Regulation in 
Dystrophin-Deficient Myoblasts 
From the results obtained, MyHC has been shown to be expressed later in C2C12-
minidystrophin myoblasts than in C2C12-eGFP myoblasts. It is not expressed in dfd13 
myoblast transfectants after 10 days of differentiation, indicating that dfd13 myoblasts 
have impaired differentiation ability/capacity even following the introduction of 
minidystrophin. Nevertheless, by introducing minidystrophin into dfd13 myoblasts Akt 
activation is increased compared to the control myoblasts (dfd13-eGFP) during the non-
differentiated stage. There is no evidence concerning whether dystrophin and Akt 
directly interact. Based on the fact that dystrophin anchors the extracellular matrix to 
the cytoskeleton which stabilises the sarcolemma membrane, it is thought that it controls 
signalling conveyance, particularly the Igf-PI3K/Akt pathway. Igf-1 binds to Igf-1R 
which is embedded in the plasma membrane/sarcolemma membrane. Minidystrophin 
seems to improve PI3K/Akt signalling in dystrophin-deficient myoblasts by increasing 
myoblast stabilisation so that Igf-1R can function correctly. The use of  minidystrophin 
may be the reason why Akt activation could not be fully recovered, as it is less activated 
upon differentiation (Figure 7.4). 
Activation of Akt by doxycycline (DOX) treatment to control Akt1 expression 
via a transgene expression system has been shown to promotes myofibre regeneration 
and improve muscle function in dystrophin-deficient mdx mice (Kim et al. 2011). They 
also reported that the induction of Akt activation after the onset of peak pathology (>6 
weeks) was even better, as Akt was found to have a faster regenerative response within 
the muscle. Akt has also been reported to be associated with integrin-linked kinase 
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(ILK), which can phosphorylate Akt. As ILK expression is found to be ncreased in the 
mdx mouse due to α7β1 integrin elevation, this may also have contributed to the 
accumulation of the phosphorylated-Akt during the non-differentiated stage.  
The expression of p70S6K was shown to increase in minidystrophin-myoblasts 
when compared to eGFP-myoblasts. The expression pattern remained the same, 
indicating that minidystrophin has raised the activation level (Figure 7.4G). p70S6K is 
controlled by Akt via a series of phosphorylation events by mTORC1. Phosphorylation 
of p70S6K at Thr389 is important for further phosphorylation prior to full activation. 
Activation/phosphorylation of p70S6K stimulates its activity for several substrates, 
including translation initiation factor eIF-4B which is involved in the translation pre-
initiation complex (Tchevkina and Komelkov 2012). This occurrence indicates that 
protein synthesis regulation in dystrophin-deficient myoblasts is improved after the 
introduction of minidystrophin.  
7.3.2 Minidystrophin∆H2-R19 Reduces FoxO3a Expression and Increases the 
LC3B Conversion Ratio in dfd13 Myoblasts During Differentiation 
Autophagy is inhibited in MD and is emerging as an important process, especially 
during myoblast differentiation through the elimination of proteins and organelles. The 
conversion of LC3B as well as autophagy flux has been shown to be reduced in 
dystrophin-deficient myoblasts and minidystrophin was introduced in order to assess 
whether this scenario could be improved. The data showed that the introduction of 
minidystrophin into dystrophin-deficient myoblasts increased autophagy. FoxO3a as 
reduced while Beclin1 was increased which might balance autophagy activation during 
differentiation. C2C12-minidystrophin myoblasts exhibited high levels of FoxO3a and 
Beclin1 and consequently, LC3B was also expressed at a higher level (Figure 7.6) since 
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both FoxO3a and Beclin1 regulate LC3BI for autophagy activation (Mammucari et al., 
2007).  
Autophagy has been identified as a new therapeutic target in DMD and  by 
Palma and colleagues (2012) demonstrated that a low-protein diet in mdx mice 
ameliorates dystrophic features after 3 months’ consumption. In their study, the low-
protein diet was characterised by a low amino-acid intake and autophagy reactivation 
was shown to improve the dystrophic phenotype in mdx mice, together with enhance 
LC3BII and FoxO3 expression.  
7.3.3 Minidystrophin∆H2-R19 Reduces PLC-γ1 Activation and Alters the ER 
Stress Level and UPR Activation in Dystrophin-Deficient Myoblasts 
A study by Sabourin et al. (2012) demonstrated that the entry of Ca2+ is regulated by 
PLC activation, as well as PKC regulation (Sabourin et al. 2012). PLC activation leads 
to PIP2 cleavage to become IP3 and DAG. The released IP3 has a high affinity to bind 
to IP3-R on the ER and subsequently causes Ca
2+ release into cytoplasm. The release of 
Ca2 disturbs the interaction between Ca2+ and Ca2+ protein chaperons, and thus impairs 
protein folding in the ER. From the data obtained, PLC activation is reduced in dfd13-
minidystrophin myoblasts compared to dfd13-eGFP myoblasts, indicating that 
minidystrophin affects PLC activation in dystrophin-deficient myoblasts (Figure 7.7). 
As a result, the Ca2+ concentration is constantly kept in the appropriate range and 
subsequently maintains the ER stress level during myoblasts differentiation. 
ER stress is affected by Ca2+ concentration regulation, which is connectively 
associated with protein folding. Ca2+ and Ca2+ protein chaperons stabilise protein 
folding intermediates; therefore, protein signalling that controls Ca2+ regulation, as well 
as UPR activation, is important in order for myoblasts to dynamically achieve terminal 
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differentiation. Over the last decade there have been many reports of the reduction of 
Ca2+ in the ER (Burr and Molkentin 2015). In addition, various methods have been used 
to increase or restore Ca2+ level in the ER, i.e. overexpression of SERCA1a, which can 
increase Ca2+ intake into the ER.  
In this study minidystrophin was used to restore the ER stress level. However, 
from the data obtained (Figure 7.7), CHOP expression in dfd13-minidystrophin 
myoblasts is lower when compared to dfd13-eGFP myoblasts, indicating that 
minidystrophin causes a reduction in the ER stress level. This was much worse in 
C2C12-minidystrophin myoblasts, where CHOP expression was almost undetectable. 
It is also thought that high levels of CHOP and FoxO3a could lead to cell cycle arrest 
and/or apoptosis. It has been reported that the interaction of CHOP with FoxO3a 
regulates BH3-only protein expression, such as BAD protein. From the data obtained, 
it can be seen that dfd13 myoblasts, including dfd13-eGFP myoblasts, exhibit high 
levels of FoxO3 and CHOP at the end of the differentiation period (day 10), suggesting 
that these myoblasts are prone to apoptosis. This is in line with the defective autophagy 
mentioned previously. From this study it can also be suggested that C2C12-
minidystrophin myoblasts, as well C2C12-eGFP myoblasts are invulnerable to 
apoptosis. 
Furthermore, UPR activation via ATF6 and PERK showed a reduction in 
activation. However, the level of activation is higher compared to dfd13-eGFP 
myoblasts, indicating that minidystrophin improves ATF6 activation. As CHOP is less 
expressed, it is thought that ATF6 up-regulates other ER stress markers and UPR 
proteins, such as Grp78. ATF6 is a transcription factor that is activated during ER stress 
and is capable of binding to ER stress-response elements (ERSE) to control the 
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expression of ER-localised molecular chaperons, such as BiP/Grp78, for unfolded 
protein refolding in the ER. ATF6 also regulates other UPR genes, such as XBP-1. 
Although both the ATF6 and IRE1 pathways can up-regulate CHOP, the PERK 
pathway predominates its expression through ATF4 translation (reviewed in Li et al., 
2014). From data obtained, reduction of PERK activation via phospho-eIF2α  improves 
dfd13 survival. 
7.3.4 Minidystrophin∆H2-R19 Changes PKC Phosphorylation and 
Subsequently Changes ERK1/2 Activity 
There has been a lack of study on PKC expression and activation, especially concerning 
specific isoforms, within myoblasts. PKC has not been shown to be correlated directly 
with dystrophin; however, it has been reported to be involved in cation entry in 
dystrophin-deficient myoblasts (Sabourin et al., 2012). It has been demonstrated that 
inhibition of PLC and PKC in dystrophin-deficient myoblasts restores elevated cation 
entry to the normal level. Nascent PKC is needed to achieve full maturation via a series 
of phosphorylation events involving HSP90 (Heat-shock protein-90), PDK1 and 
mTORC2. HSP90, PDK1 and mTORC2 bind to the kinase domain, c-terminus and the 
turn and hydrophobic motif, respectively. Fully mature PKC is released into the 
cytoplasm with pseudo-substrate blocking until the specific substrate, i.e. Ca2+ and 
DAG, binds to it for activation. 
The phosphorylation of PKC-α at Thr638 is higher in C2C12-minidystrophin 
myoblasts compared to C2C12-eGFP myoblasts, while dfd13-minidystrophin 
myoblasts exhibit a similar level as in dfd13-eGFP myoblasts until day 7 of 
differentiation.  However, unlike dfd13-eGFP myoblasts, expression at day 10 remains 
the same as at day 7 (Figure 7.8). From this data, minidystrophin can be suggested to 
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indirectly control the phosphorylation of PKC-α in dfd13 myoblasts at an appropriate 
level, since the substrate (Ca2+ and DAG) is finely regulated by PLC-γ1. 
PKC-βII also showed a reduction of phosphorylation at Thr641 and increased 
phosphorylation at Ser660 in dfd13-minidystrophin myoblasts. This indicates that 
minidystrophin affects PKC phosphorylation. Increased phosphorylation at Ser660 is in 
line with increased rictor activity as previously mentioned (Figure 7.5). Minidystrophin 
also increases the phosphorylation of PKC-βII at Ser660 in non-differentiated dfd13-
minidystrophin myoblasts and thus increases downstream protein i.e. ERK2, activity 
(Figure 7.8H). Phosphorylation at Ser660 is important in order for PKC to be released 
into the cytoplasm where its kinase activity is activated by DAG and Ca2+. In addition, 
rictor-mTORC2 was not activated in dfd13 myoblasts (Figure 7.5), yet phosphorylation 
could still be detected, indicating that other proteins in addition to mTORC2 may be 
able to phosphorylate this site. 
Minidystrophin had an impact on the phosphorylation of PKC-βII at Ser660 , 
which was increased in both types pf minidystrophin myoblasts, even in dfd13 
myoblasts  where rictor is not active. This indicates that phosphorylation of PKC-βII at 
Ser660 is regulated by minidystrophin; however, it is uncertain whether direct or 
indirect regulation occurs.  
7.4 Conclusions 
Minidystrophin∆H2-R19 can partly improve protein signalling in dystrophin-deficient 
myoblasts. 
Key finding(s): 
• Minidystrophin∆H2-R19 does not increase differentiation in dfd13 
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• Increases protein synthesis activation. 
• Increases autophagy activation/modulation. 
• Reduces PLC-γ1 activation and the ER stress level. 
• Increases ERK2 activation during the non-differentiated/proliferation stage. 
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Chapter 8 - Final Discussion 
Duchenne muscular dystrophy is the most prevalent muscle disease characterised by 
muscle degeneration, loss of muscle regeneration and premature death. It is caused by 
mutation in DMD gene on X-chromosome mostly deletions of one or more exons that 
disrupt the reading frame and lead to complete loss of dystrophin expression. 
Dystrophin expressed in differentiated myofibres plays important role to connects 
extracellular matrix with cystoskeleton through the dystrophin-associated glycoprotein 
complex (DGC). However, the underlying protein signalling pathway in dystrophin-
deficient myoblast that could contribute to DMD pathogenesis are still remains to be 
elucidated. 
 In this study, dystrophin-deficient myoblasts (dfd13) isolated from muscle of 5-
week-old mdx mouse has been used as a model for dystrophic myoblasts. In chapter 3, 
it has been shown that the myoblast did not achieve the terminal differentiation 
characterised by lower myotube formation and absent of fast-myosin heavy chain 
expression but higher desmin expression after 10 days culture under low mitogen 
conditions. This pax7-expressing myoblasts also exhibit high pax7 expression and was 
found localised to ER, golgi and recycling endosome suggesting that pax7 is 
misregulated. For the first time, it is suggested that KPNA2 associated with pax7 to 
form a translocation complex. Current database from STRING showed that KPNA2 
interacts with SUMO-protein ligase where it was reported that SUMOylation occurred 
on lys85 of pax7 (Luan et al. 2013) thus pax7-KPNA2 interaction is suggested occurred. 
The Igf-1/PI3K/Akt is conserved pathway and has been reported impaired in 
skeletal muscle mdx mouse. In chapter 4, it was showed that high PTEN expression may 
caused the reduction of PI3K activation relatively, while the actual activity showed 
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accumulation. It also has been found that Akt was inactivated  (Ser473) due to 
inactivation of rictor-mTOR. Therefore, subsequent downstream protein of Akt; 
mTORC1 and p70S6K, were shown inactivated indicating that protein synthesis 
regulation is impaired.  
Due to inactivation of Akt, It can be suggested that pax7 signalling is also 
impaired. In this study, it is hypothesized that glycogen synthase kinase-3 (GSK3), one 
of the Akt downstream protein targets, is not to be completely activated. A previous 
study proved that Pax7 interacts with GSK3 through Wnt signalling. Therefore, it can 
be suggested that Pax7 involvement in GSK3/β-catenin signalling may be impaired. 
GSK3 is a downstream protein in the Igf-1 pathway and generally known as a 
regulator of glycogen metabolism. Under Igf-1 stimulation, activated-Akt (protein 
kinase B) is responsible for directly phosphorylating GSK3β at the Ser9 residue. This 
phosphorylation suppresses its activation and thus changes downstream activities. In 
unstimulated conditions, GSK3β is present in its active form (non-phosphorylated). 
which targets primed substrates such as phosphorylated-β-catenin, which has previously 
been phosphorylated by casein kinase (CK1) at the Ser45 residue. GSK3β subsequently 
phosphorylates β-catenin at Ser33, Ser37 and Thr41 prior to proteasome degradation. 
Recently, a study by Zhuang et al. (2014) demonstrated that Pax7 also interacts 
with β-catenin in the regulation of Wnt Signalling. This binding inhibits myoblast 
differentiation by repressing activation of T-cell factor/lymphoid enhancer factor 
(TCF/LEF). TCF/LEF protein is responsible for activating promoters to induce target 
genes that are involved in myoblast differentiation (Zhuang et al., 2014). It is also has 
been reported that wnt expression is reduced in mdx mouse indicating that wnt 
signalling impairment thus could cause ubiquitin-proteosome system activation in 
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dystrophin-deficient myoblasts. Consequently, active GSK3β could phosphorylates β-
catenin (destabilises) and targets it for ubiquitination and subsequent proteasomal 
degradation.  
Evidence from many groups has suggested that autophagy is impaired in mdx 
mouse (De Palma et al. 2012; Sandri et al. 2013; Neel et al. 2013). In this study, 
inactivation of Akt also may caused autophagy impairment in dystrophin-deficient 
myoblasts. There were two possible pathway has been suggested involved in this 
regulation; 1) Accumulation of autophagy related genes; Becn1, Atg5 and Atg7, as it 
highly expressed via FoxO3a-mediated, and 2) inactivation of mTORC1 that fail to 
inhibit autophagosome initiation complex formation; Becn1/Vps34/FIP200. The results 
of this study demonstrate an excessive autophagosome formation with reduction of 
autophagy flux indicated that autophagy is defective in dystrophin-deficient myoblast 
(chapter 5).  
In chapter 6, it has been suggested that accumulation of PTEN expression has 
caused high activation of PLCγ1 subsequently increased enzymatic activity for PIP2 
cleavage. As consequences, this study also suggested that Ca2+ leakage from ER lumen 
via the opening of IP3R due to IP3 binding.  This finding may supported an accumulation 
of Ca2+ concentration in cytoplasmic region in line with previous study (Burr and 
Melketin, 2015). In regard to Ca2+ leakage, ER stress level (CHOP expression level) 
has been shown reduced at the beginning of differentiation. In the meantime, activation 
of PERK (phospho-eIF2α expression level) was increased whilst ATF6 was decreased 
indicating that dystrophin-deficient myoblast is prone to apoptosis and has defects 
ERAD machinery. Altered PKC maturation also demonstrated that PKC could not 
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function well as Erk, the downstream protein of PKCα, showed reduction of activation 
via RAF-MEK pathway.  
 Due to several impairment described above, it can be concluded that dystrophin-
deficient myoblast has impaired ability to differentiate prior to play role in muscle 
development as well as muscle regeneration in mdx mouse, and this could be the same 
happened in DMD patient. 
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Chapter 9 - Future Work 
This sections describe future work that could be conducted to further the understanding. 
9.1 Pax7 Study 
From the data obtained in Chapter 3, it is unclear as to whether KPNA2 is the actual 
protein that functions as the protein translocator. Therefore, further experiments need 
to be performed in order to reveal its function, i.e. a nuclear transport assay, live cell 
imaging. It would also be beneficial to know whether the high expression of KPNA2 
resembles high expression of Pax7, which may be a reason why dystrophin-deficient 
myoblasts are unable to achieve terminal differentiation. 
As discussed in Section 3.3.2.2, future work on Pax7 protein signalling is 
proposed. A study by Zhuang et al. (2014) demonstrated that Pax7 interacts with β-
catenin during Wnt signalling. In Wnt signalling, GSK3β is a subunit of the β-catenin 
destruction complex, and it is protein found downstream of Akt, (previously shown to 
be inactive in PI3K/Akt signalling) which is activated. Therefore, it is proposed that 
Wnt signalling is also impaired in dystrophin-deficient myoblasts.   
9.2 Improving Minidystrophin Functionality  
As previously mentioned, minidystrophin can only partly improve protein signalling, 
i.e. protein synthesis regulation and autophagy modulation. Therefore, it is suggested 
that full-dystrophin may have the potential to improve protein signalling and ameliorate 
the dystrophic phenotype in the mdx mouse as well as in DMD patients. As full-length 
dystrophin restoration confronted a massive problem as the large size of dystrophin 
protein, new method has to be developed.   
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APPENDIX 2. Material suppliers 
Amersham Pharmacia Biotech UK Ltd (Amersham Place, Little Chalfont, 
Buckinghamshire, HP7 9NA, UK)  
• Anti-Rabbit Ig biotinylated species specific F(ab)2 fragment from Donkey (Cat 
No. RPN1064)   
• Biotinylated Anti-mouse IgG (whole antibody from goat) (Cat No. RPN1177)  
• Protein A Sepharose CL-4B beads (Cat No. 17078001) 
Beckman Coulter (UK) Ltd ( Oakley Court, Kingsmead Business Park, London 
Road, High Wycombe HP11 1JU, UK)  
• AvantiTM 30 centrifuge  
Becton Dickinson UK Ltd (The Danby Building, Edmund Halley Road, Oxford 
Science Park, Oxford, Oxfordshire OX4 4DQ)  
• Purified mouse anti-Caveolin 3 monoclonal Antibody(Cat No. 610420)  
• Rabbit polyclonal anti-Caveolin 1 Antibody (Cat No. 610060)    
Becton Dickinson Labware (Becton Dickinson Company, Frankline Lakes, NJ, 
USA)  
• 15 mL falcon tubes BLUEMAXTM Polypropylene Conical tube (Cat No. 35-
2096)  
• 50 ml falcon tubes BLUEMAXTM Polypropylene Conical tube (Cat No. 35-
2070)  
Bio-Rad Laboratories Ltd (Bio-Rad House, Maxted Road, Hemel Hempstead, 
Hertfordshire, HP2 7DX, UK)  
• Mini Protean II Electrophoresis Cell (Cat No. 1653301)  
• Mini Trans-blot blotting Cell (Cat No. 170-3930)  
Carbolite (Parsons Lane, Hope, Hope Valley, S33 6RB, UK)  
• Carbolite Incubator  
Dako UK Ltd (Dako UK Ltd, Cambridge House, St. Thomas Place, Ely 
Cambridgeshire CB7 4EX)   
• Dakocytomation Fluorescence Mounting Medium (Cat No. S3023; Lot No. 
301514EFG 010104)  
Developmental Studies Hybridoma Bank (DSHB, Department of Biological 
Science, University of Iowa, 007 Biology Building East, Iowa City, IA52242, USA)  
• Anti-MF20  
• Mouse monoclonal anti-Pax7 antibody  
Eppendorf (Eppendorf UK Ltd, Endurance House, Vision Park, Chivers Way, 
Histon, Cambridge CB24 9ZR, UK)  
 236 
• Thermomixer 5436  
Fisher Scientific UK Ltd (Bishop Meadow Road, Loughborough, Leicestershire, 
LE11 5RG, UK)  
• Boric Acid (Cat No. B380053) 
• Diaminoethanetetra-acetate acid disodium salt (EDTA) (Cat No. D070053)  
• DyLight(TM) 800 Conjugates-Streptavidin Thermo Scientific Pierce (Cat NO. 
PN21851)  
• Ethanol, Class 3, analytical reagent grade (Cat No. E/0650DF/17)  
• Glycine (Cat No. G/P460/53)  
• Haemocytometer (Cat No. 0630030)  
• Methanol (Cat No. M/4000/PK4)  
• Nitric acid S.G. 1.42 (70%) (Cat No. N/2300/PB17)  
• Sodium Chloride (Cat No. 102415K)  
• Tri-Sodium Citrate (Cat No. S332053)  
• Sodium dodecyl sulphate (SDS; Cat No. S/5200/53; Batch No.0398855)  
• 2-propanol (iosopropanal; Cat No. P/7490/17; Batch No. 0380943)  
• TRIS (hydroxylmethyl methylamine; Cat No.T/P630/53) Xylene (Cat No. 
1330207)  
Geneflow Ltd (Fradley Business Centre, WoodEnd Lane, Fradley, Staffordshire, 
WS13 8NF, UK)  
• Protogel, 30% Acrylaminde, 0.8% (w/V)  
• Bis-Acrylaminde Stock Solution (37.5:1)  
GMBH & CO. KG (Janke & Kunkel-Str. 10, 79219 Staufen, Germany / 
Deutschland)  
• IKA®KS 130 basic orbital shaker   
Grants Instruments (Cambridge) Ltd, UK (29 Station Road, Shepreth, 
Cambridgeshire, SG8 6GB, UK)  
• Water Bath  
Invitrogen Ltd (Inchinnan Business Park, 3 Fountain Drive, Paisley, PA4 9RF, 
UK)  
• Alexa Fluor® 488 F(ab')2 fragment of goat antimouse IgG (H+L)(Cat No. 
A11017)  
• Alexa Fluor® 488 F(ab')2 fragment of goat antirabbit IgG (H+L)(Cat No. 
A11070)  
• Dulbecco's Modified Eagle Medium (1×) without Glutamine (Cat No. 21969-
035)  
• Geneticin (G418 sulphate)(Cat No. 11811-031)  
• GIBCO BRL 58 horizontal electrophoresis apparatus Kanamycine sulfate (Cat 
No. 11815-024)    
 237 
• LipofectamineTM 2000 (Cat No. 11668-027; Lot No. 867692)  
• LipofectamineTM LTX & Plus Reagent (Cat No. A12621)  
• Luria Broth Base (Cat No. 12795027; Lot No. 80245231))  
• 2-Mercaptoethanol (50MM) (Cat No. 31350010; Lot No. 26F0140)  
Jenkons (Scientific) Ltd (Cherrycourt Way, Stanbridge Road, Leighton Buzzard, 
Bedforshire, LU7 4UA, UK)  
• Uvitec, UV light box  
Kendro Laboratory Products Plc (Stortford Hall Park, Bishop's Sortford, 
Hertfordshire, CM23 5GZ, UK)  
• Labofuge 300 Heraeus centrifuge Heraeus Incubator (D-6450)  
Leica Microsystems Ltd, UK (Davy Avenue, Knowlhill, Milton Keynes, MK5 8LB, 
UK)  
• Inverted microscope-Leica  
• DMIRB Reichert-Jung 1150/Autocut microtome  
LI-COR Biotechnology - UK Ltd (St. John's Innovation Centre, Cowley Road, 
Cambridge, CB4 0WS, UK)  
• Odyssey® infrared imaging system Odyssey anti-mouse IRDye® 680 (Cat No. 
92632220; Lot No. B80908_011)  
Marval [Premier International Foods (UK) Ltd, Bridge Road, Long Sutton, 
Spalding, Lincs PE12 9 EQ, UK]  
• Non-fat milk  
Molecular Device Ltd (135 Wharfedale Road, Winnersh Triangle, Winersh, 
Wokingham, RG41 5RB, UK)  
• Emax microplate reader  
NanoWorld AG (Rue Jaquet-Droz 1, CH-2002 Neuchâtel, Switzerland)  
• Rectangular Si cantilevers type CONT-L  
New Brunswick Scientific (Eppendorf UK Ltd, Endurance House, Vision Park, 
Chivers Way, Histon, Cambridge CB24 9ZR, UK)  
• INNOVATM 433 refrigerated incubator shaker  
New England BioLabs (UK) Ltd (75/77 Knowl Piece, Wilbury Way, Hitchin, 
Herts. SG4 0TY, UK)  
• Prestained Protein Marker, Broad Range (7-175 kDa) (Cat No. P7708S)  
Nikon UK Limited (380 Richmond Road, Kingston Upon Thames, Surrey, KT2 
5PR, UK)  
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• Eclipse Ti inverted microscope  
Nunc Plasticware (Life Technologies Ltd., 3 Fountain Drive, Ichinnan Business 
Park, Paisley, PA4 9RF, UK)  
• CryoTubeTM vials (Cat No. 375353)  
• Large culture flasks (175 cm2) (Cat No. 147589A)  
• Medium culture flasks (75 cm2) (Cat No. 156462)  
• Small culture flasks (25 cm2) (Cat No. 156367)  
• 30 mm polystyrene petri dish (Cat No. 150318)  
• 60 mm polystyrene petri dish (Cat No. 150288)  
• 10 cm polystyrene petri dish (Cat No. 150350)  
• 24-well plates (Cat No. 143982A) 48-well plates (Cat No. 150787)  
• 96-well plates (Cat No. 167008A)  
PALL Life Sciences (Europa House, Havant Street, Portsmouth, Hampshire, PO1 
3PD, UK)  
• Sterile Acrodisc® Syringe 32 mm Filters with 0.45 μm Supor® Membrane (Cat 
No. 4654)  
Panasonic (Panasonic House, Willoughby Road, Bracknell, Berkshire RG12 8FP, 
UK)  
• microwave  
PerkinElmer (PerkinElmer, Saxon Way Bar Hill, Cambridge, Cambridgeshire, 
CB23 8SL, UK)  
• Streptavidin-Texas Red® (Cat No. NEL721001EA)  
Pierce (Perbio Sciences UK Ltd, Century House, High Street, Tattenhall, 
Cheshire, CH3 9RJ, UK)  
• Albumin Standard Samples (Cat No. 23209)  
• Coomassie® Protein Assay Reagent (Cat No. 1856209)  
Roche Diagnostic Ltd (Bell Lane, Lewes, East Sussex, BN7 1LG, UK)  
• Protease Inhibitor Cocktail tablets (Cat No. 1836153)  
Sanyo (1-300 Applewood Cres. Concord. Ont, L4K 5C7, UK)  
• Soni-pre150 machine (Sonicator)  
SARSTEDT (SARSTEDT Ltd, 68 Boston Road, Beaumont Leys, Leicester LE4 
1AW, UK)  
• Cell scraper (Cat No. 83.1830)  
School of Bioscience Stores, Birmingham University, UK (University of 
Birmingham, Edgbaston, Birmingham, B15 2TT, UK)  
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• Foil, 450 Caterwrap (Cat No. FOI11CC/WRA1)  
• 5 ml bijoux tube  
Sigma-Aldrich (Sigma-Aldrich Company Ltd, Fancy Road, Poole, Dorest, BD12 
4QH, UK)  
• Ammonium Persulfate (APS; Cat No. A3678)  
• Ampicillin (Cat No. A9518)  
• Bovine Serum Albumin (BSA) Fraction V (Cat No. A3059)   
• 4’,6-Diamidino-2-phenylindole dihydrochloride (DAPI) (Cat NO. D8417) 
• Dimethyl Sulfoxide (DMSO)(Cat No. D2650)  
• Dithiothreitol (DTT) (Cat No. D9779)   
• Fetal Bovine Serum (FBS)-Heat inactivated (Cat No. F9665)  
• Gelatin (Cat No. G1890)  
• L-Glutamine 200 mM (Cat No. G7513)  
• Glycerol (Cat No. G5516)  
• HEPES (Cat No. H4034)  
• Horse Serum (HS)-Heat inactivated (Cat No. H1138)  
• Hydrogen Peroxide Solution (Cat No. H1009)  
• IGEPAL® CA-630 (Octylphenyl-polyethylene glycol) (Cat No. I8896)  
• 2-Mercaptoethanol (Cat No. M7522-100ML; Lot No. 01496DK)  
• Minimum Essential Medium Eagle (MEM)-Alpha Modification (1×) (Cat No. 
M4526)  
• t-octylpheoxypolyethoxyethanol (Triton X-100) (Cat No.T9284)  
• Paraformaldehyde (Cat No. 76240)  
• Penicillin/Streptomycin solution (100×), cell culture tested (Cat No. P0781)  
• Phalloidin 
• Tetramethylrhodamine B isothiocyanate (Cat No. P1951)  
• Polyethylene glycol MW 8,000 (Cat No. 81268)  
• Polyethylene glycol sorbitan monolaurate (Tween®20) (Cat No. P7949)  
• Potassium Chloride KCl (Cat No. P9333)  
• Sodium phosphate Dibasic Na2HPO4 (Cat No. S7907)  
• Sodium phosphate Monobasic NaH2PO4 (Cat No. S8282)  
• N,N,N',N'-Tetramethylethylenediamine (TEMED; Cat No. T9281)  
• Trypsin (porcine trypsin in 0.2% EDTA‧4Na, 0.9% Sodium Chloride (Cat No. 
T4174))   
Sony (Pipersway, Thatcham, Berkshire RG19 4LZ, UK)  
• Gel imaging camera,  
Spectronic Camspec Ltd (Tudor House, Barley Hill Road, Garforth, Leeds LS25 
1DX, UK)  
• Camspec M501 Single Beam Scanning UV/Visible Spectrophotometer  
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Stuart Scientific Co. Ltd (Holmethorpe Industrial Estate, Redhill, Surrey RH1 
2NB, UK) Gyro-Rocker Shaker (STR9)  
• Hybridization Oven/Shaker (SI 20H)  
Swann-Morton Ltd (Swann-Morton Limited, Owlerton Green, Sheffield, S6 2BJ, 
UK)  
• Sterile Disposable Scalpel (Cat No.0508)  
Terumo UK Ltd (3 Unily Grove, Off School Lane, Knowsley Industrials Park, 
Knowsley, Merseyside, L34 9GI, UK)  
• 18 gauge needles (1.2×40 mm) (Cat No. NN-1838R)  
VECTOR LABORATORIES LTD. (VECTOR LABORATORIES LTD. 3 Accent 
Park, Bakewell Road, Orton Southgate, Peterborough, PE2 6XS, United 
Kingdom) 
• ImmEdge Hydrophobic Barrier Pen (Cat No. H4000)  
VWR International, Formerly “BDH” (Merk Ltd, Hunter Boulevard, Magna 
Park, Lutterworth, Leics, LE17 4XN, UK)  
• Coverglass- 24 mm × 50 mm (Cat No. 406-0188-82)  
• Glass Coverslips-9mm2 (Cat No. 631-0169)  
• DePex mounting medium (Cat No. 361252B)   
• Magnesium Chloride 6-hydrate (Cat No. 101494V)  
• Sodium Azide (Cat No.10369 2K)   
• Sodium Hypochlorite (Cat No. 301696S)  
• Superfrost Plus Microscope Slides (Cat No. 6310108)   
The Wolfson Centre for Inherited Neuromuscular Disease (CIND)  
• Mouse anti-dystrophin antibody (MANDRA1 7A10) (Morris et al., 1998; 
Nguyen et al., 1992)  
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APPENDIX 3. Recipes 
Cell culture medium and buffer preparation:  
IN-VITRO CELL CULTURE:  
C2C12/dfd13 cell culture medium:   
DMEM + 10% FCS + 1% P/S + 1%L-Glutamine  
450 ml Dulbecco's Modified Eagles Medium (DMEM; Invitrogen Ltd, UK),  
50 ml Fetal Bovine Serum (FCS) Batch tested (Sigma-Aldrich, UK),  
5 ml L-Glutamine (Sigma-Aldrich, UK),  
5 ml Penicillin/Streptomycin (P/S; Sigma-Aldrich, UK) 
C2C12/dfd13 differentiation medium:   
DMEM + 2% HS + 1% P/S + 1%L-Glutamine  
480 ml Dulbecco's Modified Eagles Medium (DMEM; Invitrogen Ltd, UK),  
10 ml Horse Serum (HS) Batch tested (Sigma-Aldrich, UK),  
5 ml L-Glutamine (Sigma-Aldrich, UK),  
5 ml Penicillin/Streptomycin (P/S; Sigma-Aldrich, UK)  
10× PBS (phosphate buffered saline)  
8 g NaCl (Fisher Scientific, UK),  
0.2 g KCl (Sigma-Aldrich, UK),  
1.15 g Na2HPO4 (Sigma-Aldrich, UK),  
0.2 g NaH2PO4 (Sigma-Aldrich, UK),  
100 ml dH2O (PH7.4)  
Trypsin:  
Trypsin (porcine trypsin in 0.9% sodium chloride solution; Sigma-Aldrich, UK) in PBS  
IMMUNOSTAINING:   
Fixation  
4 g Paraformaldehyde + 100 ml 1× sterile PBS  
Weight 4g Paraformadehyde (Sigma-Aldrich, UK) and add to preheated (60°C) PBS in 
a fumehood and allow dissolving in 65°C rocking oven, ensuring temperature did not 
go above 70 °C, as PFA is explosive at high temperatures.  
PBST  
PBS + 150 mM NaCl  + 0.05% Tween20® 500 ml PBS,  
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1.46 g NaCl, 0.25 ml Tween20® (Sigma-Aldrich, UK)   
Running Buffer  
3 g Tris (Fisher Scientific Ltd, UK),  
14.42 g Glycine (Fisher Scientific Ltd, UK),  
1 g SDS (Fisher Scientific Ltd, UK)  
Made up to 1 litre with dH2O  
1.5 M Tris-HCl   
18.17 g Tris Made up to 100 ml with dH2O pH to 8.8 with concentrated HCl (Fisher 
Scientific Ltd, UK)  
1.0 M Tris-HCl  
12.1 g Tris  Made up to 100 ml with dH2O pH to 6.8 with concentrated HCl (Fisher 
Scientific Ltd, UK)  
10% SDS  
10 g SDS made up to 100 ml with dH2O  
10X TBS (Tris-buffered saline)  
24.2 g Tris,   
80 g NaCl   
Made up to 100 ml with dH2O pH to 7.6 with concentrated HCl  
Blocking Buffer  
15 ml 10× TBS (see above) 135 ml dH2O,  
0.15 ml Tween®20,   
7.5 g non-fat dry milk (Marvel, UK)  
Wash Buffer (TBST)  
100 ml 10× TBS (see above),  
900 ml dH2O, 1 ml Tween®20   
Primary Antibody Dilution Buffer  
2 ml 10× TBS,  
18 ml dH2O,  
20 ul Tween®20,  
1 g BSA (Sigma-Aldrich, UK)  
 
